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Abstract  
Different studies spanning the diagnosis, the outcome and the treatment of the disease have been 
performed to investigate the spectrum of epilepsy. The topics were: 1. The differential diagnosis 
between epilepsy and another common clinical condition (PNES); 2. The verification if epilepsy 
could be a marker of genetic diseases characterized by intellectual disability and behavioural 
abnormalities (idic(15) syndrome); 3.The assessment of the long-term outcome of the disease 
to identify different prognostic patterns; 4.The investigation of the frequency and clinical 
features of drug-resistant epilepsy (DRE) with reference to the number of antiepileptic drugs 
(AEDs).  
In 1/3 of cases a confident diagnosis of PNES/ES can be established by epileptologists on video 
data only. Compared to epileptologists, psychiatrists demonstrated to be less accurate in 
diagnosing PNES but more attuned to capture the subtleties of human behaviour. Investigating 
the patients and their witnesses using ad-hoc structured questionnaires, some variables were 
highly predictive of PNES diagnosis. These instruments may be useful clinical tools in settings 
not offering the facilities for a correct diagnosis and in cases where video-EEG monitoring has 
failed. In the study on the characterisation of idic(15) syndrome, epilepsy was used as disease 
tracer. It was found to be one of the few symptoms with satisfactory agreement but not a marker 
of this genetic syndrome. To verify if the epilepsy course and treatment response is static or 
dynamic, a population based-study in a well-defined area of Italy was performed. DRE patients 
(1/6 patients with active epilepsy in the general population) can reach 2-year remission (24.9 
%) at 20 years and also early terminal remission (1.3%). AEDs given at diagnosis are retained 
in the majority of cases and the withdrawal can be predicted by age at diagnosis, sex, disease 
characteristics and varies among drugs. 
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1. Background and rationale 
1.1 The disease 
Epilepsy is a symptom complex arising from an altered brain function, which may be secondary 
to a variety of structural or functional changes to the central nervous system (CNS). The cardinal 
manifestations of epilepsy are the epileptic seizures, recurrent paroxysmal events characterized 
by stereotyped behavioural alterations reflecting the neural mechanisms involved by the 
epileptic process. In most cases, the disease can be diagnosed through a careful history or by the 
observation of a seizure. The interictal electroencephalogram (EEG) is of limited value in 
making the diagnosis, as highlighted in a meta-analysis in which the overall pooled sensitivity 
of routine EEG (up to 60 minutes recording with the international 10-20 electrode placement 
system) was 44% and the pooled specificity was 80% (Bouma et al, 2016). An aetiologic factor 
can be identified in several cases, but in the majority of patients the cause is unknown. 
Clinical conditions characterized by transient alteration of consciousness and/or behaviour fall 
in the differential diagnosis of epilepsy leading to false-positive diagnoses. These diseases 
include, among others, psychogenic non-epileptic seizures (PNES) that, along with the differing 
distribution of genetic and environmental risk factors, are possible explanations of the 
heterogeneous frequency, course and consequences of the disease in the world. 
The investigation of the spectrum of epilepsy is the focus of the present thesis. In doing this, I 
have performed different studies spanning the diagnosis, the outcome and the treatment of the 
disease. The topics covered include: 1. The differential diagnosis between epilepsy and another 
common clinical condition (PNES); 2. The verification if epilepsy could be a marker of genetic 
diseases characterized by intellectual disability and behavioural abnormalities; 3. The 
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assessment of the long-term outcome of the disease and the identification of different prognostic 
patterns; 4. The investigation of the dynamic nature of drug-resistant epilepsy (DRE) with 
reference to the treatments given during the course of the disease. Our findings will be discussed 
in the context of the available knowledge and a critical appraisal of the frequency and outcome 
of epilepsy as reported in the literature. 
 
1.1.1. Definitions and terminology 
While all people with epilepsy experience seizures, not all individuals with seizures have 
epilepsy. Epileptic seizures may occur in the context of an acute CNS insult (structural, 
systemic, toxic or metabolic). These events (provoked or acute symptomatic seizures) are 
intended as an acute manifestation of the insult and may not recur when the underlying cause 
has been removed or the acute phase has elapsed (Beghi et al. 2010). According to the 
International League Against Epilepsy (ILAE), epilepsy is a disease of the brain defined by any 
of the following conditions: (1) at least two unprovoked (or reflex) seizures occurring >24 h 
apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the 
general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 
10 years; (3) diagnosis of an epilepsy syndrome (Fisher et al, 2014). An unprovoked seizure is 
a seizure occurring in a person aged one month or older, occurring in the absence of precipitating 
factors. Unprovoked seizures include events occurring in the absence of a recognized 
aetiological or risk factor (idiopathic and cryptogenic seizures), in patients with antecedent 
stable (non-progressing) central nervous system (CNS) insults (remote symptomatic seizures), 
or in those with progressive CNS abnormalities such as brain tumors, genetic, metabolic or 
degenerative conditions (progressive symptomatic seizures). Unprovoked seizures may be 
single or recurrent. Seizures with onset within a restricted area of one hemisphere are classified 
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as focal (formerly partial), whereas those with onset in both hemispheres are classified as 
generalized. Different subtypes exist within these two main categories. While terminology has 
changed over time we will in this chapter keep the terminology used in the original reports when 
they are cited. 
Although epilepsy is, by definition, a chronic clinical condition, patients may achieve seizure 
remission at variable intervals after the onset of seizures. In epidemiological studies “epilepsy 
in remission with treatment” is defined by the absence of seizures for at least five years in 
patients still receiving antiepileptic drugs (AEDs). Epilepsy in remission without treatment 
(terminal remission) is seizure remission for at least five years in patients off medications at 
time of ascertainment (ILAE Commission, 1993). These cases represent the inactive epilepsy. 
By contrast, active epilepsy is defined as being treated with AEDs or having at least one seizure 
in the preceding 2 or 5 years regardless of treatment (Thurman et al, 2011). The ILAE uses the 
term “epilepsy resolved” for cases seizure free for ten years of which the last five off medication 
(Fisher et al., 2014).  
 
1.1.2. Drug-resistant epilepsy 
Studies performed in clinical cohorts showed that 30-40% of patients with epilepsy were 
resistant to the available antiepileptic treatments (Kong et al, 2014; Brodie et al, 2012; Schiller, 
2009). In the general population, this percentage seems to be lower, about 15-20% (Sillanpää 
and Schmist 2006; Berg et al 2012; Picot et al, 2008). This difference can be attributed to 
selection bias, as in the case of tertiary referral centers for epilepsy, the presence of cases with 
severe epilepsy syndromes is more frequent. Data from these cases may also reflect the use of 
different criteria for the definition of drug resistance, the variable number of drugs used, and a 
different follow-up duration. 
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Berg and colleagues (2006) proposed a strict definition: 1. Uncontrolled seizures with an 
average frequency of 1+ per month for at least 2 years; 2. Use of at least 3 different antiepileptic 
drugs (in monotherapy or in combination); 3. Treatment failure due to lack of control of seizures 
or withdrawal for adverse reactions. Less strict definitions have also been used, such as those 
proposed by Arts and colleagues (1999): seizure freedom from at least 3 to 6 months. 
Accordingly, the prevalence of DRE may vary from 9 to 24% of cases according to the selection 
criteria used (Berg and Kelly, 2006). 
To produce a correct estimate of the prevalence and incidence of drug-resistant epilepsy, 
representative samples of the general population of patients with epilepsy and a definition shared 
by the scientific community are needed. The International League Against Epilepsy (ILAE) has 
recently formulated a new definition of drug-resistance, thus providing a basis for its use in 
clinical practice. DRE has been considered as having failed at least two well-tolerated and 
appropriately chosen AEDs, as monotherapy or in combination, to achieve seizure freedom 
(Kwan et al., 2010). To date, no one study has been performed to assess the actual frequency of 
drug-resistant epilepsy in well-defined geographic areas.  
 
1.1.3.  Psychogenic non-epileptic seizures 
PNES are often indistinguishable from epileptic seizures behaviourally, but the EEG recorded 
during the event does not show epileptiform abnormalities (Benbadis, 2013; Gedzelman and 
LaRoche, 2015). The physiologic basis of PNES is not well-understood. They are believed to 
represent an experiential or behavioural response to emotional or social distress leading to 
temporary loss of control, a form of conversion or somatoform disorder (Reuber, 2008; Reuber, 
2009). 
  Giussani G. 
18 
 
The risks, treatments and prognosis of the two diagnoses (epilepsy vs. PNES) differ 
substantially, so accurate diagnosis is critical to the health and well-being of patients. For 
example, epileptic seizures (ES) that last > 5 minutes (i.e., status epilepticus) (Trinka et al, 2015) 
are life-threatening and require immediate emergency treatment. PNES that last > 5 minutes are 
rarely physically harmful and typically do not require any emergency treatment. Diagnosing 
true PNES as ES exposes patients to unnecessary treatment with anti-epilepsy medicines. 
Diagnosing true ES as PNES withholds appropriate treatment, increasing risk of adverse 
outcomes such as sudden-unexplained death in epilepsy (SUDEP) or other medical 
complications (Reuber et al, 2004). Recording typical events during inpatient, long-term, video-
EEG monitoring (VEM) is the recognized gold-standard method for diagnosis. History, physical 
examination, events and verbal descriptions observed directly by witnesses are not sufficiently 
diagnostic if alone, although they do provide valuable clues. However, it is not known whether 
combining these different characteristics predict diagnosis with sufficient accuracy. One of the 
aims of this thesis is to test this hypothesis. 
Most neurologists consider PNES a complex disorder of psychiatric origin, and, as such, a 
condition that is not of their competence. However, for at least two decades, cases with PNES 
have represented up to one third of the patients with refractory seizures admitted to the epilepsy 
units for diagnostic investigations, in numbers comparable to surgical candidates (Benbadis et 
al, 2004). These figures have been consistent and epileptologists, constantly facing the 
differential diagnosis between ES, PNES, and other non-epileptic seizures of non-psychogenic 
nature, can no longer ignore the condition. 
The disorder has been known since the ancient times and appears ubiquitously. Cases with 
PNES have been described in the industrially developed as well as in the developing countries 
across ethnicities and cultures (Farghaly et al, 2013; Asadi-Pooya et al, 2013; Alessi and 
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Valente, 2013; An et al, 2010; Cronje and Pretorium, 2013). The estimated incidence of PNES 
varies from 1.4 cases per 100,000 per year (about 4% of the incidence of epileptic seizures) 
according to an Icelandic study (Sidurdardottin and Olaffson, 1998) to 3 cases per 100,000 per 
year, according to an epidemiological work conducted in Ohio (USA) (Szaflarsky et al, 2000). 
Since these data are derived from VEM-proven cases followed in specialized neurology centers, 
such figures are likely to be an underestimate. Three-quarters of patients with PNES are female 
(Lesser, 1996). The age of onset is “most commonly” between the age of 15 and 25 years, and 
the disorder is “most commonly” diagnosed between the ages of 25 to 35 years (Reuber et al, 
2008). In 20-30% of patients with seizures the nature of the disorder is unrecognized (Smith et 
al, 1999). The mean delay between the first seizure manifestations and the diagnosis of PNES 
is about 7-8 years (Reuber et al, 2002; de Timory et al, 2002). A number of patients may also 
present PNES manifestations after years of epileptic seizures. The mean delay in diagnosing 
this group (PNES+ES) is 16 years (de Timory et al, 2002). Therefore, epilepsy itself can in fact 
be regarded as a risk factor for the occurrence of PNES (Reuber et al, 2003). The incidence of 
PNES associated with ES is unknown. 
Despite the alleged “low incidence”, the burden of PNES on the individual and society is 
significant because it affects predominantly young adults in the prime of life and because, when 
symptoms strike, they are highly disruptive. Two studies found that patients with PNES 
experience their life as more stressful than patients with epilepsy, also because their coping 
mechanisms are less effective (Tojek et al, 2000, Frances et al, 1999). The disorder greatly 
affects productivity. According to a US survey, 69% of 84 patients with PNES were employed 
at the time their seizure started but only 20% of them still had a job at the time they underwent 
VEM (Martin et al 2003).  
Clinical characteristics of PNES: 
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The semiology of PNES varies greatly from case to case. According to the predominant 
manifestations of the attack, the following types of PNES can be identified (Magaudda et al, 
2016) : 
-Hypermotor: with generalized motor phenomena, rhythmic (resembling grand mal seizure) or 
disordered, like hyperkinetic frontal seizures. 
-Akinetic (syncope-like if associated with fall): mainly characterized by unresponsiveness 
without motor phenomena (absence-like), with or without fall.  
-With subjective symptoms: paraesthesiae, experiential phenomena (visual, acoustic, dejà-vu or 
vecu, anxiety, fear - without all the features of a panic attack, confusional state). 
-Focal motor like: with partial clonic or tonic phenomena. 
Because of the variety of presentations and the close resemblance of many types of PNES with 
ES, the distinction between the two conditions may be difficult, at least when based on verbal 
descriptions by patients or direct witnesses. At close scrutiny, however, differences may become 
apparent, in certain types of seizures more than others. For instance, the evolving manifestations 
of an epileptic motor seizure follows a predictable path based on the anatomical organization of 
the neuronal networks involved by the progression of the ictal discharge. On the contrary, the 
motor manifestations of PNES follow a different scheme, which lacks anatomical coherence 
and is tinged with emotional or theatrical features. Nonetheless, it is long known that even the 
eye of an expert clinician cannot distinguish with certainty a hypermotor frontal lobe seizure 
from a hypermotor PNES (Saygi et al 1992, Leis et al 1992, Beleza and Pinho 2011). Similarly, 
episodes of staring and unresponsiveness or drop seizures, although suggeting a psychogenic 
origin, necessitate documentation by a trained professional or the concomitant EEG to reveal 
their true nature. Recently, the difficulty of distinguishing PNES with subjective symptoms from 
parietal lobe ES has been brought to clinical attention (Mc Gonigal et al, 2014).  
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As said before, the recommended gold standard for a definitive diagnosis is the analysis of the 
habitual attacks recorded during VEM. This allows direct observation of the semiology of the 
attack and an assessment of whether the concomitant EEG (“ictal” EEG) shows paroxysmal 
discharges (epilepsy) or remains normal (PNES). It also allows the recording of ECG, EMG and 
postictal EEG changes which may be of significance. However, even this approach has its 
limitations. First of all, in many areas around the world, including Europe, facilities providing 
VEM are difficult to access or not available. In addition, frontal lobe hypermotor seizures not 
only closely mimic the semiology of PNES but also often do not show obvious paroxysmal 
changes in the surface ictal EEG, thus precluding a definite diagnosis (Kanner et al 1990, Saygi 
et al 1992, Leis et al 1992, Beleza and Pinho 2011). Finally, in a number of cases no events are 
recorded during the VEM, despite attempts to precipitate the habitual seizures. 
When a definitive documentation is lacking, the diagnosis of PNES can be only presumptive, 
based on historical and clinical data considered to be “typical” of this disorder. There are a 
number of studies reporting that certain “signs” or “symptoms” are pathognomonic of the 
disorder as being significantly more frequent in patients with PNES compared to patients with 
epilepsy. The presence of one or more of such features provides important clues for the 
differential diagnosis (high sensitivity) although their specificity is often insufficient to establish 
the diagnosis with certainty (Avbersek and Sisodiya, 2010). Clusters of such “typical” signs 
have certainly more clout or “weight” than individual signs, but none, so far, has replaced the 
value of observing the habitual attacks on video with the concomitant EEG. In the study of Syed 
et al 2011, performed reviewing seizures videos and collecting information through 
eyewitnesses interviews, a cluster of three signs resulted to be significant for PNES diagnosis, 
even if eyewitnesses were not so reliable in reporting them. In another study performed using a 
patient and an observer questionnaire (Reuber et al, 2011), witnesses were more often aware of 
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seizure triggers and a relationship between PNES and emotional stress than patients. Patients 
with PNES reported different information from their witnesses and patients with epilepsy about 
their seizure events, there are more reticent, they describe the event as a space/place they go 
through (Plug et al, 2009, Rawlings and Reuber 2016). Unfortunatly some signs could not be 
collected because patients could be completely unaware and unwitnessed during the seizure 
event. In this cases the use of video is required. 
The Nonepileptic Seizures Task Force of the International League Against Epilepsy (ILAE) 
developed guidelines on standards for the diagnosis of PNES (LaFrance et al, 2013). Minimum 
requirements for a staged approach to the diagnosis are outlined, based on a review of the 
literature that include a variety of diagnostic approaches: review of past history, semiology of 
the attacks, EEG findings, ambulatory EEG findings, results of VEM, neurophysiologic testing, 
neurohumoral testing, neuroimaging, neuropsychological testing, hypnosis, and conversation 
analysis. The Task Force, based on the expertize of the participating panel and a compound 
assessment of data predominantly collected from patients with confirmed diagnosis of PNES, 
has concluded that the combination of patient history and direct recording of the attacks on 
video-EEG is the diagnostic standard. However, because VEM is not available worldwide, or 
for some patients events cannot be recorded, the group proposed four categories of PNES 
diagnosis based on ‘degree’ of certainty, depending on the available information:  
• Documented PNES – diagnosis relies on clinical history plus a VEM recording of habitual 
events (“gold standard”). 
• Clinically established PNES – diagnosis supported by the clinical history, a clinician witness 
and ambulatory EEG recording of habitual event or events without video. This diagnosis would 
be appropriate if a clinician witness observed a seizure and documented the symptoms and signs 
typically found in PNES, such as resistance to eye-opening, or if a clinician could review a non-
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EEG event by video or in person. 
• Probable PNES - this diagnosis is based on clinical history, a clinician review of video 
recording or witnessing live events, and a normal interictal EEG. This diagnosis would be 
appropriate if a clinician could review a home or cell phone video recording of seizure activity 
or witness it in person. 
• Possible PNES – diagnosis relies on clinical history from the patient or witness and a normal 
interictal EEG. At minimum, a patient’s history and description of events and an eyewitness 
description could help identify possible PNES, but without the clinician “observing the ictus on 
video or in person, an alternative diagnosis of epilepsy would have to be considered very 
carefully.”  
Even if the VEM of the attacks remains the “gold standard” in all cases, in current clinical 
settings the diagnosis of PNES may be within reach in other circumstances. For instance, when 
a health professional can demonstrate the preservation of certain “avoidance” or “self-defense” 
mechanisms during the patient’s apparent state of unconsciousness; or when an experienced 
professional, reviewing the habitual attacks recorded on video (even a home video) and without 
concomitant EEG can determine that the single manifestations, or the sequence in which they 
occur, represent a “physiological” or a “psychological” event. The above evidence would be 
further reinforced if habitual attacks recorded on ambulatory EEG (without video) were not 
associated with ictal discharges.  
Producing such evidence is not free of limitations. Most of all, it requires the presence, and if 
necessary the intervention, of health professionals familiar with the semiology of both ES and 
PNES and who could make a reliable judgment on whether there is sufficient proof in favor of 
one diagnosis or the other.  
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The diagnosis of PNES must be supported also by the “clinical history” (LaFrance et al, 2013) 
and it implies a careful survey of antecedent events – remote and recent – as possible aetiological 
factors, as well as the identification of precipitating factors that may trigger the attacks. To those 
we may add the specification of individual personality traits and behavioural characteristics that 
may constitute the facilitating and perpetuating factors. Although the VEM documentation of 
habitual seizures is usually regarded as the gold standard test confirming the diagnosis, the 
history-taking is the most important clinical tool in the diagnostic process, needed to define if 
the events captured by VEM are typical of habitual seizures. 
All these observations give rise to interesting speculations regarding the psychophysiology of 
PNES (Reuber, 2009). Obviously, the appreciation of the multifactorial complexity of the 
aetiology of PNES is essential to institute effective therapeutic strategies.  
Contrary to epilepsy that can be either transmitted genetically (primary/idiopathic epilepsy) or 
acquired secondarily to a brain injury (secondary/symptomatic epilepsy), PNES appears to be 
an exclusively acquired disorder. It is reasonable to assume that at the origin there is a distant 
or recent traumatic experience that, combined with environmental factors and a characteristic 
psychological and personality profile, leads to the manifestations of PNES.  
Approximately 90% of patients with PNES report significant traumatic experiences in the past 
(Fiszmann et al, 2004). Such “injuries”, mostly of psychological nature, seem to be less 
important aetiological factors in men (Oto et al, 2005), in those with a late onset of the attacks 
(Duncun et al, 2006), and those with learning difficulties (Duncun et al, 2008). Traumatic events 
can occur in adults and can be “physical” (see: war veterans (Dwortzky et al, 2005) or victims 
of rape) or “work-related” (e.g.the loss of the job in a successful adult male). Presumably, they 
all represent a shattering experience that deeply destabilizes the individual. The results of Alper 
et al 1993, support the impression that childhood abuse is more common among patients with 
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conversion NES than with epilepsy, and suggest that in some cases childhood abuse may be a 
contributory pathogenic factor.  
As summarized in the review by Reuber (Reuber, 2008), trauma is present in the history of 
32.4% to 88% of patients with PNES compared to 8.6% to 37% in the history of patients with 
epilepsy. Sexual abuse was more represented (24% vs. 7.1%) than physical abuse (15.5% vs. 
2.9%). Thus, history of abuse is significantly more frequent in PNES than epilepsy. These figures 
are probably an underestimate considering that many patients may be reluctant to admit and 
discuss past events of such intimate nature, particularly in certain cultures. It is apparent from 
these data and from the experience of those familiar with this condition that sexual abuse is a 
frequent, although not necessarily a mandatory component in the pathogenesis of PNES. The 
role of trauma in the pathophysiology of PNES has been studied closely by Hingray (Hingray et 
al, 2011). Patients with history of trauma have at least one psychiatric comorbidity or antecedent 
and a higher median score for dissociative mechanisms (p<0.001). No patient in the no-trauma 
group had a history of psychiatric comorbidity or current psychiatric disorders. Patients without 
history of trauma, besides absence of psychiatric comorbidity, report more frequently 
"frustration situations" as triggering factors of PNES and subsequent sick leaves as perpetuating 
factors (p=0.001).  
Such information suggests that exploring the psychological risk factors and the psychiatric 
comorbidities are just as important for the differential diagnosis as the analysis of the semiology 
of the attacks.  
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1.2 Epidemiology of epilepsy 
1.2.1. Incidence  
The worldwide annual incidence of epilepsy from 24 to 190 per 100,000. The overall incidence 
of epilepsy in high income countries ranges from 24 and 71.0 per 100,000 per year (Table 1.1). 
In low/middle income countries the incidence of the disease is higher (Table 1.2) and is up to 
190 per 100,000.  
1.2.2. Prevalence  
The overall prevalence of epilepsy ranges from 2.7 to 105 per 1,000 population, although in the 
majority of the published reports the rate of active epilepsy varied from 4 to 8 per 1,000. The 
prevalence of active epilepsy is generally lower in high income countries (Table 1.3) than in 
low/middle income countries (Table 1.4), which may reflect a lower prevalence of selected risk 
factors (mostly infection and trauma), a more stringent case verification, and the exclusion of 
isolated provoked and unprovoked seizures. In a systematic review and meta-analysis of 197 
prevalence studies, the point prevalence of active epilepsy was 6.4 per 1,000 (95%CI 5.6-7.3) 
and the lifetime prevalence was 7.6 per 1,000 (95%CI 6.2-9.4) (Fiest et al, 2017). The 
prevalence was lowest in infancy and tended to increase with age, with a peak at 20-29 years 
and a subsequent decrease. Both lifetime and active period prevalence were higher in 
low/middle income countries than in high income countries, but the difference for active 
epilepsy was not significant. These differences can be mostly explained by the differing 
distribution of the risk factors and the shorter life expectancy in the latter.  
As with incidence, the prevalence of epilepsy tends to prevail in men (Fiest et al, 2017). 
However, this finding is not consistent across studies and, with few exceptions, is not 
statistically significant. In multiracial populations, the lifetime prevalence of epilepsy is more 
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prevalent in blacks than in whites (7.5 vs. 5.9 per 1,000) but, among whites, the prevalence was 
higher in Hispanics than in non-Hispanics (7.5 vs. 4.7 per 1,000) (Kelvin et al, 2007). Ethnic 
and racial differences and different socio-cultural environments may explain the heterogeneity 
of the figures.  
Focal seizures are commoner than generalized seizures both in children and adults. In 
prevalence studies in adults from high income countries, focal seizures were reported in 55-60% 
of cases, generalized seizures in 26-32%, and unclassifiable seizures in 8-17%. Different figures 
are present for children (36-66%, 30-62%, and 2-4%), mostly depending on a different 
distribution of epilepsy syndromes, and for low/middle-income countries (11-55%, 26-86%, and 
0-19% respectively), as a consequence of a less accurate diagnostic ascertainment of minor 
seizures (other than generalized tonic-clonic) (Forsgren, 2004).  
The prevalence of epilepsy types has been mostly studied in children and adolescents from 
Baltic and Scandinavian countries (Forsgren, 2004). In Estonia, the prevalence of idiopathic 
epilepsies in children was 1.2 per 1,000, and that of cryptogenic epilepsies was 1.0 per 1,000. 
In Lithuania, focal epilepsies in children were the commonest syndromic category (2.3 per 
1,000) followed by generalized epilepsies (1.3 per 1,000) and undetermined epilepsies (0.6 per 
1,000). Focal epilepsies were the predominant syndromic category in 41-54% of cases from 
Sweden, Finland and Norway, followed by generalized (37-48%) and unclassified (5-10%). In 
these countries, idiopathic partial epilepsy with centro-temporal spikes was 5-17%, absence 
epilepsy 6-8%, juvenile myoclonic epilepsy 1-5%, West syndrome 0.5-8%, and Lennox-Gastaut 
syndrome 2-6%.  
Socio-economic background affects the frequency of epilepsy both in high income and in 
low/middle income countries (Beghi & Hesdorffer, 2014). A strong correlation was detected 
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between the prevalence of epilepsy and social deprivation, defined by unemployment, no car in 
the household, overcrowded households, and households not occupied by the owner.  
1.3 Prognosis of epilepsy 
The overall prognosis of epilepsy is favorable in most patients. Reports from several low/middle 
income countries (where patients with epilepsy are largely untreated) give prevalence and 
remission rates overlapping to those of high income countries (Beghi et al, 2015). As in most 
low/middle income countries the incidence of epilepsy is higher than in high-income countries 
and increased mortality may explain only in part the difference between incidence and 
prevalence, spontaneous remission of seizures is a likely explanation. In addition, contrary to 
the old reports, studies done in the last 30 years in newly diagnosed patients have consistently 
shown that 55-68% of cases tend to achieve prolonged seizure remission (Table 1.5). However, 
in a long-term population-based study done in patients with childhood-onset epilepsy, different 
remission patterns were seen. Half of the patients entered terminal remission, without relapse 
and one fifth after relapse. One third had a poor outcome in terms of persistent seizures after 
remission or without any remission (Sillanpaa & Schmidt, 2006). These patterns have been 
confirmed in part by others (Brodie et al, 2012; Shorvon & Goodridge, 2013; Berg & Rychlik, 
2015; Giussani et al, 2016).   
The risk of relapse after a first unprovoked seizure range from 23 to 71% (Beghi, 2003). 
Population-based studies provided more homogeneous relapse rates at one (36-37%) and two 
years (43-45%). In a systematic review of 16 reports, the average recurrence risk was 51% (95% 
CI 49-53%) (Berg & Shinnar, 1991). After a first unprovoked seizure, the probability of a 
relapse decreases with time. 50% of seizure relapses occur of recurrences occur within 6 months 
from the initial seizure and 76-96% within 2 years. A documented aetiology of the seizure and 
an abnormal EEG pattern are the two most consistent predictors of recurrence. The pooled two-
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year recurrence risk is lowest for an idiopathic or cryptogenic first seizure with a normal EEG 
(24%; 95% CI 19-29%), intermediate for a remote symptomatic seizure (48%; 95% CI 34-62%) 
with normal EEG or an idiopathic/cryptogenic seizure with an abnormal EEG (48%; 95% CI 
40-55%), and highest with a remote symptomatic seizure with an abnormal EEG (65%; 95% CI 
55-76%) (Berg & Shinnar, 1991). Interictal EEG epileptiform abnormalities tend to be 
associated with a higher risk of seizure recurrence than non-epileptiform abnormalities. Seizures 
occurring during sleep are associated with a higher risk of recurrence both in children and in 
adults. Focal seizures are also correlated with a higher risk of recurrent seizures, even after 
controlling for etiology and EEG abnormalities. A positive correlation between seizure relapse 
and family history of seizures has been confirmed in patients with idiopathic or cryptogenic first 
seizures. History of acute symptomatic seizures prior to the first unprovoked seizure has been 
occasionally found to increase the risk of relapse, while evidence is inconclusive or lacking for 
sex, age, and status epilepticus. 
The prognosis of untreated epilepsy can be assessed only in low income countries where 
epilepsy is largely untreated (treatment gap ranging from 70 to 94%) (Mbuba et al, 2008). In a 
population-based study done in Ecuador the cumulative annual incidence rate was 190 per 
100,000 and the prevalence rate of active epilepsy was 7 per 1,000, which implies a remission 
rate of at least 50% (Placencia et al, 1992). Similar prevalence rates of active epilepsy were 
found in other countries (Watts, 1992; Nicoletti et al, 2009). These findings lend support to the 
hypothesis that spontaneous remission of epilepsy is a common event.  
Generally, treatment started when at least two unprovoked seizures have occurred. After a 
second unprovoked seizure, the risk of a third seizure has been estimated as 73% and, among 
those with a third unprovoked seizure, the risk of a fourth as 76% (Hauser et al, 1998). 
Population-based studies on the long-term prognosis of treated epilepsy report a 58-65% 
  Giussani G. 
30 
 
cumulative 5-year remission rate at 10 years (Table 1.5). This number rises to about 70% by 20 
years following seizure onset.  
Aetiology of epilepsy is by far the strongest prognostic predictor for seizure recurrence in 
patients with epilepsy. Genetic (formally idiopathic) epilepsy has a better chance of seizure 
remission than structural, infectious, metabolic, immune (ex-symptomatic) or unknown (ex-
cryptogenic) epilepsy (Schaffer et al, 2017). In the Rochester, Minnesota, symptomatic 
epilepsies had a significantly lower chance of 5-year remission compared to idiopathic 
epilepsies (30 vs. 42% at 15 years), patients with congenital neurological dysfunction have the 
lowest chance to reach seizure remission (Annegers et al, 1979). Lower remission rates in 
patients with symptomatic epilepsies were found in several European countries (Beghi et al, 
2015). Other indicators of 5-year remission in the Rochesterstudy included absence of EEG 
epileptiform abnormalities (OR 1.6) and absence of generalized tonic-clonic seizures. In the 
National General Practice Study of Epilepsy (NGPSE) in the UK, the number of seizures after 
the first seizure was the only independent predictor of 1- and 2-year remission (MacDonald et 
al, 2000). 
Sander (1993) proposed four different prognostic groups: 1. Excellent prognosis (~20-30% of 
the total) with high probability of spontaneous remission (benign focal epilepsies, benign 
myoclonic epilepsy in infancy, and epilepsies provoked by specific modes of activation, i.e. 
reflex epilepsies); 2. Good prognosis (~ 30-40%) with easy pharmacological control and 
possibility of spontaneous remission(childhood absence epilepsy, and some focal epilepsies); 3. 
Uncertain prognosis (~ 10-20%), which may respond to drugs, but tend to relapse after treatment 
withdrawal  (juvenile myoclonic epilepsy, and most partial symptomatic or cryptogenic 
epilepsies); 4. Poor prognosis (~ 20%) in which seizures tend to recur despite intensive treatment 
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(epilepsies associated with congenital neurological defects, progressive neurological disorders, 
and some symptomatic or cryptogenic partial epilepsies).  
1.3.1. Mortality of epilepsy 
The mortality rate of epilepsy ranges from 1 to 8 per 100,000 population per year, but 
international vital statistics give annual mortality rates of 1-2 per 100,000 (Gaitatzis & Sander, 
2004).  
Based on population-based studies investigating mortality in high income countries, the 
standardized mortality ratio (SMR) for incident unprovoked seizures or epilepsy was found to 
range from 1.6 to 3.0 (Thurman et al, 2016). In prospective and retrospective incidence cohorts, 
the SMR for epilepsy ranges from 1.6 to 5.3 in children and adults (Table 1.6). The SMR is 
generally higher among children, due to lower mortality rates in the general population, and also 
higher during the first years after diagnosis (Thurman et al., 2017). In low/middle income 
countries (Table 1.7), the annual mortality rate in people with epilepsy is higher than in high 
income countries and ranges from 9.7-45.1 deaths per 1,000, with a median of 2.6 (range 1.3-
7.2) (Levira et al, 2017). Median SMRs are slightly higher in men than in women (SMR 5.0 vs. 
4.5) and relatively higher SMRs in children and adolescents, patients with symptomatic 
epilepsies, and those reporting less adherence to treatment. 
 
1.4 Aetiology of epilepsy 
Comorbidities in epilepsy represent an important burden (Keezer et al 2016). Several somatic 
and psychiatric comorbidities tend to prevail significantly in people with epilepsy when 
compared to the general population (Gaitatzis et al, 2012; LaFrance et al, 2008). Several 
mechanisms can explain the association between epilepsy and a number of comorbidities, 
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including causal relation, shared risk factors and bidirectional effects. Factors clearly associated 
with the development of epilepsy must be identified before accepting the concept of a causal 
association between a brain insult and the occurrence of epileptic seizures. First, the timing of 
the seizure(s) must be identified, to separate acute symptomatic from unprovoked seizures. 
Second, the frequency and spectrum of epilepsy and putative aetiological factors in the general 
population must be assessed to define the fraction of epilepsies associated to a given risk factor 
and the risk of epilepsy attributable to that factor. Third, the accuracy and validity of the 
diagnostic process must be considered. Fourth, evidence of a causal relationship should be 
produced to exclude the possibility of a chance association even at the presence of a well-
established aetiological factor. This requires the satisfaction of specific criteria, including 
temporal sequence, strength and consistency of association, biological gradient and plausibility. 
The ILAE proposes classification into six different categories: structural, genetic, infectious, 
metabolic, immune, as well as an unknown aetiological group (Scheffer et al, 2017).  
In incidence studies, the proportion of cases with documented aetiology has been reported to 
vary from 13.7% in Ethiopia to 51.6% in Poland (Beghi, 2004). The differences are mostly 
explained by the structure of the population at risk, the prevalence of the aetiological factors in 
the local environment, the study design, and the extent of the diagnostic process to identify 
etiologies. In the Rochester, Minnesota population (where the majority of cases were included 
before the era of modern neuroradiology), epilepsy was idiopathic/cryptogenic in about two-
thirds of patients. The commonest aetiological factors included cerebrovascular disease 
(10.9%), congenital neurological disorders (8.0%), trauma (5.5%), neoplasm (4.1%), 
degenerative disorders (3.5%), and infection (2.5%) (Hauser et al, 1993). Aetiological factors 
varied significantly with age, congenital disorders being most common in children aged less 
than 14 years and cerebrovascular disorders in the elderly.  
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To some part, the risk of epilepsy is accounted for by genetic factors. Despite the increasing 
pace of gene discovery in the epilepsies, the contribution of specific genes still needs to be 
elucidated. In epidemiology, the role of the genetic components has been mostly explored by 
studies of familial aggregation of epilepsy, studies on paternal and maternal transmission, and 
twin studies. However, these studies often suffer from methodological limitations including 
referral and reporting biases, small sample size, ambiguous disease definition, and lack of 
controls (Hauser & Hesdorffer, 1990). Siblings and offspring of patients with epilepsy have a 
two- to threefold increased risk to develop epilepsy. In offspring of patients with epilepsy, the 
cumulative incidence of unprovoked seizures at age 25 is about 6%, as opposed to 1-2% of the 
general population (Hauser & Hesdorffer, 1990). The risk of seizures among offspring of 
mothers with epilepsy exceeds that of offspring of fathers with epilepsy. If a proband has an 
early age at onset of seizures, there is an increased risk of seizures among siblings and offspring. 
The risk of unprovoked seizures is highest among siblings of probands with generalized 
epilepsy and is related to seizure type (mostly tonic-clonic or absence) and EEG abnormalities 
(mostly generalized spike and slow wave patterns). In the only comprehensive study in first-
degree relatives of probands with epilepsy (Peljto et al, 2014), the cumulative incidence of the 
disease to age 40 years was 4.7%, accounting for a three-fold increased risk (measured by the 
standardized incidence ratio, SIR) compared to the general population. A significantly increased 
risk was found for idiopathic generalized epilepsy (SIR 5.0; 95%CI 3.2-7.4), generalized 
epilepsy due to structural-metabolic causes (SIR 3.9; 95%CI 1.0-8.2) and focal epilepsy (SIR 
4.8; 95%CI 1.6-9.9). A five-fold increased incidence of epilepsy was found in the offspring of 
female probands, restricted to focal epilepsy. The results of this and other epidemiological 
studies providing heritability estimates support the concept that epilepsy has a robust genetic 
component. 
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Although the role of pre- and perinatal risk factors in the etiology of epilepsy seems established, 
most of the studies provide inconsistent findings and indicate, at best, a moderate association. 
These results may be explained by the use of differing definitions of pre- and perinatal factors, 
the study populations, the methods of ascertainment of the cause-effect relationship, and the 
sample size.  
Mental retardation and cerebral palsy are markers of brain dysfunction, which explains the 
significant association with epilepsy. In a systematic review of 38 studies, the pooled prevalence 
among people with intellectual disabilities was 22.2% (95%CI 19.6-25.1) with increase with the 
disability level (Robertson et al, 2015). In the U.S. National Collaborative Perinatal Project, a 
study following newborns prospectively up to age 7, epilepsy occurred in 34% of children with 
cerebral palsy and it was present in 19% of children developing epilepsy (Nelson & Ellenberg, 
1987). In this cohort, the risk of mental retardation was 5.5 times higher among children 
developing epilepsy a after febrile seizure than in children with a febrile seizure alone. Epilepsy 
was more common in individuals with severe/profound mental retardation compared to 
mild/moderate mental retardation (Hauser & Hesdorffer, 1990).  
 
1.4.1 Epilepsy and multiple disabilities 
About 30% of patients evaluated for epilepsy are disabled (Genton et al 1996). 
Disabilities associated with epilepsy include neurological and/or sensory dysfunction, mental 
retardation, psychiatric and/or behavioural problems. Several aetiological factors have been 
described causing the association between epilepsy and disability (Genton 1996). The frequency 
of epilepsy in these patients is directly proportional to the severity of the mental disability 
(Hagberg and Kyllerman, 1983; Corbett J, 1985; 79-89; Salbreux et al, 1979; Col 1981) and in 
institutionalized patients (Iivanianen et al 1985; Mariani et al, 1986). 
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Focusing on the prevalence of epilepsy as function of aetiology in disability, prenatal 
encephalopathies are less epileptogenic than perinatal and postnatal (Iivanainen 1985, Ingram 
1964). Epilepsy is a common condition in prenatal encephalopathies caused by genetic 
syndromes, like Fragile-X (Fra-X) syndrome (25-40%), tuberous sclerosis (70%), Sturge-Weber 
(80%), Rett Syndrome (72%), Aicardi syndrome (100%), Angelman syndrome (90%). Another 
syndrome in which epilepsy is recurrent (exceeding 75% of cases) is the 15q11-13 duplication 
syndrome (idic(15)) (Battaglia, 2008), a rare syndrome characterized by an unspecific 
phenotype, clinical heterogeneity and a wide spectrum of severity, and for which no formal 
characterisation has been attempted. The incidence is estimated to be 1 per 30,000 live births 
with a sex ratio of 1:1 (Schinzel and Niedrist, 2001).  
In this thesis I focus on this genetic syndrome as an example in order to validate the diagnosis 
of a genetic epilepsy syndrome characterized by intellectual disability and abnormal behaviour. 
The aim was to detect a cluster of signs and symptoms, laboratory and instrumental tests useful 
to discriminate this condition from the diseases that fall in the differential diagnosis (other 
neurodevelopmental disorders with mental retardation, intellectual disability, epilepsy and 
altered behaviour) and understand if epilepsy could be used as a marker of the disease.  
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Table 1.1.  Incidence (per 100,000 per year) of epilepsy in high income countries. 
Author, year Country (§) Age Incidence rates Notes 
Camfield, 1996 Canada Children 46.0  
Christensen, 
2007 
Denmark All ages 68.8  
Beilmann, 1999; 
Oun, 2003 
Estonia All ages 35.4-45.0  
Gaily, 2016; 
Saarinen, 2016; 
Keranen, 1989; 
Sillanpaa, 1998; 
Sillanpaa 2006 
Finland All ages 24.0-124.0 Higher rates in 
infants 
Freitag, 2001 Germany Children  60.3  
Olaffson, 1996; 
Olaffson, 2005 
Iceland All ages 33.3-46.5  
Loiseau, 1990 France All ages   
Cesnik, 2013; 
Casetta, 2012; 
Giussani, 2014; 
Granieri, 1983 
Italy All ages 32.5-57.0 Higher rates in 
children 
Nakano, 2014 Japan All ages 24-53 Higher rates in 
older ages 
De Graaf, 1974; 
Breivik, 2008 
Norway All ages 32.8-46.8 Higher rates in 
children 
Pavlovic, 1998 Serbia Children 650.0 Cumulative 
incidence 
Forsgren, 1996; 
Brorson, 1987 
Sweden All ages 50.0-56.0  
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Jallo, 1997 Switzerland All ages 71.0  
MacDonald, 
2000; Eltze, 
2013 
United 
Kingdom 
All ages 46.0-70.1 Higher rates in 
infants 
Hauser, 1993; 
Holden, 2005; 
Zarrelli, 1999; 
Hauser, 1993 
United States All ages 35.0-71.0 Higher rates in 
administrative 
data 
Joensen, 1986 Faroe Islands All ages 42.0  
Kotsopoulos, 
2005 
The 
Netherlands 
>13 years old 29.5  
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Table 1.2. Incidence (per 100,000 per year) of epilepsy in low/middle income countries. 
Author, 
Year 
Country (§) Age Incidence rates Notes 
Debouverie, 
1993 
Burkina-Faso All ages 83.0  
Lavados, 
1992 
Chile All ages 113.0  
Placencia, 
1992 
Ecuador All ages 122.0-190.0 Urban and rural 
area; reasons for 
this difference 
not identified 
Tekle-
Heimanot, 
1997 
Ethiopia All ages 64.0  
Mani, 1998 India All ages 49.3  
Winkler, 
2009 
Tanzania All ages 81.1  
Kaiser, 1998 Uganda All ages 215.0  
Li, 1985 China All ages 35.0  
Ibinda, 2014; 
Mung’ala-
Odera, 2008 
Kenya All ages 39.16-187.0 Lower rates in 
women and 
higher rates in 
children 
El Tallawy, 
2010 
Egypt All ages 43.14  
Houinato, 
2013 
Benin All ages 10.5  
Jallon, 1999 Martinique All ages 64.1  
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Ba-Diop, 
2014 
Sub-Saharan 
Africa 
All ages 81.7  
Burneo, 2005 Latin America All ages 77.7-190  
Medina, 2005 Honduras All ages 92.7  
Dogui, 2003 Tunisia Children 102.1  
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Table 1.3. Prevalence (per 1,000) of active epilepsy in high income countries. 
Author, year Country (§) Age Prevalence 
ratios 
Notes 
D’Souza, 2012 Australia All ages 4.4  
Christensen, 
2007 
Denmark All ages 6.0  
Beilmann, 1999; 
Oun, 2003  
Estonia All ages 3.6-5.3 Lower ratios in 
children and 
higher in adults 
Picot, 2008 France Adults 5.4  
Sillanpaa 
1973;Keranen, 
1989; Eriksson, 
1997 
Finland All ages 3.2-6.3 Lower ratios in 
children  
Olaffson, 1999 Iceland All ages 4.8  
Gallitto, 2005; 
Cossu, 2012; 
Giussani, 2015; 
Giussani, 2016; 
Granieri, 1983 
Italy All ages 3.0*-7.9 *Aeolian 
Islands 
Nakano, 2014; 
Oka, 2006 
Japan All ages 2.7-40.0 Lower ratios in 
children and 
higher in older 
ages 
Waaler, 
2000;Syvertsen, 
2015 
Norway All ages 5.1-6.5 Lower ratios in 
children 
Bilikiewicz, 
1988 
Poland >16 years 3.7  
Luengo, 2001, 
Benavente, 
2009; Garcia-
Martin, 2012 
Spain All ages 4.1-6.3 Higher ratios in 
adolescents 
Brorson, 1987; 
Forsgren, 1992; 
Sidenvall, 1996; 
Bolin, 2015 
Sweden All ages 4.2-8.8 Lower ratios in 
children 
De La Court, 
1996 
The Netherlands Adults and 
elderly 
9.0  
Goodridge, 
1983; Wallace, 
United 
Kingdom 
All ages 4.0-8.0  
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1998; 
MacDonald, 
2000; Wright, 
2000; Gaitatzis, 
2004; Steer, 
2014 
Hauser, 1991; 
Kobau, 2004; 
Holden, 2005; 
Chong, 2013; 
Ablah, 2014 
United States All ages 7.2*-21.0 *Only adults in 
Georgia and in 
Tennessee 
Chen, 2006; 
Hsie, 2008 
Taiwan All ages 2.7*-4.2 Lower ratios in 
adults 
Tellez-Zenteno, 
2004; Prasad, 
2011; Schiariti, 
2009 
Canada All ages 4.03-5.5  
Al Rajeh, 2001 Saudi Arabia All ages 6.5  
Josipovich-Jelic, 
2011 
Croatia All ages 10.9  
Joensen, 1986  Faroe Islands All ages 7.6  
Endziniene, 
1997 
Lithuania Children 4.2  
Kruja, 2012 Albania All ages 14.2  
Pavlovic, 1998 Serbia Children 6.5  
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Table 1.4. Prevalence (per 1,000) of active epilepsy in low-middle income countries 
Author, year Country (§) Age Prevalence 
ratios 
Notes 
Nicoletti, 1999 Bolivia All ages 11.1  
Lavados, 1992 Chile All ages  17.7  
Placencia, 
1992; Cruz, 
1999; Del 
Brutto 2005 
Ecuador All ages 6.7-22.62 Higher ratios in 
migrant 
populations 
Tekle-
Heimanot, 
1990 
Ethiopia All ages 5.2-29.46 Higher ratios in 
the Zay society 
after a door-to-
door survey 
Radhakrishnan, 
2000; 
Banerjee, 
2009; Pandey, 
2014 
India All ages 4.9-7.0 Higher ratios in 
children 
Aziz, 1997; 
Malik, 2011 
Pakistan All ages 7.0-9.98  
Gracia, 1990 Panama All ages 22.0-57.0 Lower ratios in 
Panama City 
populations than 
in the Caribbean 
Coast 
Dent, 2005; 
Winkler, 2009; 
Hunter, 2012 
Tanzania All ages 2.91-8.7 Lower ratios in 
adults and higher 
in a door-to door 
survey 
Attia-
Romdhane, 
1993 
Tunisia All ages 4.0  
Marino, 1987; 
Gomes, 2002; 
Borges, 2004 
Brazil All ages 
5.1-8.2 active 
13.0 lifetime 
 
Gomez, 1978; 
Pradilla, 2003; 
Velez, 2006 
Colombia All ages 
10.3 active 
19.5 lifetime 
 
Li, 1985; 
Kwong, 2001; 
Wang, 2003; 
Fong, 2008; 
China All ages 
1.52 – 4.4 active 
23.5 lifetime 
Lower ratios in 
adults with active 
convulsive 
epilepsy 
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Zhao, 2010; 
Hu, 2014; Pi, 
2014 
Mendizabal, 
1996; Garcia-
Noval, 2001 
Guatemala All ages 5.8-18.0* Higher ratios in 
two rural 
Guatemalan 
communities 
Sridharan, 
1986 
Libya All ages 2.3  
Lee, 2012 Korea All ages 2.41  
Aziz, 1997; 
Karaagac, 
1999; Onal, 
2002; Aydin, 
2002; 
Huseynoglu, 
2012; 
Velioglu, 
2010; 
Canpolat, 
2014; Ozkan, 
2015 
Turkey All ages 2.5-8.6 Lower ratios in 
adolescents and 
higher rates in 
children 
El Tallawy, 
2010; 
Farghaly, 2013 
Egypt All ages 2.1-6.9 Lower ratios in 
adults 
Ebrahimi, 2012 Iran All ages 7.9  
Lomidze, 2012 Georgia All ages 8.8  
Gonzales, 2015 Peru Adults 15.3-25.0-35.6 Lower ratios in 
the urban group, 
middle ratios in 
the rural group, 
higher ratios in 
migrant group. 
Mung’ala-
Odera, 2008; 
Ibinda, 2014 
Kenya All ages 2.59-11.0 Lower ratios in 
active convulsive 
epilepsy, higher 
ratios in children 
Wagner, 2014 South Africa All ages 7.0  
Osakwe, 2014 Nigeria All ages 4.7-20.8 Lower ratios in 
the rural 
community and 
higher ratios in 
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the semi-rural 
community 
Ngugi, 2013; 
Ba-Diop, 2014 
Sub-Saharan 
Africa 
All ages 7.0-14.8  
Ndoye, 2005 Senegal All ages 14.2  
Preux, 2011 Cambodia All ages 5.8  
Yemadje, 
2012; 
Houinato, 2013 
Benin All ages 8.2-12.7* 
* Capture-
recapture method 
in rural 
community 
Lower ratios in 
≥15 years 
Nitiema, 2012 Burkina Faso All ages 45.0 Lifetime 
Magalov, 2012 Azerbaijan All ages 9.02  
Coleman, 2002 Gambia All ages 4.9 Lifetime 
Burneo, 2005 Latin America All ages 6.0-43.2 Lifetime 
Birbeck, 2004 Zambia All ages 12.5  
Balogou, 2007 Togo All ages 15.7  
Rajbhandari, 
2004 
Nepal All ages 7.3  
Medina, 2005 Honduras All ages 15.4  
 Cameroon All ages 104.97  
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Table 1.5. Population-based longitudinal studies on the remission rates in epilepsy 
 
Author, 
year 
Country 
(§) 
Age Follow-up 
time,  
years 
%(duration) remission 
Sillanpaa, 
2014 
Finland Children 45  61% (5-yr) 
MacDonald, 
2000; 
Lhatoo, 
2001; 
Cockerell, 
1995; 
Cockerell, 
1997;  
United 
Kingdom 
All ages 
Up to 12  
  
 
 
95% (1-yr)   
86% (3-yr) 
up to 71% (5-yr)  
54% (5-yr terminal)  
Annegers, 
1979; Berg, 
2015 
United 
States 
All ages Up to 20  76% (5-yr)  
In children 95% (1-yr), 92% (2-yr), 
89% (3-yr), 81% (5-yr)  
Wakamoto, 
2000 
Japan Children 19  62.8% (5-yr)  
Jonsson, 
2011 
Sweden All ages 10  
 
In children 75.6%  
In adults 68 % (1-yr),64% (3-yr), 
58% (5-yr)  
Geerts, 
2010 
Holland Children 15  71% (5-yr terminal) 
Camfield, 
2005 
Canada Children 8 71% (3-yr)  
Okuma, 
1981 
Japan All ages 3-10 56, 59 and 62 % (terminal 
remission)  
Nicoletti, 
2009 
Bolivia All ages 10 43.7% (5-yr)  
Houinato, 
2013 
Benin  All ages 18 months 45% (total seizure remission)  
Placencia, 
1992 
Ecuador All ages 4 21% (terminal remission)  
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Table 1.6. Community-based studies of mortality in epilepsy in high-income countries 
Author, year Country (§) Age Mortality 
measures 
Notes  
Camfield, 
2002 
Canada Children SMR 7.5  
Sillanpaa 
2013; 
Nevalainen, 
2013 
Finland All ages SMR 6.4* 
HR 3.21 
*Children 
Rakitin, 2011 Estonia Adults SMR 2.6  
Holst, 2013 Denmark < 35 years old HR 11.9  
Olafsson, 
1998; 
Rafnsoon, 
2001 
Iceland All ages SMR 1.6 
W 0.79 
M 2.25 
 
Zielinsky, 
1974 
Poland All ages SMR 1.8  
Nilsson, 1997; 
Lindsten, 2000 
Sweden  All ages SMR 2.5-3.6* *≥15 years old 
Cockerell, 
1997; Lhatoo, 
2001; Morgan, 
2002; Neligan, 
2011 
United 
Kingdom 
All ages SMR 2.1-3.0  
Hauser, 1980; 
Berg, 2004; 
Benn, 2008; 
Nickels, 2012 
United States All ages SMR 1.7-
7.54* 
Children 
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Table 1.7. Community-based studies of mortality in epilepsy in low-middle income 
countries 
Author, year Country (§) Population Mortality 
measures 
Notes  
Nicoletti, 2009 Bolivia All ages SMR 1.34  
Mu, 2011; 
Ding, 2013 
China All ages SMR 2.9-4.9 Lower ratios in a 
follow-up survey and 
higher rates in a 
prospective study  
Ngugi, 2014 Kenya All ages SMR 6.5  
Houinato, 
2013 
Benin All ages Mortality rate 
22.2 per 1,000 
 
Kochen, 2007 Argentina All ages  SMR 2.45  
Kaiser, 2007 Uganda All ages SMR 7.2  
Carpio, 2005; 
Banerjee, 2010 
India All ages SMR 0.76-
2.58* 
Lower ratio in a 
postal and telephone 
survey among the 
Parsi community and 
higher ratio in a two-
stage door-to-door 
survey of a stratified 
random sample in 
Kolkata 
Kamgno, 2003 Cameroon All ages Mortality rate 
28.9 per 1,000 
 
Carpio, 2005 Mali All ages Mortality rate 
34.9 per 1,000 
 
Tsai, 2005 Taiwan All ages Mortality rate 
0.8 per 
100,000 
 
Carpio, 2005 Ecuador All ages  SMR 6.3  
Carpio, 2005 Martinique  All ages SMR 4.25  
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1.5 Aims of the PhD thesis 
As indicated above, epilepsy is a chronic clinical condition affecting both sexes and all ages 
with worldwide distribution; the disease can be also defined as a symptom complex arising from 
a number of disordered brain functions, which may be secondary to a variety of pathologic 
phenomena. The heterogeneity of the epilepsies, some of them rare and/or difficult to ascertain, 
raise a number of unsolved problems.   
Open questions include, among others: 
- Still about one-third of patients seen in epilepsy centers have non-epileptic attacks, most 
of which of psychogenic origin; the early identification of these attacks is still a matter 
of debate; 
- For several clinical conditions characterized by epilepsy associated with intellectual 
disability and abnormal behavior, there is a virtual lack of clinical diagnostic criteria as 
the phenotype is fairly unspecific; 
- The distribution of DRE and the prognostic patterns in well-defined population-based 
samples are still ill-defined. 
The ultimate aim of my thesis is to contribute to a better definition of the phenotype of epilepsy 
by helping to exclude diseases that could fall in the differential diagnosis (e.g. PNES), predicting 
the diagnosis of an epileptic syndrome based on an accurate assessment of the phenotype, and 
investigating the outcome of the disease in relation to the response to the available treatments 
along different pathways: 
1-using epilepsy as marker of disease; 
2- analyzing the response to treatment as a marker of the prognosis of the disease; 
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3- using samples representative of the general population.  
To fulfill this aim, I worked on three subprojects:  
1. The study of the phenotypes of non-epileptic seizures of psychogenic origin.  
2. The validity of the diagnosis of INV-Dup 15, a rare genetic epilepsy syndrome with a non-
specific phenotype; 
3. The assessment of the prevalence, incidence, the long-term prognosis and treatment response 
of DRE in a well-defined population.  
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2. Introducing the characterisation studies 
The first two projects presented in the next two sections of my thesis consist of two studies on 
the characterisation of two different conditions: 
- The first is PNES, a borderline condition between neurology and psychiatry with greatly 
variable manifestations that often resemble those of epileptic seizures.  
- The second is a genetic syndrome with an unspecific phenotype in which epilepsy is a 
common clinical feature, idic(15) syndrome; 
The aim of these two studies is to characterise the diagnosis of PNES and idic(15) syndrome 
without the gold standard diagnostic instruments, that are respectively the VEM (PNES) and the 
genetic analysis (idic(15)) and to identify clinical signs and symptoms able to discriminate with 
high specificity and sensitivity these two different conditions. 
Previous reports, that are part of my PhD program, have been completed in the framework of 
the PNES MI-RO project: 
- Erba G, Bianchi E, Giussani G, Langfitt J, Juersivich A, Beghi E. A new patient-oriented 
questionnaire for differentiating epileptic from psychogenic non-epileptic seizures. Value, 
limitations, future directions. JNNP 2017 (submitted). 
- Beghi M, Erba G, Cornaggia CM, Giussani G, Bianchi E, Porro G, Russo M, Beghi E. 
Engaging Psychiatrists in the diagnosis of PNES. What can they contribute? Seizure 2017 
(submitted). 
- Erba G, Beghi E, Magaudda A, Bianchi E, Giussani G, Di Rosa G, Laganà A, Chiesa V, 
Juersivich A, Langfitt J. In response: Towards a quantitative assessment of psychogenic 
nonepileptic seizures. Epilepsia,2016;57:1011-2.  
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-Erba G, Giussani G, Juersivich A, Magaudda A, Chiesa V, Laganà A, Di Rosa G, Bianchi E, 
Langfitt J, Beghi E. The semiology of psychogenic nonepileptic seizures revisited: Can video 
alone predict the diagnosis? Preliminary data from a prospective feasibility study. Epilepsia, 
2016;57:777-85. 
 
 
3. The MI-RO PNES Project 
Abstract 
The first aim of this study was to investigate if, when and to what extent, a paroxysmal event 
captured on video and interpreted by epileptologists could contribute to the differential 
diagnosis without EEG. This information would be particularly relevant when the EEG is not 
available or in case clinicians may elect to screen the events of patients with mixed seizure 
disorders on video before referral to a monitoring unit. Five neurologists were asked to review 
23 videos of seizures events of 21 unselected consecutive patients admitted for video-EEG 
monitoring (VEM). They were asked to rate the videos for quality and content, and to choose 
the correct diagnosis among epileptic seizures (ES); PNES; Other nonepileptic seizures (NES); 
“Cannot Say”. They were also requested to explain in their words the reasons they considered 
to reach the diagnosis. In about 1/3 of cases, a confident diagnosis of PNES/ES based on the 
analysis of video data alone can be established. Our results benefit all affected patients, 
particularly those with no access to VEM units.  
The second aim was to verify if four psychiatrists blinded to the diagnosis could predict the 
diagnosis of psychogenic non-epileptic seizures (PNES) by reviewing videos of seizures of 
various types and to compare the accuracy and the criteria leading to the diagnosis by the 
psychiatrists with those used by epileptologists, using the same methodology. Psychiatrists were 
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found to be less accurate than neurologists in diagnosis PNES but were more attuned to capture 
the subtleties of human behaviour, or subjective experiences as the effects of hidden internal 
conflicts, contributing a new lexicon in defining PNES. 
The last aim was to investigate if two ad-hoc questionnaires investigating semiology and 
comorbidities of PNES coud be an alternative diagnostic tool when VEM is not available or not 
able to capture events. The two instrument assembled in this study, one for patient and one for 
their witnesses demonstrate to be useful tools, as they helped identifying variables predicting 
PNES diagnosis. Seven variables with high sensitivity (SE) and specificity (SP), of which 5 
statistically significant, emerged as diagnostic predictors from patients questionnaire. They 
comprised three historical items: head injury, physical abuse and chronic fatigue; two warning 
signs: heart racing and tingling or numbness; one triggering sign: headache; one postictal 
symptom: physical pain. Side-to-side head movements and eyes closed were the statistically 
significant variables emerged from the analysis of witness questionnaire.  
  
3.1 PREDICTING THE DIAGNOSIS OF PSYCHOGENIC NON EPILEPTIC 
SEIZURES (PNES) VERSUS EPILEPTIC SEIZURES (ES). 
3.1.1 Introduction 
The diagnosis of PNES constitutes a major challenge, because of greatly variable 
manifestations, often resembling those of epileptic seizures (ES) (Gedzelman and LaRoche, 
2014). No single feature has proved to be pathognomonic, although a recent study found that 
the diagnosis is associated with a distinct cluster of signs (Syed et al 2011). As said before, the 
gold standard (GS) for a definitive diagnosis of PNES is the documentation of a normal EEG 
during events with semiology and a patient’s history consistent with the diagnosis of PNES. 
Thus, the GS implies accessibility to a monitoring unit with specialized reviewers and services. 
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Nonetheless, VEM could fail to capture the events, despite induction attempts, and it will not 
differentiate certain types of frontal lobe ES from PNES. Moreover, the diagnosis of PNES, 
depends primarily on clinician’s judgment and, unlike epilepsy, its reliability cannot be 
objectively verified by pathology or treatment outcome. 
In an attempt to assess the accuracy of VEM, 22 board certified neurologists actively practicing 
in epilepsy centers from USA and Europe were asked to predict the diagnosis in 22 consecutive 
patients with mixed seizure types (PNES, ES and other nonepileptic events) based exclusively 
on VEM (Benbadis et al, 2009). Interrater agreement was moderate across all 3 diagnostic 
categories (k = 0.57) and was moderate for PNES (k = 0.57; substantial for ES (k = 0.69) and 
low for other nonepileptic episodes. The conclusion was that the diagnosis of these disorders 
based on combined VEM data presents inherent difficulties and particularly it might be affected 
by subjective components. Furthermore, adherence to current standard of care will prevent or 
delay the diagnosis in many patients worldwide who have no access to a VEM facility.  
The ILAE task force considered advantages and limitations of home-recorded videos but did 
not recommend their use because the diagnostic yield of typical events recorded by witnesses 
has not been properly evaluated. Of the two modalities used in VEM, video recording is 
technically easier to obtain and less expensive than a video with simultaneous EEG. An earlier 
study demonstrated that, in a proportion of cases, neurologists could make a confident diagnosis 
of ES/PNES based entirely on videotapes recorded by hospital staff with a handheld camcorder 
(Samuel and Duncan, 1994). More recent studies have confirmed that the differential diagnosis 
between ES and PNES based on video alone is possible but requires neurological training (Ristić 
et al, 2015). Training of medical students through video-based modules of ES and PNES 
improves accuracy of seizure diagnosis (Seneviratne et al, 2014). It has been also demonstrated 
that trained epileptologists, blind to the EEG, contrary to untrained eyewitnesses, could easily 
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recognize key signs characteristic of either syndrome simply analyzing seizures on video, (Syed 
et al, 2011). Thus, there is evidence that in the hands of capable reviewers, video monitoring 
alone could represent a useful clinical tool.  
The aim of this study was to investigate if, when and to what extent, a paroxysmal event captured 
on video and interpreted by experts in epilepsy could contribute to the differential diagnosis 
without the aid of simultaneous EEG. This information would be particularly relevant when the 
simultaneous EEG is not available or in case clinicians may elect to screen the events of patients 
with mixed seizure disorders on video before referral to a monitoring unit. 
 
3.1.2 Methods 
This study is part of a larger project currently in progress between the University of Rochester 
(UR) and three Italian Institutions: IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”, 
Milan; University of Messina, and Azienda Ospedaliera San Paolo, Milan, Italy. The study was 
approved by the Research Subject Review Board (RSRB) of the UR.  
3.1.2.1 Patients 
Patients 18 years and older consecutively admitted between July 1 and September 10, 2014 at 
the UR were asked to participate. Patients were excluded if they lacked intellectual capacity to 
answer questionnaires designed for the project. We enrolled prospectively all patients who 
consented. For each of them, at discharge, a representative audio-video segment, deprived of 
the EEG tracing, was submitted to five independent raters, for review and prediction of 
diagnosis. An epileptologist/electroencephalographer chose the most significant video of the 
seizures of each patient, among all the events recorded during VEM, that was used to reach the 
gold standard diagnosis in the Univeristy of Rochester Unit. Each video was clipped starting 20 
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minutes before and ending 20 minutes after the seizure event. Where possible, videos included 
testing of patient’s responsiveness by staff.  
 
3.1.2.2.  Raters 
The five raters were USA board certified neurologists/child neurologists (or the Italian 
equivalent) all practicing full time in tertiary Epilepsy Centers. The four raters from the Italian 
Institutions (R-1, R-2, R-3, R-4), were blind to the EEG findings, to the patient’s history and 
comorbidities and were unaware of the final diagnosis. The fifth rater (R-5) was a faculty 
member of the epilepsy unit at UR. Though not responsible for direct patient care during the 
admission, R-5 was not blind but was specifically instructed not to access history, lab results or 
additional vignettes while reviewing the submitted video. This rater was included to investigate 
how awareness of ancillary clinical information would influence the rating. 
Individual raters’ profiles are reported in Table 3.1.1. All raters received their training through 
an epilepsy/clinical neurophysiology fellowship. 
 
3.1.2.3.  Procedure  
Each rater was asked to review each video and render a diagnosis based only on audiovisual 
information. Raters were also asked if the video was technically satisfactory and “adequate”, 
providing all the information necessary for the diagnosis and, if not, why. We considered a video 
adequate for the task if at least 3/5 raters agreed that the video was sufficiently informative. 
Raters were given four diagnostic options and forced to choose one among the following: 1) ES, 
defined according to the 1981 ILAE classification (Commission 1981); 2) PNES, classified 
according to the six categories proposed by Seneviratne et al. (Seneviratne er al 2010): 1. 
Rhythmic motor; 2. Hypermotor; 3. Complex motor; 4. Dialeptic; 5. Nonepileptic auras; 6. 
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Mixed; 3) Other NES, due to paroxysmal non-epileptic events other than psychogenic (syncope 
or other dysautonomic manifestations, migraine, movement disorder, panic attacks, etc.); 4) 
“Cannot Say”. 
 In addition, raters had to specify the main reasons leading to the diagnosis of choice and 
describe any behavioural observations contributing to their diagnostic decision.  
Each rater worked independently and filed the data into a database set up at the IRCCS-Istituto 
di Ricerche Farmacologiche “Mario Negri” in Milano, Italy for statistical analysis.  
Diagnostic accuracy was assessed as the ability of each rater to correctly predict the GS 
diagnosis, based on audiovisual evidence alone. The GS diagnosis was that established by the 
clinical team after a comprehensive evaluation of the patient’s risk factors, co-morbidities, 
psychosocial status, results of neurological exam and neuro-imaging, video semiology, EEG 
findings including purely electrical seizures, and the results of monitoring other physiologic 
parameters (ECG, blood pressure, orthostatic testing, blood sugar, etc.) as appropriate. Accuracy 
in predicting the GS diagnosis was presented as the proportion of raters that correctly predicted 
the GS.      
Inter-rater agreement was calculated among all raters, between pairs of raters, and between each 
rater and the GS using Fleiss’ Kappa (Fleiss, 1971), with 95% confidence intervals (CI). Kappa 
values were used to assess overall agreement across all diagnostic categories (PNES, ES, Other 
NES, Cannot Say), and agreement in differentiating between the diagnosis of ES, PNES, Other 
NES and Cannot Say. Kappa values were classified as poor (<0.00), slight (0.01–0.20), fair 
(0.21–0.40), moderate (0.41–0.60), substantial (0.61– 0.80), almost perfect (0.81–1.00) (Landis 
and Koch, 1977). This classification of the magnitude of Kappa values is only for descriptive 
aims and does not refer to statistical significance. Data were analyzed using the SAS statistical 
package (version 9.2; SAS Institute Inc, Cary, NC, USA).  
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For each seizure that was reviewed, each rater’s comments were surveyed and a list was 
compiled of all individual signs or symptoms identified as significant and their relative 
frequency. In addition, any specific observations (the sequence of certain manifestations, 
patient’s affect, incongruous behaviour) was noted underpinning the raters’ diagnostic 
reasoning. 
  
3.1.3 Results  
A total of 21 patients were enrolled. Each had at least one typical event recorded on video. 
Twenty patients reported one type of event. Case # 3 reported three types of events (3a, 3b, 3c.). 
Therefore, 23 videos were submitted to each rater for review.  
 
3.1.3.1 Video quality 
Raters considered “adequate” 10 of the 23 videos submitted (43%) whereas 13/23 (57%) were, 
in their judgement, “inadequate”. This was mainly due to technical deficiencies or insufficient 
information (i.e., patient responsiveness not tested or incompletely tested, patient out of screen 
or poorly visible, defective audio). 
 
3.1.3.2. Raters’ accuracy in predicting the diagnosis 
Table 3.1.2 shows the degree of concordance between raters’ diagnostic predictions and GS 
diagnosis. The table includes the two cases (#7 and #16) where the clinical team had reached no 
definite diagnosis (NDD).  
All five raters were correct in predicting the diagnosis in 7/23 cases (30.4%). Of these, three had 
ES and four PNES. In contrast, none of the five raters was in agreement with the GS diagnosis 
in 5/23 cases (21.7%): three had Other NES, one PNES and one NDD. 
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 The ability to predict the diagnosis in the remaining 11 cases was intermediate (Table 3.1.2).  
Since raters predicted the diagnosis based on the information contained in the video, each event 
was reviewed in order to try to identify the clues influencing the raters’ decision. Success (5/5 
raters correct) was related to events characterized predominantly by motor manifestations 
whereas failure (0/5 raters correct) was related to events characterized mainly by subjective 
sensory symptoms. Figure 3.1.1 shows the correlation between different degrees of accuracy 
and type of events recorded on video (motor in red, non-motor in blue). Success rate was higher 
for ES and PNES with motor manifestations and lower for Other NES, ES or PNES with no 
motor manifestations. Moreover, the number of signs identified as significant by the reviewer 
(shown in Table 3.1.3) seemed to correlate with accuracy. In the group of 7 videos correctly 
predicted by all raters the total number was 56, (average 8 signs/video, range: 5-11) compared 
to 20 in the group of 5 videos where all raters had failed (average 4 signs/video, range: 1-8).  
Finally, to assess the influence of video quality on raters’ accuracy, the rate of success was 
mapped against video quality as perceived by the reviewers. Out of the 7 cases where all raters 
were correct, 5 videos were adequate and 2 not adequate. In contrast, in the 5 cases where all 
raters had failed, the proportion was reversed with 1 video adequate against 4 not adequate. 
 
3.1.3.3.  Interrater agreement 
The overall agreement among athe 5 raters was moderate (k= 0.52, 95% CI 0.44-0.60). The 
agreement was moderate for ES diagnosis (k=0.53, 95% CI 0.39-0.67), substantial for PNES 
(k=0.63, 95% CI 0.49 - 0.77), and fair for Other NES (k=0.21, 95% CI 0.07-0.35). 
Table 3.1.4 shows inter-rater agreement within each pair of raters and between each rater and 
the GS. Combining all diagnoses, agreement between pairs of raters was higher between R-1 
and R-2 (k=0.73), R-4 and R-5 (k=0.69), R-1 and R-5 (k=0.63). The pairs with the highest 
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agreement varied when limiting the diagnosis to PNES and ES (Other NES excluded). The 
overall agreement was in the moderate range for raters R-5 (k=0.58), R-4 (k=0.56), R-1 
(k=0.49); it was substantial or above for two of the diagnostic categories: respectively, 0.81, 
0.63, 0.82 for PNES; 0.90, 0.81, 0.81 (almost perfect) for ES. It was remarkably lower for Other 
NES. In comparison, kappa values for raters R-2 and R-3 were lower in all categories.  
For all videos, agreement among the 5 raters was only slightly higher when inadequate videos 
were excluded (k=0.59, 95% CI 0.45-0.63). 
 
3.1.3.4. Video content and raters’ strategy leading to the diagnosis of choice. 
Table 3.1.3 lists in order of decreasing frequency and by diagnostic category the specific terms 
used by raters to describe the signs that caught their attention. The observable signs and 
symptoms reported for the ES and PNES categories, where raters were most accurate in 
predicting the diagnosis, were by far more numerous than for the Other NES and Cannot Say 
categories.  
The term “semiology” was the most frequently mentioned, either as positive statement, to 
indicate that it was a key element to the diagnosis, mostly in the case of ES and PNES, or as 
negative, to state that it was not consistent with either ES or PNES or was not sufficiently 
definable, that was most likely the case of Other NES.  
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3.1.4 Tables and Figure 
Table 3.1.1. Individual profiles of raters 
 R-1 R-2 R-3 R-4 R-5 
Age (years) 56 48 39 39 32 
Title 
Neurologist, 
child 
neurologist 
Neurologist Child neurologist Neurologist Neurologist 
Caring for patients with epilepsy 
(years) 
30 15 9 9 2.5 
Monthly hours for  
patients with epilepsy 
50 60 30 150 100 
Monthly visits for patients with 
seizures 
25-50 >50 >50 >50 >50 
Adults/children 90% adults 90% adults 100% children 99% adults 
75% adults, 25% 
children 
Blind to patients' info and EEG Yes Yes Yes Yes No 
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Table 3.1.2. Accuracy of raters in predicting the diagnosis 
Vide
o 
Adequa
cy of 
video 
Semiolo
gy 
Gold standard  
 
Reviewer diagnosis Accuracy 
   
Diagnos
is 
Seizure 
type 
 
R-1 R-2 R-3 R-4 R-5  
1 Yes Motor ES 
Focal with 
sec. gen. 
 
ES ES PNES ES ES 4/5 
2 No 
Non-
motor 
Other 
NES 
Dysautono
mic  
 
CANNOT 
SAY 
CANNOT 
SAY 
PNES PNES 
CANN
OT 
SAY 
0/5 
3a No Motor PNES 
Complex 
motor 
 
PNES PNES PNES PNES PNES 5/5 
3b No Motor PNES Mixed  PNES Es PNES PNES PNES 4/5 
3c No 
Non-
motor 
PNES 
Non-
epileptic 
aura 
 
CANNOT 
SAY 
ES 
CANNOT 
SAY 
CANNOT 
SAY 
CANN
OT 
SAY 
0/5 
4 Yes Motor PNES 
Rhytmic 
motor 
 
PNES PNES PNES PNES PNES 5/5 
5 No Motor ES 
Focal with 
sec. gen. 
 
ES ES PNES ES ES 4/5 
6 No Motor PNES 
Rhytmic 
motor 
 
PNES PNES PNES PNES OTHER 4/5 
7 Yes 
Non-
motor 
NDD 
-  
PNES PNES PNES PNES OTHER 0/5 
8 Yes Motor ES 
Focal with 
sec. gen. 
 
ES ES ES ES ES 5/5 
9 Yes Motor PNES 
Rhytmic 
motor 
 
PNES PNES PNES 
CANNOT 
SAY 
PNES 4/5 
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10 Yes Motor ES 
Focal with 
sec. gen. 
 
ES ES ES ES ES 5/5 
11 Yes Motor ES 
Focal with 
sec. gen. 
 
ES ES ES ES ES 5/5 
12 No 
Non-
motor 
Other 
NES 
Dysautono
mic  
 
CANNOT 
SAY 
ES 
CANNOT 
SAY 
ES 
CANN
OT 
SAY 
0/5 
13 No Motor ES 
Focal with 
sec. gen. 
 
ES ES OTHER 
CANNOT 
SAY 
CANN
OT 
SAY 
2/5 
14 Yes 
Non-
motor 
ES 
Simple 
Focal 
 CANNOT 
SAY 
CANNOT 
SAY 
CANNOT 
SAY 
ES ES 2/5 
15 Yes Motor ES 
Complex 
Focal 
 
ES PNES PNES ES ES 3/5 
16 No 
Non-
motor 
NDD 
-  
ES ES 
CANNOT 
SAY 
CANNOT 
SAY 
CANN
OT 
SAY 
3/5 
17 No 
Non-
motor 
PNES 
Non-
epileptic 
aura 
 
PNES PNES 
CANNOT 
SAY 
PNES PNES 4/5 
18 No 
Non-
motor 
Other 
NES 
Dysautono
mic  
 CANNOT 
SAY 
CANNOT 
SAY 
OTHER OTHER OTHER 3/5 
19 Yes Motor PNES 
Complex 
motor 
 
PNES PNES PNES PNES PNES 5/5 
20 No 
Non-
motor 
Other 
NES 
Dysautono
mic 
 
CANNOT 
SAY 
CANNOT 
SAY 
CANNOT 
SAY 
CANNOT 
SAY 
CANN
OT 
SAY 
0/5 
21 No 
Non-
motor 
PNES 
Dialeptic  
PNES PNES PNES PNES PNES 5/5 
 
Legend: ES= epileptic seizures; PNES= psychogenic non-epileptic seizures; NES= non-epileptic seizures. 
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Table 3.1.3. Signs and symptoms leading to the diagnosis 
Signs  Compound 
frequency  
ES PNES Other 
NES 
CANNOT 
SAY 
Semiology 28 
1, 5, 10, 11, 14, 
15 3a, 3b, 4, 6, 17, 19, 21 2, 18, 20 7 
Wax/waning 21 1, 15 
3a,3b, 4, 6, 9, 17, 19, 
21   7 
Subjective feelings 17 
 
3c, 4,  17 12, 18, 20   
Automatisms 13 5, 8, 10, 13, 15       
Shaking 11 1, 15 3a, 4, 6, 9,    7 
Long duration 10   3a, 3b, 4, 9, 17, 19 2   
Dystonic posturing 10 1, 5, 8, 10, 15 3b, 4, 19, 21     
Slow Post-ictal recovery 10  5, 8, 10, 11, 14 3b     
Short duration  9  5, 10, 11, 15 3c 18   
Eyes close 8   3a, 4, 19, 21     
[Forced] head deviation 8 1, 5, 10, 11, 15       
Expression of emotionality 7 
 
4, 17     
Modality of onset: out of 
sleep 7 1, 8, 13   2   
Eyes open 6 5, 8, 10       
Increased tone 6 1, 5, 10, 11  9     
Crying 6   21   7 
Loss of consciousness 6 5, 10, 11, 15 3b, 3c     
Preserved consciounsess 6   3a, 3b,  2 7, 16 
Tremors 5   3a, 3b, 6   7 
Slumping 5 
 
3a, 19, 21     
Modality of onset: abrupt 5 5, 10 4, 9, 21     
Modality of onset: gradual 5 15 3a, 3b, 9     
Confusion 4 8, 10, 14       
Fast Post-ictal recovery 4 
 
3a, 3c, 4     
Asynchrony 3 1,5,10       
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Tingling 2   3c, 21     
Arrhythmicity 1 
 
19     
Internal sensation 1       7 
Visual distortion 1 
 
    16 
Hyperventilation 1       7 
Synchrony 0 0       
Rhythmicity 0 0       
 
Legend: ES= epileptic seizures; PNES= psychogenic non-epileptic seizures; CANNOT SAY= no diagnosis possible.  
Numbers in the table refer to the specific seizure-video for which that particular sign was mentioned as being significant. 
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Table 3.1.4. Interrater agreement 
  Overall  PNES  ES  Other NES 
Pair Kappa 95% CI  Kappa 95% CI  Kappa 95% CI  Kappa 95% CI 
R-5 vs. R-1 0.63 0.38 - 0.88  0.81 0.40 - 1.00  0.70 0.29 - 1.00  -0.07 -0.48 - 0.34 
R-5 vs. R-2 0.37 0.12 - 0.62  0.62 0.21 - 1.00  0.35 -0.06 - 0.76  -0.07 -0.48 - 0.34 
R-5 vs. R-3 0.44 0.19 - 0.69  0.37 -0.04 - 0.78  0.49 0.08 - 0.90  0.33 -0.08 - 0.74 
R-5 vs. R-4 0.69 0.44 - 0.94  0.62 0.21 -1.00  0.90 0.49 - 1.00  0.45 0.04 - 0.86 
R-1 vs. R-2 0.73 0.44 - 1.00  0.82 0.41 - 1.00  0.63 0.22 - 1.00  -* - 
R-1 vs. R-3 0.48 0.21 - 0.75  0.56 0.15 - 0.97  0.40 -0.01 - 0.81  -0.05 -0.46 - 0.36 
R-1 vs. R-4 0.54 0.27 - 0.81  0.82 0.41 - 1.00  0.62 0.21 - 1.00  -0.02 -0.43 - 0.39 
R-2 vs. R-3 0.34 0.07 - 0.61  0.56 0.15 - 0.97  0.25 -0.16 - 0.66  -0.05 -0.46 - 0.36 
R-2 vs. R-4 0.40 0.11 - 0.69  0.63 0.22 - 1.00  0.45 0.04 - 0.86  -0.02 -0.43 - 0.39 
R-3 vs. R-4 0.48 0.23 - 0.73  0.56 0.15 - 0.97  0.40 -0.01 - 0.81  0.64 0.23 - 1.00 
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R-5 vs. GS 0.58 0.33 - 0.83  0.81 0.40 - 1.00  0.90 0.49 - 1.00  0.15 -0.26 - 0.56 
R-1 vs. GS 0.49 0.24 - 0.74  0.82 0.41 - 1.00  0.81 0.40 - 1.00  -0.10 -0.51 - 0.31 
R-2 vs. GS 0.35 0.08 - 0.62  0.63 0.22 - 1.00  0.45 0.04 - 0.86  -0.10 -0.51 - 0.31 
R-3 vs. GS 0.30 0.05 - 0.55  0.39 -0.02 - 0.80  0.40 -0.01 - 0.81  0.23 -0.18 - 0.64 
R-4 vs. GS 0.56 0.31 - 0.81  0.63 0.22 - 1.00  0.81 0.40 - 1.00  0.32 -0.09 - 0.73 
 
*No reviewers give the response “Other”. Legend: PNES= psychogenic non-epileptic seizures; ES= epileptic seizures. 
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Figure 3.1.1. Correlation between accuracy and type of events 
 
 
 
Legend: Figure 1 shows the association between degrees of accuracy (x axis) and type of 
events recorded on video (number of videos on y axis): motor PNES in blue with dots, motor 
ES in blue with orizontal lines, non-motor PNES in red with dots, non-motor ES in red with 
orizontal lines and other NES/cannot say in red with vertical lines. 
ES= epileptic seizures; PNES= psychogenic non-epileptic seizures; NES= non-epileptic 
seizures. 
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3.2 Engaging Psychiatrists in the diagnosis of PNES. What can they contribute? 
3.2.1 Introduction 
The second step of the MI-RO Study was to investigate if, how, and to what extent a group 
of psychiatrists could predict the diagnosis on pure visual information, reviewing blindly the 
same videos submitted to epileptologists in the previous part of the study, and to compare 
the accuracy as well as the criteria leading to the diagnosis of the psychiatrists against the 
epileptologists. 
Based on the results of previous trials challenging various categories of medical providers 
in comparison to fully trained epileptologists (Syed et al, 2011; Samuel et al, 1994; Ristić et 
al 2015; Seneviratne et al, 2014; MacDonald et al, 2014), our expectation was that 
psychiatrists would fail, mainly because largely unfamiliar with the semiology of ES and 
because the characteristic features that distinguish ES from PNES reflect neurological 
measures predominantly reported by epileptologists. 
3.2.2 Methods 
The study population is the same reported in the previous step of the MI-RO Study (Erba et 
al, 2016). 
3.2.2.1 Raters and Procedure 
Unlike the previous study, the four raters were board certified psychiatrists, with varying 
degree of seniority, of knowledge about epilepsy and exposure to patients with seizure 
disorders (Table 3.2.1). Each rater was blind to the EEG findings, to the patient’s history and 
comorbidities, and unaware of the final diagnosis established by the clinical team. The task 
was to review the same videos submitted to epileptologists in the previous study [8] and 
render a diagnosis out of the following options:   
 ES, defined according to the 2017 ILAE classification (Fisher et al, 2017); 
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 PNES, classified according to the six categories proposed by Seneviratne et al 
(2010): 1. Rhythmic motor, 2. Hypermotor, 3. Complex motor, 4. Dialeptic, 5. 
Nonepileptic auras, and 6. Mixed;  
 Other nonepileptic seizures (NES), due to paroxysmal nonepileptic events other than 
psychogenic (syncope or other dysautonomic manifestations, migraine, movement 
disorder, panic attacks, etc.);  
  “Cannot Say.”  
In addition, raters had to specify the reasons leading to the diagnosis and describe any 
behavioural observations contributing to their diagnostic decision. 
Each rater worked independently and filed the data into a database set up at the IRCCS-
Pharmacological Research Institute “Mario Negri” in Milano, Italy, for statistical analysis. 
Diagnostic accuracy was assessed as the ability of each individual rater to correctly predict 
the GS diagnosis, based on audiovisual evidence alone. The GS diagnosis was the result of 
a comprehensive evaluation of multiple factors. These included the patient’s risk factors, 
comorbidities and psychosocial status; neurological, neuroimaging, interictal EEG findings 
and the characterization of the events (when recorded). This was based on video semiology, 
ictal EEG findings (including purely electrical seizures), and the results of monitoring other 
physiologic parameters such as electrocardiography, blood pressure, orthostatic testing, 
blood sugar, and so on as appropriate. In the two cases where by GS no diagnosis was 
possible (NDP), the rater’s response “Cannot say” was considered correct. Raters’ accuracy 
in predicting the GS diagnosis was presented as the proportion of raters that correctly 
predicted the GS. 
3.2.2.2 Statistical analysis 
As with the diagnosis made by the epileptologists, interrater agreement was calculated 
among all raters, between pairs of raters, and between each rater and the GS using Fleiss’ 
Kappa (Fleiss, 1971) with 95% confidence intervals (CIs).  
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3.2.3 Results 
Table 3.2.2 correlates the clinical characteristics of the 23 events submitted for review with 
the accuracy of the four blind psychiatrists vs. four blind epileptologists in predicting the GS 
diagnosis as a group and as individual raters.  
All four psychiatrists were concordant and correct (4/4) in 3/23 video-events, compared to 
8/23 when raters were trained epileptologists. The superiority of the epileptologists is also 
apparent when the concordance in accurately predicting the diagnosis for each individual 
video was < 4/4 (i.e.: 3/4; 2/4; 1/4; 0/4). Comparison between the two groups shows 12 
points (+) advantage in favor of the epileptologists compared to 4 points in favor of the 
psychiatrists.  
Kappa values confirm the discrepancy between the two groups. While overall concordance 
among the four epileptologists was 0.50, it was 0.18 among the four psychiatrists, similar 
differences are found in the Kappa values by type of seizures, varying from 0.20 to 0.66 
(epileptologists) and from -0.03 to 0.21 (psychiatrists) (Table 3.2.3). Likewise, agreement 
within pairs of epileptologists showed Kappa values varying from 0.34 to 0.73 (Table 3.2.4) 
whereas agreement among pairs of psychiatrists was much lower, ranging from –0.2 to 0.37 
(Table 3.2.5). Surprisingly, however, agreement of each individual rater with the GS yielded 
superimposable K values in the two groups, ranging from 0.30 to 0.56 among epileptologists 
(Table 3.2.4) and from 0.01 to 0.45 among psychiatrists (Table 3.2.5). Therefore, despite 
widespread disagreement among themselves and frequent failures as a group, our results 
indicate that individual psychiatrists were almost as accurate as epileptologists in predicting 
the correct diagnosis after reviewing the same events recorded on video.  
Success or failure was not correlated to any particular type of event (epilepsy, psychogenic, 
other physiologic or cannot say). However, raters PS3 and PS4 chose the diagnosis “Cannot 
say” more often (7/23) than PS1 and PS2 (3/23) while the epileptologists were less variable 
(6/23, R1 and R3; 4/23, R-2; 5/23, R-4). 
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The comments provided by the four psychiatrists to justify the diagnosis of choice varied 
considerably in format and detail from rater to rater, with PS1 being the most attentive and 
articulate. In essence, like the epileptologists, psychiatrists paid considerable attention to 
body movements, ostensibly the most obvious signs of the events’ semiology exhibited on 
video. Starting from the body parts involved, they considered head/eyes/mouth deviation 
and lateralized limb posturing as clear indicators of ES versus predominant involvement of 
trunk/hips/fingers as suggestive of PNES. Similarly, they remarked on resistance to eye 
opening, ‘one single shake’, sudden onset or abrupt interruption, ‘on/off’ and high frequency 
movements as indicators of PNES, but also emphasised more subtle behavioural aspects 
such as ‘slow motion’, irregular, unpredictable, shaking. Likewise, they often failed to see 
the progression of movements from tonic to clonic, from fast to slow, from focal to 
generalized to the more disorganized motions defined as other “non-epileptic” or pseudo-
myoclonic. Finally, while directly mentioning specific types of movement as ‘side-to-side’ 
or ‘out of synchrony’, they preferred describing pelvic thrusting as ‘arc de circle’ or ‘hips 
more involved’ or ‘body motions with sexual connotations’.  
Special attention was given to the presence of “automatisms”, distinguishing stereotyped, 
out of context, complex motor activity (such as aimlessly looking around), typical of 
complex focal seizures, from comparable motor manifestations that, at close scrutiny, 
appeared more purposeful or deliberate such as ‘subject puts herself at the center of attention’ 
(17) or ‘slow movements of one hand only’ (3b) or both hands (21) and more “in context” 
such as ‘movements of postural adjustment’ or ‘mirror movements’ imitating the examiner 
(3a) or ‘partially in touch with the context but distant, as if confused or waiting to gain time’ 
(14). Likewise, certain gestures such as ‘bringing hands to the chest’ or to the head ‘as if in 
pain’ or ‘holding arms by the breasts’ (3b, 4) were interpreted by psychiatrists as indicative 
of an inner conflict or suffering. With few exceptions, most of these observations were 
mentioned to support the diagnosis of PNES. 
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Finally, psychiatrists pointed out a number of motor system’s inconsistencies such as 
‘holding up a seemingly hypotonic arm’, ‘falling without body hypotonia’ or discrepancies 
such as the incompatible association between level of consciousness and myoclonic 
movements’ (3b), as well as behavioural inconsistencies such as the subject’s calm, ‘almost 
placid’ appearance during motor arrest ‘while holding hand with the nearest person’ (21). 
Table 3.2.6 shows a series of representative comments typically made by psychiatrists 
correlating each observation with the number of videos, the rater, the rater’s diagnosis and 
the GS diagnosis.  
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3.2.4 Tables 
Table 3.2.1. Individual profile of raters. 
Rater Years in 
practice 
Formal 
education 
in epilepsy 
(Yes/No) 
N. of patients with 
seizure disorders 
seen 
during clinical 
practice 
Degree Specialty 
training 
PS1 30 YES Hundreds MD Psychiatry 
PS2 12 YES 6/year MD Psychiatry 
PS3 30 NO 15/year MD Psychiatry 
PS4 10 NO 15/year MD Psychiatry 
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Table 3.2.2. Accuracy of psychiatrists vs. epileptologists in predicting the gold standard diagnosis 
Video Semiology Gold standard PS1 PS2 PS3 PS4 Psychiatrists’accuracy Epileptogists’ accuracy 
1 Motor ES ES PNES ES ES 3/4 3/4 
2 Non-motor Other ES Cannot say PNES ES 0/4 0/4 
3a Motor PNES PNES PNES PNES PNES 4/4 4/4 
3b Motor PNES PNES PNES ES PNES 3/4 3/4 
3c Non-motor PNES PNES Cannot say Cannot say Other   1/4 + 0/4 
4 Motor PNES PNES PNES PNES Cannot say 3/4    4/4 + 
5 Motor ES ES ES ES PNES 3/4 3/4 
6 Motor PNES Cannot say PNES Other Cannot say 1/4        4/4 + + + 
7 Non-motor NDP PNES Other Cannot say PNES   1/4 + 0/4 
8 Motor ES ES PNES ES ES 3/4   4/4 + 
9 Motor PNES ES PNES PNES ES 2/4   3/4 + 
10 Motor ES ES ES ES PNES 3/4   4/4 + 
11 Motor ES ES ES ES ES 4/4 4/4 
12 Non-motor Other Cannot say ES Cannot say Cannot say 0/4 0/4 
13 Motor ES ES ES ES Cannot say    3/4 + 2/4 
14 Non-motor ES Other ES Cannot say Cannot say 1/4 1/4 
15 Motor ES ES ES ES PNES    3/4 + 2/4 
16 Non-motor NDP Other ES Cannot say PNES 1/4    2/4 + 
17 Non-motor PNES Other Cannot say Cannot say PNES 1/4      3/4 + + 
18 Non-motor Other Other Other Cannot say Cannot say 2/4 2/4 
19 Motor PNES Other PNES PNES ES 2/4      4/4 + + 
20 Non-motor Other Cannot say ES ES Cannot say 0/4 0/4 
21 Non-motor PNES PNES PNES PNES PNES 4/4 4/4 
       4+ 12+ 
PS: psychiatrist; NDP: no diagnosis possible; ES: epileptic seizure; PNES: psychogenic non-epileptic seizure. 
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Table 3.2.3. Agreement among four psychiatrists and among four epileptologists 
 Kappa 95% CI 
Psychiatrists   
Overall  0,18 0,08 0,28 
PNES 0,21 0,03 0,39 
ES 0,29 0,11 0,47 
Other -0,03 -0,21 0,15 
Epileptologists    
Overall  0.50 0,32 0,68 
PNES 0.66 0,54 0,78 
ES 0.48 0,36 0,60 
Other 0.20 0,08 0,32 
ES: epileptic seizure; PNES: psychogenic non-epileptic seizure 
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Table 3.2.4. Agreement within pairs of epileptologists and between each epileptologist and gold standard 
  Overall  PNES  ES  Other 
Pair Kappa 95% CI  Kappa 95% CI  Kappa 95% CI  Kappa 95% CI 
R1 vs. R2 0.73 0.44 - 1.00  0.82 0.41 - 1.00  0.63 0.22 - 1.00  -* - 
R1 vs. R3 0.48 0.21 - 0.75  0.56 0.15 - 0.97  0.40 -0.01 - 0.81  -0.05 -0.46 - 0.36 
R1 vs. R4 0.54 0.27 - 0.81  0.82 0.41 - 1.00  0.62 0.21 - 1.00  -0.02 -0.43 - 0.39 
R2 vs. R3 0.34 0.07 - 0.61  0.56 0.15 - 0.97  0.25 -0.16 - 0.66  -0.05 -0.46 - 0.36 
R2 vs. R4 0.40 0.11 - 0.69  0.63 0.22 - 1.00  0.45 0.04 - 0.86  -0.02 -0.43 - 0.39 
R3 vs. R4 0.48 0.23 - 0.73  0.56 0.15 - 0.97  0.40 -0.01 - 0.81  0.64 0.23 - 1.00 
R1 vs. GS 0.49 0.24 - 0.74  0.82 0.41 - 1.00  0.81 0.40 - 1.00  -0.10 -0.51 - 0.31 
R2 vs. GS 0.35 0.08 - 0.62  0.63 0.22 - 1.00  0.45 0.04 - 0.86  -0.10 -0.51 - 0.31 
R3 vs. GS 0.30 0.05 - 0.55  0.39 -0.02 - 0.80  0.40 -0.01 - 0.81  0.23 -0.18 - 0.64 
R4 vs. GS 0.56 0.31 - 0.81  0.63 0.22 - 1.00  0.81 0.40 - 1.00  0.32 -0.09 - 0.73 
*no reviewers give the response “Other”. 
ES: epileptic seizure; PNES: psychogenic non-epileptic seizure: R: rater; GS: gold standard; CI: confidence interval 
 
  
  Giussani G. 
77 
 
 
Table 3.2.5. Agreement within pairs of psychiatrists and between each psychiatrist and gold standard 
  Overall  PNES  ES  Other 
Pair Kappa 95% CI  Kappa 95% CI  Kappa 95% CI  Kappa 95% CI 
PS1 vs PS2 0,19 -0.06; 0.44  0,31 -0.10; 0.72  0,27 -0.14; 0.68  0,16 -0.25; 0.57 
PS1 vs PS3 0,27 0.02; 0.52  0,32 -0.09; 0.73  0,63 0.22; 1.00  -0,15 -0.56; 0.26 
PS1 vs PS4 0,34 0.09; 0.59  0,31 -0.10; 0.72  0,51 0.10; 0.92  -0,15 -0.56; 0.26 
PS2 vs PS3 0,37 0.12; 0.62  0,51 0.10; 0.92  0,45 0.04; 0.86  -0,07 -0.48; 0.34 
PS2 vs PS4 -0,2 -0.45; 0.05  -0,09 -0.50; 0.32  -0,29 -0.70; 0.12  -0,07 -0.48; 0.35 
PS3 vs PS4 0,06 -0.21; 0.33  -0,09 -0.50; 0.32  0,11 -0.30; 0.52  -0,05 -0.46; 0.36 
PS1 vs GS 0,39 0.14; 0.64  0,51 0.10; 0.92  0,72 0.31; 1.00  0,03 -0.38; 0.44 
PS2 vs GS 0,43 0.18; 0.68  0,63 0.22; 1.00  0,53 0.12; 0.94  0,23 -0.18; 0.64 
PS3 vs GS 0,45 0.20; 0.70  0,51 0.10; 0.92  0,72 0.31; 1.00  -0,12 -0.53; 0.29 
PS4 vs GS 0,01 -0.24; 0.26  0,09 -0.32; 0.50  0,18 -0.23; 0.59  -0,12 -0.53; 0.29 
ES: epileptic seizure; PNES: psychogenic non-epileptic seizure; PS: psychiatrist; GS: gold standard; CI: confidence interval 
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Table 3.2.6. Original observations of psychiatrists 
Video 
# 
Original observations 
Diagnosis of 
choice 
Diagnosis GS 
3a 
Apparent loss of contact after prolonged photic stimulation (PS1) PNES PNES-Motor  
Purposeful postural adjustments during eyes opening and closing (PS1) PNES PNES-Motor  
Absence of agitated behaviour + calm breathing (PS3) PNES PNES-Motor  
Event induced by stress (prolonged photic stimulation) (PS4) PNES PNES-Motor  
3b 
Subtly regains contact bringing hands to chest  (PS1) PNES PNES-Motor  
Apparent thoracic pain + slow hand movements (PS4) PNES PNES-Motor  
3c 
Bilateral sensory misperceptions (PS1) PNES PNES-Non motor 
Mantains contact during psychomotor slowing (PS1) PNES PNES-Non motor 
Tendency to disengage from context (PS1) PNES PNES-Non motor 
4 
No pelvic trusting but movements with sexual connotation (PS1) PNES PNES-Motor  
Apparent confusion during perception of pain (PS1) PNES PNES-Motor  
"Non-epileptic" movements of arms and legs (PS3) PNES PNES-Motor  
Indifferent to what has happened (PS3) PNES PNES-Motor  
Alert behaviour during seizure (PS4) PNES PNES-Motor  
7 
Looks astonished, slow motions and diffuse malaise (PS1) PNES NDP-Non motor 
"Dissociation symptoms" (feels like shaking even if not apparent) (PS2) Other NDP-Non motor 
Emotional behaviour (PS2) Other NDP-Non motor 
8 Twilight state, with partial detachment (PS1) EPILEPSY EPILEPSY-Motor 
9 Arc de circle (PS2) PNES PNES-Motor  
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Questionable impairment of consciousness/seizure only in presence of witness (PS3) PNES PNES-Motor  
10 Indifference (PS4) PNES EPILEPSY-Motor 
13 "Morpheic" event (PS2) EPILEPSY EPILEPSY-Motor 
14 Appears partially in touch with context but distant, as if confused or wanting to gain time (PS1) Other 
EPILEPSY-Non 
motor 
15 Indifferent attitude (PS4) PNES EPILEPSY- Motor 
17 During the event, subject puts herself at the centre of attention (PS1) Other PNES-Non motor 
19 Seizure only when people present (PS3) PNES PNES-Motor  
21 
 
Falls on bed (no injury) without apparent reasons (PS1, PS2, PS3) PNES PNES-Non motor 
"Almost placid" during motor arrest + holding hand of nearest person if still in touch (PS1) PNES PNES-Non motor 
PNES: psychogenic non-epileptic seizure; GS: gold standard; PS: psychiatrist; NDP: no diagnosis possible.
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3.3 A new patient-oriented questionnaire for differentiating epileptic from psychogenic 
non-epileptic seizures. Value, limitations, future directions 
3.3.1 Introduction 
In the previous sections of this study we investigated how experienced epileptologists, blind 
to the EEG findings and other clinical information, can predict the diagnosis by simply 
reviewing the semiology of events captured on video in about one third of cases (Erba et al., 
2016). Here we investigate the predictive value of structured questionnaires designed to 
collect directly from patients and eyewitnesses information about personal history, 
characteristics of the events and specific risk factors.    
The aim was to establish whether and to what extent such instrument could represent a useful 
addition to the investigation routinely performed by care providers in specialized centers or 
be a viable surrogate when such facilities are not accessible. 
3.3.2 Methods 
3.3.2.1 Eligibility Criteria and Setting 
Consecutive new patients above the age of 18 and with no evidence of cognitive impairment 
admitted for investigation of seizures to the long term monitoring unit of the University of 
Rochester, NY, were eligible for the study. 
3.3.2.2 The questionnaires 
Two ad hoc questionnaires, one for patients (Questionnaire A) and one for witnesses 
(Questionnaire B), were assembled based on features reported in the literature as 
characteristically associated with ES or PNES and all other signs and symptoms that, 
according to our clinical experience, could help differentiating the two syndromes. They 
consisted of an eclectic array of signs and symptoms known from the literature to correlate 
with the diagnosis of either ES or PNES. They incorporated items that were part of pre-
existing instruments, one in particular that, based on sensitivity/specificity values, had 
identified 3 diagnostic indicators for PNES and 3 for ES out of 45 video-documented signs 
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(Syed et al 2011). However, since our aim was to build a comprehensive, broad-based 
instrument, we equally considered analogous tools used for other more specific purposes 
(Rugg-Gunn et al 2001) as well as reports highlighting the discriminatory value of single 
clinical features (Rosemergy et al, 2013; Sen et al 2007). In addition, we added all other 
signs and symptoms that, according to our clinical experience, could help differentiating the 
two disorders. Contrary to previous questionnaires, mostly designed to guide trained 
professionals through an exhaustive scrutiny of the semiology of the events (Syed et al 2011; 
Rugg-Gunn et al 2001), the distinctive features of Questionnaire A and B were to encourage 
patients and eyewitnesses to tell their story, how they felt, what they saw. Consequently, the 
wording had to be easily accessible to lay/untrained people and was geared to explore 
subjective experiences (patients) and the recall of critical observations (eyewitnesses). 
Questionnaire A, focused on patients past history, specific risk factors, precipitating events 
and comorbidities. It also gave special attention to triggering or warning signs and to the 
subjective experiences that may occur in patients with either ES or PNES before, during and 
after the typical events. Questionnaire B focused on the semiology of the events, namely the 
manifestations reportedly characteristic of ES and PNES, to document the objective 
observations made by the eyewitness when the patient is or appears to be unconscious.  
It is well documented that the discriminatory abilities of caregivers in detecting characteristic 
features of the events is far inferior to that of epileptologists (Syed et al 2011; Rugg-Gunn 
et al 2001). In addition, retrospective contributions of eyewitness depend on the recall of 
what an untrained observer has noticed at the time of the event. Thus, the aim of 
Questionnaire B was twofold: 1) determine how contributory an account based on the late 
recollections of a nonprofessional witness can be; 2) define which signs, among those 
reported as typically associated with ES or PNES, are more likely to be noticed and reported.  
When patients and witnesses described more than one type of event (i.e. convulsions, staring, 
unresponsiveness, loss of time, etc.), the same set of questions was replicated for each of the 
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three most frequent events. Efforts were made to formulate the questions in lay terms at 7th 
grade level to optimize comprehension and facilitate self-administration. A non-physician 
assistant was present during the collection of data to clarify issues when necessary. 
Questionnaires A and B were administered prospectively, during the early part of the 
admission before the diagnosis was known.  
Questionnaire A was revised after testing the first set of 21 subjects, mainly to improve 
clarity without altering the content. During this process, and without the benefit of an interim 
analysis, it appeared that some questions pertaining to symptoms of somatization were too 
generic for an effective discrimination between ES and PNES. Therefore, they were 
removed. Nonetheless, in the final analysis patients’ answers to all questions, including those 
removed, were assessed. 
The full sets of questions contained in the original version of Questionnaire A and 
Questionnaire B are available in the Appendix.  
The electronic version of questionnaires was based on REDCap and the patients were 
instructed to use by themselves the program. REDCap is a web application for building 
and managing online surveys and databases. There was always a study-staff person present 
ready to help where needed. 
3.3.2.3 Final diagnosis    
The final diagnosis was based on the convergence of the following: presence, or absence, of 
specific risk factors in the patient’s history; findings on VEM/EKG monitoring; results of 
psychiatric and neurological assessments. In case a definite diagnosis could not be reached 
the case was removed from analysis. 
3.3.2.4 Data analysis  
Using the information obtained from each single question included in questionnaires A and 
B, a list of variables representing specific signs, symptoms and risk factors was created. Each 
variable was coded as present, absent or “missing” when the patient/witness did not know 
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or did not want to respond. If the patient had more than one seizure type, a sign, symptom 
or risk factor was considered as present if recorded in one or more seizure types and as absent 
if recorded in none. Since the aim was to assess the discriminating value, we independently 
calculated specificity (SP) and sensitivity (SE) of each variable analyzing the direct 
responses of patients and witnesses against the final diagnosis. We compare exclusively 
patients with proven diagnosis of PNES versus patients with proven ES. All subjects with 
both PNES and ES or with other types of events were excluded. In order to identify variables 
that would correctly confirm or exclude a PNES diagnosis with high probability and to 
exclude those too common or too uncommon in either group, we followed the criteria 
adopted by Syed et al. (Syed et al., 2011): 1) either SE or SP must be at least 80%; 2) both 
SE and SP must be no less than 50%. In addition we tabulated all variables with SE and SP 
between 60% and 80%. We also tested the statistical significance of the selected variables 
using the Fisher’s exact test.  
3.3.3 Results 
3.3.3.1 Study sample 
 A total of 50 patients were enrolled in the study. The final diagnosis was PNES (20), ES 
(12), Other type (5), ES+PNES (1) and no diagnosis possible (12). Four subjects were unable 
to complete questionnaire A because of early discharge. From the remaining 46 subjects, 18 
were excluded due to diagnosis of other events or no diagnosis, leaving 28 questionnaires A 
eligible for analysis: 17 were completed by patients with PNES (76% female; mean age 39.2 
/ standard deviation, SD 12.5) and 11 by patients with ES (64 % female; mean age 40.4 / SD 
19.4).    
Questionnaire B was not obtained in 21 cases because a reliable witness could not be reached 
or identified. Of the remaining 29 subjects, 13 were excluded because the diagnosis was 
other events (5) or no diagnosis (8). This left a total of 16 questionnaires B eligible for 
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analysis: 6 pertained to patients with PNES (gender 50% female; mean age 34.0 / SD 9.5) 
and 10 to patients with ES (gender 70% female; mean age 41.6 / SD 20.0).  
3.3.3.2 Patient burden 
The task of filling the questionnaire was well tolerated. Approximately half of the 
participants chose to self-administer the questionnaire and had no difficulties in using the 
electronic version. Most subjects required little or no assistance from the clinical coordinator 
who was present during the task. 
3.3.3.3 Questionnaire acceptability 
In this study, with the exception of one patient who refused to discuss his upbringing, all 
other subjects had no apparent hesitation in disclosing history of abuse or other sensitive 
information despite being aware that they were entitled to skip embarrassing questions.    
3.3.3.4 Sensitivity (SE) and Specificity (SP) of patient’s responses to questionnaire A 
Table 3.3.1 shows the 7 variables in Questionnaire A (patient) that met the pre-set criteria of 
high SE and SP, indicating whether the variable was present or absent in either group. Three 
variables pertained to the event’s prodromal phase: headache, heart racing and tingling or 
numbness; one to the post-ictal phase: physical pain. The remaining three concerned the 
subject’s history: two risk factors (head injury, physical abuse) and chronic fatigue. Sexual 
and emotional abuse and none of the psychiatric co-morbidities reached the discriminating 
threshold as they were seldom reported in both groups. The p-value was significant for all 
variables except for tingling and numbness (p= 0.1150) and physical abuse (p= 0.0540). 
Response rate was complete for all questions except for chronic fatigue, an item investigated 
only in the early version of questionnaire A.  
Table 3.3.2 shows the 6 variables in questionnaire A below the pre-set threshold but with 
SE/SP no less than 50% and either SE or SP between 60% and 80%. Again, three of them 
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concerned the prodromal and post-ictal phase and three the patient’s history, one of which 
was a risk factor (emotional abuse). 
 
3.3.3.5 Sensitivity and Specificity of the witness responses to questionnaire B  
Table 3.3.3 shows the only 2 variables in Questionnaire B that reached the discriminating 
threshold and significant p-value. They represented two ictal signs: head moving from side 
to side and eye closure, observed in at least one of the witnessed seizures.  
Table 3.3.4 shows the 4 variables in Questionnaire B below threshold but with SE/SP no less 
than 50% and SE or SP between 60% and 80%. Three were related to the event’s semiology 
(i.e. ictal on/off movements) and one to a special ictal function (being talked out of seizures.)   
All other variables of Questionnaire A and B did not reach the minimum threshold (see 
Supplementary Tables 3.3.1 and 3.3.2).      
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3.3.4 Tables 
Table 3.3.1. Patient questionnaire: PNES (#17) vs. ES (#11): list of all variables with sensitivity or specificity above pre-set threshold. 
Question Variable 
PNES   ES 
SE SP 
p-
value Present Absent 
Not 
indicated 
  Present Absent 
Not 
indicated 
13 Headache (trigger) 11 6  -  1 10  - 64.7 90.0 0.0060 
24/33/42 Heart racing (Warning) 9 8  -  1 10  - 52.9 90.9 0.0407 
24/33/42 Tingling or numbness (Warning) 9 8  -  2 9  - 52.9 81.8 0.1150 
30/39/48 
Feel in physical pain (after 
seizure) 
10 7  -  1 10  - 58.8 90.9 0.0161 
50 
Head injury with loss of 
consciousness ≥5 min. (History) 
10 7  -  1 10  - 58.8 90.9 0.0161 
56 Physical abuse (History) 10 7  -  2 9  - 58.8 81.8 0.0540 
62 Fatigue* (History) 6 0 11   1 6 4 100 85.7 0.0047 
 
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
*Investigated only in the first 21 patients. 
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Table 3.3.2. Patient questionnaire: PNES (#17) vs. ES (#11): list of all variables with both sensitivity and specificity no less than 50% and 
sensitivity or specificity between 60 and 80 (below the pre-set threshold). 
 
Question Variable 
PNES   ES SE SP p-value 
Present Absent 
Not 
indicated 
  Present Absent 
Not 
indicated 
   
15 
Bright/flashing 
lights (trigger) 
      9       8 .  4 7 . 52.94 63.64 0.4601 
16 
Feeling 
overwhelmed 
(trigger) 
      12        5 .  4 7 . 70.59 63.64 0.1212 
28/37/46 
Trouble speaking 
(after seizure) 
11 6 .  4 7 . 64.71 63.64 0.2458 
58 
Emotional abuse 
(History) 
9 8 .  4 7 . 52.94 63.64 0.4601 
67 
Gerd reflux 
(Diagnosis) 
3 3 11  1 6 4 50.00 85.71 0.2657 
90 
Self-inflicted 
injuries (History)  
9 8 .  3 8 . 52.94 72.73 0.2530 
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
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Table 3.3.3. Witness questionnaire: PNES (#6) vs. ES (#10): list of all variables with sensitivity or specificity above pre-set threshold. 
Question Variable 
PNES   ES 
SE SP 
p-
value Present Absent 
Not 
indicated 
  Present Absent 
Not 
indicated 
24/47/70 
Side-side head movements in at 
least one of the witnessed seizures 
4 2  -  0 9 1 66.7 100 0.0110 
25/48/71 
Ictal eye closure in at least one of 
the witnessed seizures 
4 2  -   0 9 1 66.7 100 0.0110 
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
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Table 3.3.4. Witness questionnaire. PNES (#6) vs. ES (#10): list of all variables with both sensitivity and specificity no less than 50% and 
sensitivity or specificity between 60 and 80 (below the pre-set threshold). 
Question Variable PNES   ES SE SP p-value 
Present Absent Not 
indicated 
  Present Absent Not 
indicated 
   
19/42/65 On/off shaking or 
stiffening 
3 3 .  1 9 . 50.00 90.00 0.1181 
22/45/68 Being “talked out” of 
seizures 
2 2 2  3 6 1 50.00 66.67 1.0000 
28/51/74 Breathing pattern (Ictal) 3 3 .  4 6 . 50.00 60.00 1.0000 
30/53/76 Sudden fall (Ictal) 3 2 1  3 6 1 60.00 66.67 0.5804 
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
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4. STUDY OF THE CHARACTERIZATION OF THE DIAGNOSIS OF IDIC(15) 
SYNDROME  
Abstract 
Idic(15) syndrome, is a rare neurogenetic disorder resulting from several genetic 
mechanisms the most frequent of which is a supernumerary marker chromosome 15. The 
disease is characterized by an unspecific phenotype, clinical heterogeneity and wide range 
of severity. The aims of this project were: 1. The identification of symptoms, signs and 
instrumental findings, singly or in various combinations, favoring the early diagnosis of the 
idic(15) syndrome; 2. The correlation of the clinical and instrumental findings to the 
diagnosis; 3. The characterization of the diagnosis of the idic(15) syndrome; 4. The 
assessment of extent to which epilepsy can be considered a characteristic feature of the 
disease. 
Another important aim was to verify the identification and detection of specific signs or 
symptoms by different experts in a homogeneous and objective way. 
32 patients (16 cases and 16 controls), age and sex matched, were enrolled and 5 raters blind 
to the diagnosis revised the patients information in three different steps: 1. Clinical charts 
review; 2. Video of neurological examination and patients’ behaviour; 3. Instrumental tests 
examination (EEG, MRI, CT-Scan). Control patients were subjects with different 
neurodevelopemental disorders that fell in the differential diagnosis recruited from the same 
settings as the patient group. 
Variables easily recognized in patients by raters with a good agreement (>0.6, calculated 
with Kendall’s coefficient W) where almost the same of those described by Battaglia (2008), 
but high scores of SE and SP were found only for hypotonia and feeding difficulties in the 
newborn period. When considering these two variables as present in the same patients, SP 
increased to 87.5 and SE decreased to 36.3. These two variables, when combined, help to 
discriminate only to some extent idic(15) syndrome from other neurodevelopemental 
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disorders: 76% of patients with these signs have the disease and 64% of patients without 
these signs cannot be diagnosed with idic(15) syndrome. Analysing the results reported in 
the three steps by the raters, step 1 and 2 made a greater contribution to the correct diagnosis 
than step 3. EEG, MRI and CT-Scan deviated raters from a correct differential diagnosis 
probably because the results of instrumental investigations reflect a subjective interpretation 
of the electrophysiological and imaging findings. 
 
4.1 Introduction 
The idic(15) syndrome has received little attention because of its rarity, the fairly unspecific 
phenotype, the clinical heterogeneity, and the wide spectrum of severity. Although attempts 
have been made to identify common clinical features (hypotonia, developmental 
delay/intellectual disability, autistic behaviour, and epilepsy) (Battaglia, 2008), no formal 
characterization has been attempted with the intent to select clusters of symptoms, signs and 
laboratory/instrumental tests, which could be used in the differential diagnosis with other 
neurodevelopmental disorders characterized by mental retardation, intellectual disability, 
epilepsy, and altered behaviour. The contribution to the diagnosis of individual symptoms 
and/or signs and their combinations could not only favor an early diagnosis of the idic(15) 
syndrome, but could also help defining any genotype-phenotype correlation and are a 
valuable reference for epidemiological studies. 
4.1.1. The phenotype and genotype of idic(15) syndrome 
idic(15) syndrome is a rare neurogenetic disorder resulting from several genetic mechanisms 
the most frequent of which is a supernumerary marker chromosome 15, also known as Inv 
Dup (15) - Idic(15) -Tetrasomy 15q, with an incidence at birth of approximately 1 in 30,000 
and an almost equal distribution in males and females (Battaglia, 2008). Interstitial 15q11-
13 duplications and triplications have been less frequently described (Repetto et al, 1998; 
Schinzel et al, 1994). The prevalence of chromosome 15q11-13 duplications is estimated in 
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1 in 600 patients with developmental delay (Piard et al, 2010). Both Inv Dup (15) and 
interstitial 15q11-13 duplication are included in a broad clinical phenotypic spectrum (Rocha 
et al, 2012). A case of mosaicism for Inv Dup (15) in an adult healthy man was also described 
(Guanciali-Franchi et al, 2008).  
The main clinical features consist of early central hypotonia, joint hyperlaxity, short stature, 
developmental delay, intellectual disability, impairment of verbal expressive language, 
autistic-like behaviour, epilepsy with a wide variety of seizure types and interictal EEG 
abnormalities. Feeding difficulties are reported in the newborn period and recurrent upper 
respiratory tract infections during infancy. Minor dysmorphisms are absent or subtle: high 
forehead, frontal bossing, epicanthal folds, deep set eyes, downslanting palpebral fissures, 
synophrys, low-set and posteriorly rotated ears, broad nose, short philtrum, anteverted nares, 
midface hypoplasia, large incisors, cleft palate/highly arched palate, clinodactyly, 
syndactyly, brachydactyly. Occasionally major malformations are described: ventricular 
septal defects, tetralogy of Fallot, unilateral renal agenesis, umbilical and inguinal hernias. 
Microcephaly occur in less than 20% of individuals, macrocephaly in less than 3% 
(Battaglia, 2005; Ouldim et al, 2007; Hou and Wang, 1998; Buoni et al, 2000). 
Developmental delay and intellectual disability may have a different level of severity, from 
mild to profound (Hou and Wang, 1998). 
Behavioural phenotypes range from gaze avoidance or anxiety or emotional lability to 
pronounced autistic-like features including absent expressive language, poor intention to 
communicate, echolalia, and stereotypies (hand-flapping, hand-clapping, etc.) (Battaglia et 
al, 2008). 
Epilepsy is frequent in this syndrome, but some patients have no history of seizures. Seizure 
onset can occur from infancy, often with infantile spasms (Valente et al, 2006), but also in 
childhood or even in adulthood with focal or generalized seizures types (Chifari et al, 2002). 
A wide variety of seizure types has been described even in the same patient, among which 
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epileptic spasms, generalized tonic/tonic-clonic seizures; axial tonic seizures; atypical 
absences and myoclonic absence-like seizures (Takeda et al, 2000; Elia et al, 1998; Baker et 
al, 1994). In some patients, a diagnosis of Lennox-Gastaut syndrome has been made (Rocha 
et al, 2012). Sexual abnormalities were also described, including hypospadia, cryptorchidism 
and precocious puberty (Buoni et al, 2000; Grosso et al, 2001). 
The idic(15) syndrome has a complex molecular characterization. The 15q11-q13 region is 
characterized by high instability, caused by the presence of several paralogous segmental 
duplications (Low Copy Repeats: LCRs) driving by Non Allelic Homologous 
Recombination (NAHR). NAHR occurring between these LCRs led to the delineation of 5 
breakpoint regions (BP1 to BP5) (Pujana et al, 2002). Moreover, the region has a complex 
pattern of imprinting with at least five paternally expressed genes (MKRN3, MAGEL2, 
NDN, C15orf2, snoRNAs and SNRPN-SNURF) and two maternally expressed genes 
(UBE3A and ATP10A). The PraderWilli (PWS) syndrome/Angelman syndrome (AS) 
critical region is located between BP2-BP3. Maternal and paternal deletion of these regions 
is associated with AS and PWS in about 70% of the patients affected by one of these 
conditions with the deletion occurring between BP1 and BP3 (type I) in 40% of the cases, 
and between BP2 and BP3 (type II) in the remaining 60%. The deletion is the result of either 
an inter- or an intrachromosomal rearrangement (Carrozzo et al, 1997). Type I deletion 
shows more severe phenotypes than type II (Roberts et al, 2002). More recently, deletions 
involving BP3-BP5 or BP4-BP5 have been reported in association with a wide phenotypic 
variability of abnormalities ranging from intellectual disability, schizophrenia, autism, and 
1% of idiopathic generalized epilepsy (van Bon et al, 2009). 
Duplication of the 15q11-q13 region occurs in two contexts: a complex genomic 
rearrangement resulting in the presence of a supernumerary marker chromosome visible on 
standard karyotype that is constituted by an inverted duplication (invdup(15) or isodicentric 
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chromosomes (idic(15)) or an interstitial duplication (Wang et al, 2004) which can only be 
detected by molecular cytogenetics. 
Supernumerary marker chromosome (SMC) derivative of chromosome 15 represents about 
50% of the SMCs observed in humans (Crolla et al, 2005). Two-thirds of the invdup(15)s 
had a breakpoint beyond the standard distal PWS/AS deletion breakpoint BP3 (Roberts et 
al, 2003; Leana-Cox et al, 1994) whether smaller size SMCs do not contain the PS/AS region 
and have a breakpoint at BP2. Early molecular studies showed that the majority of the 
SMC(15)s have asymmetrical breakpoints, with the two inverted arms of the SMC being 
unequal in length with an unexpected level of complexity and heterogeneity that is not seen 
in other chromosome 15 rearrangements, such as deletions and duplications. This suggests 
that multiple mechanisms are involved in the formation of large SMC(15)s  (Crolla et al, 
2005; Roberts et al, 2003; Leana-Cox et al, 1994) including post-zygotic ones (Rossi et al, 
2012). The majority of invdup(15) is of maternal origin, and could be associated with 
advanced maternal age. This sex difference is not explained, although several hypotheses 
have been suggested: NAHR does not occur in paternal gametogenesis, most affected fetuses 
are not viable, or the duplication remains undetected because carriers have normal phenotype 
(Battaglia et al, 2010). 
The idic(15) syndrome has a remarkable phenotypic and genetic variability. Based on the 
present knowledge, there are few studies on the genotype-phenotype correlation and most 
15q11q-13 duplications were studied by fluorescence in situ hybridization (FISH), that does 
not allow to detect submicroscopic copy number change and the exact chromosome 
breakpoints. 
To the best of our knowledge, this study would be the first formal diagnostic investigation 
of the idic(15) syndrome, aimed to detect, in relation to the exact extent of duplication and 
to the genes involved, clinical, neurological, behavioural and electroencephalographic 
markers for the early diagnosis. 
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4.1.2 Background and objectives 
The present study has been originated by a specific interest of the lay association 
“NonSolo15”, represented by the family members of individuals with idic(15) syndrome, 
their caring physicians, and people interested in the knowledge and care of the disease. The 
association includes a total of 30 families, some of them actively interacting with the Dup15q 
Alliance (a twin association in the United States) with the inclusion of their cases in the US 
national registry. In each family, the patient with idic(15) syndrome has been the object of 
an intensive clinical and genetic investigation.  
In the attempt to improve the knowledge of the disease and advance the diagnostic and 
therapeutic work-up, a particular interest arose on the need to establish a national registry of 
the disease. Soon it became evident that, given the present knowledge of the phenotypic 
aspects of the disease, a more accurate investigation of the clinical, laboratory and 
instrumental features and their correlation with the genetic pedigree was needed. Based on 
the results of the characterization study, the combination of symptoms, signs and other 
diagnostic findings with the best discriminatory power at different ages would be used as a 
valuable instrument for an early diagnosis of the idic(15) syndrome in clinical practice and 
for the screening of the disease upon activation of a population-based registry in well-defined 
small to medium size geographic areas. 
In this project we planned to validate the diagnosis made by child neurologists based on 
symptoms, signs and instrumental findings comparing a cohort of patients of differing age 
and sex with confirmed diagnosis of idic(15) syndrome to patients usually considered in the 
differential diagnosis as having intellectual disability, functional impairment, and 
behavioural abnormalities in various combinations. Specific aims include: 
1. The identification of symptoms, signs and instrumental findings, singly or in various 
combinations, favoring the early diagnosis of the idic(15) syndrome; 
2. The correlation of the clinical and instrumental findings to the diagnosis; 
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3. The characterization of the diagnosis of the idic(15) syndrome; 
4. The assessment of extent to which epilepsy can be considered a marker of the disease. 
The primary objective of the study is the identification of symptoms, signs and instrumental 
findings, singly or in various combinations comparing patients with idic(15) syndrome to 
patients with other neurodevelopmental disorders considered in the differential diagnosis. 
The research question to be addressed is that idic(15) syndrome differs from other 
neurodevelopmental disorders in a number of symptoms and/or signs whose combination 
defines a peculiar clinical phenotype. 
Another important aim was to verify the significance to identify and detect a single sign or 
symptoms by different experts in a homogeneous and objective way. 
 
4.2 Methods 
The study population was represented by 16 patients of all ages and either sex with idic(15) 
syndrome (the cases) and 16 patients (the controls) with other diseases involved in the 
differential diagnosis. The differential diagnosis involves other neurodevelopemental 
disorders characterized by intellectual disability, autism, abnormal behavior, functional 
impairment. The cases were mostly recruited among the members of the association 
“NonSolo15” and the controls were patients followed by child neurologist of the 
participating centers. The diagnosis of each clinical condition was the one made by the caring 
child neurologist and was based on the results of clinical, laboratory and instrumental tests 
(including genetic tests) and was selected as the gold standard. After releasing a written 
informed consent, the family members (or other legal representatives) of eligible cases and 
controls permitted the diagnostic assessment of the affected individuals, including the 
accession to the patients' medical records. For each individual included in the study, an 
accurate history was taken from a key informant. The patient underwent a full clinical 
investigation (including the neurological examination, the assessment of spontaneous 
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behaviour and his/her basic interactions with the examiner). History and clinical assessment 
were video-recorded in the caring physician's office. 
Video-recordings and all the material included in the patients' medical records (except for 
the results of the genetic tests) were examined by a commission of experts represented by 5 
child neurologists, chosen among those actively involved in the management of 
neurodevelopmental disorders. The experts (the raters) were blind to the diagnosis. Each 
rater was asked to make the diagnosis (idic(15) syndrome vs. other) indicating, for each 
diagnosis, the degree of diagnostic certainty (as definite, probable or uncertain) in three 
subsequent steps, the first after reviewing the medical records (deprived of the information 
obtained from the laboratory and instrumental tests), the second after examining the video-
recordings, and the third after examining the results of the laboratory and instrumental tests. 
At each step, a separate section of an e-CRF (see the Appendix) was filled.  
When all the tasks have been accomplished by the raters, the inter-rater agreement was 
tested.  
At the end of the study, a cluster of symptoms, signs and laboratory/instrumental findings 
were tentatively identified to help the caring physician to make an early diagnosis of idic(15) 
syndrome in a child or young adult with developmental delay, intellectual disability, epilepsy 
and behavioural disturbances in various combinations. Symptoms, signs and laboratory 
values were assessed comparing the phenotype of cases and controls.   
The identification of diagnostic criteria with differing degree of certainty helped the 
screening of patients affected by idic(15) syndrome among those with neurodevelopmental 
disorders in a given population at risk. 
4.2.1 History taking and physical examination 
A detailed history on the disease onset and course was collected through examination of the 
patient’s medical records and direct interview of the parents or legal representatives. The 
records were anonymized and deprived of any detail likely to uncover the final diagnosis. 
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The following data were collected: date of birth, sex, family history, current weight, height 
and cranial circumference, gestational week at delivery, Apgar score, weight, length and 
cranial circumference at birth, feeding difficulties in the newborn period, age at standing, 
walking and first words, number of current words, age at onset of self-feeding and playing 
(where possible), presence of recurring URI, constipation, hypogonadism, urinary tract 
defects, congenital heart defects, unilateral renal agenesis, inguinal and/or umbilical hernias. 
The following major and minor malformations were actively searched: growth restriction, 
microcephaly, macrocephaly, flat occiput, occipital groove, high forehead, frontal bossing, 
epicanthal folds, deep set eyes, downslanting palpebral fissures, synophrys, low-set and 
posteriorly rotated ears, broad nose, short philtrum, anteverted nares, midface hypoplasia, 
large incisors, cleft palate/highly arched palate, protruding tongue, drooling, prognatia, wide 
mouth, wide spaced teeth, hypopigmented skin (compared to family), light hair color 
(compared to family), light eye color (compared to family), hyperactive lower extremities, 
uplifted, flexed arms during ambulation. The presence of obesity was also investigated. 
A number of neurological signs were searched: hypotonia, wide-based gait with pronated 
or valgus-positioned ankles, ataxia, clumsiness, jerky motions, tremor, swallowing 
disorders, strabismus, brisk deep tendon reflexes, increased sensitivity to heat, abnormal 
sleep-wake cycles, developmental delay (mild, moderate severe), mental retardation. 
Psychiatric signs were also investigated: laughter/smiling, happy demeanor, easy 
excitement, echolalia, hand-flapping movements, hypermotoric behaviour, tantrums, 
stubbornness, verbal perseverance, skin picking, hyperphagia, anxiety, emotional lability, 
impulsivity, aggressiveness. 
Epilepsy, where present, was specifically investigated: seizure types, response to treatment, 
EEG findings. The presence of autistic behaviour was also investigated using the ADOS 
inventory (Battaglia et al 2008, Lord et al 2006). 
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4.2.2 Patient interview and examination 
A standardized video-recorded interview was performed in all cases and controls. The 
interview included the general and the neurologic examination, and a number of spontaneous 
and ordered activities required to assess the level of age-related self-sufficiency of the patient 
during daily living activities. Special attention was paid to the detection of the same major 
and minor malformations (if any) enlisted in the previous paragraph (history taking and 
physical examination) and the degree of functional impairment.  
Videos were accessed by the rater along with the medical records and the results of the 
laboratory and instrumental tests. 
 
4.2.3 Collection of reports of instrumental examinations (EEG, MRI, CT-SCAN) 
All instrumental examinations present in the medical records were identified and the results 
reported. Reports were also classified into normal, non-specific, and abnormal. 
On the basis of the history, the clinical findings, and the results of the laboratory and 
instrumental examinations, a diagnosis were tentatively made by each rater choosing one of 
the categories below: 
1. Idic(15) Syndrome 
2. Angelman Syndrome 
3. Pitt-Hopkins Syndrome 
4. Mowat-Wilson Syndrome 
5. Mucopolysaccharidosis type 3 
6. FOXG1 Syndrome 
7. West Syndrome 
8. Autism spectrum disorder 
9. Other neurodevelopmental disorder (to be specified) 
The level of diagnostic accuracy (definite, probable, uncertain) were also indicated. 
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4.2.4 Data collection  
Data, video-recorded interviews and instrumental examinations were collected in the 
“Unità Operativa Semplice di Epilettologia e neurofisiologiaclinica – Unità per le Gravi 
Disabilità in Età Evolutiva (UGDE) - Conegliano - Pieve di Soligo (TV)” and in the 
“U.O.C. di Neurologia e Neurofisiopatologia Clinica e Strumentale IRCCS "Associazione 
Oasi Maria SS" Troina (EN)” and sent to the raters for the characterization of the 
diagnosis. Information about history, video-recorded interviews and instrumental 
examinations were blind and sent anonymously to the raters who filled ad-hoc 
comprehensive check-list reported in the e-CRF (see the Appendix). 
4.2.4.1 Database management and quality control 
Study data were collected and managed in a web-based password-protected platform hosted 
at IRCCS – Mario Negri Institute for Pharmacological Research, Milan. Access details were 
provided to the raters in order to entry the data in the ad-hoc comprehensive e-CRF and 
validate the diagnosis. 
4.2.5 Statistical methods and data analysis 
When all the tasks were accomplished by the raters, the inter-rater agreement was tested at 
different levels using the Kendall’s coefficient of concordance (W) on the following groups: 
1. The diagnosis of idic(15) syndrome vs. other clinical condition, in general and by degree 
of diagnostic certainty; 2. For each symptom, sign and instrumental finding separately. 
Kendall’s W takes values from 0 (no agreement) to 1 (perfect agreement). 
Symptoms, signs and instrumental findings with Kendall’s W higher than 0.6 were evaluated 
in terms of SE and SP to assess the ones able to predict the diagnosis of idic(15). Either SE 
or SP must be at least 60%. Each raters examined charts and videos of all cases and all 
controls, giving a total of 160 interviews (80+80). 
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4.2.6 Regulatory and ethical compliance 
This study was planned and performed according to the principles of Good Clinical Practice 
(ICH-GCP), the declaration of Helsinki and national laws and regulations about clinical 
studies. The approval of the Independent Ethics Committees (IEC) of the recruiting centers 
were obtained before the beginning of the study. Eligible patients and controls were included 
in the study after releasing written IEC-approved informed consent, or, if incapable of doing 
so, after such consent was provided by a legally acceptable representative. 
 
4.3 Results 
4.3.1 Patients 
A total of 32 patients were enrolled, 16 cases with a diagnosis of idic(15) syndrome and 16 
controls with the following diagnoses: 5 Angelman syndrome; 2 Rett syndrome; 2 autism 
spectrum disorders; 2 Dravet syrome; 2 epileptic encephalopathies in FOXG1 syndrome; 1 
epileptic encephalopathy; 1 Pitt-Hopkins syndrome; 1 pervasive developemental disorder. 
Table 4.1 shows the description of the sample and table 4.2 the comparison, by sex, of birth 
weight, length at birth and head circumference between cases, controls and standard values 
for WHO (who.int/childgrowth/en). No differences were found between cases and controls. 
4.3.2 Concordance 
The coefficient of concordance (Kendall’s coefficient W) for the diagnosis of idic(15) 
syndrome at step 1 was 0.43 (p<0.0001); at step 2 was the same (0.43; p< 0.0001); at step 3 
was 0.31 (p= 0.0143).   
Table 4.3 includes the signs and symptoms identified in step 1 and 2 with W>0.6 for cases 
and controls specifying whether each variable was present or absent in either group along 
with SE and SP. In step 3, no signs and symptoms were found to have W>0.6. 
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Only two of these variables met the pre-set criteria of high SE and SP: feeding difficulties 
in the new-born period and hypotonia. When considering the presence of both signs in the 
same patient, SP increased to 87.5 and SE decreased to 36.3. The positive predictive value 
was 76.3 and the negative predictive value was 64.2. Epilepsy was found to have a W of 
0.84 but was evenly distributed between cases and controls. 
Comparing cases with interstitial 15q11-13 duplication (n=7) and Inv Dup (15) tetrasomy 
(n=9) the only variables significantly different between these two groups were: congenital 
heart defects, macrocephaly, high forehead, downslanting palpebral fissures, drooling, 
scoliosis, easy excitability, skin picking, aggressiveness, large incisors, wide spaced teeth, 
joint hyperlaxity, slow waves at EEG. However, for all these variables, the W concordance 
coefficient was lower than 0.60.   
4.3.3 Degree of diagnostic accuracy 
Table 4.4 reports the degree of accuracy of the diagnosis (No, Uncertain, Probable, Yes) for 
all raters for 80 observations among cases and 80 among controls (each patient being 
considered as many times as the number of raters). Considering the single answers, the No 
answers in the control group decreased from 57.5% to 55.0% from step 1 to step 2 and 
increased to 57.5% at step 3; the Uncertain answers increased from 16.3% to 22.5%; the 
Probable answers decreased from 22.5% to 17.5%; the Yes answers decreased from 3.8% to 
2.5%. In the case group, the No answers increased from 26.5% to 32.5%; the Uncertain 
answers increased from 16.3% at step 1 to 21.3% at step 2 and decreased to 16.3% at step 3; 
Probable answers remained the same at step 1 (46.3%) and 2 (47.5%) and decreased at step 
3 (38.5%); the Yes answers decreased from 11.3% (step1) to 6.3% (step 2) and then 
increased at 12.5% at step 3.  
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4.4 Tables 
Table 4.1. Description of the sample 
  Cases Controls 
  N % N % 
Sex     
F 8 50.0 8 50.0 
M 8 50.0 8 50.0 
  Median IQR Median IQR 
Age 9.5 6.5-12.0 9.5 6.5-12.5 
Gestational age 40.0 38.0-40.0 39.0 38.0-40.0 
Weight at birth 3.2 2.8-3.4 3.3 2.7-3.4 
Length at birth 49.8 46.5-51.0 50.0 49.0-52.0 
Head circumference 34.0 32.5-35.5 34.0 33.0-34.5 
Apgar score 9.0 8.0-9.0 9.0 9.0-9.0 
F, females; M, males; IQR, interquartile range. 
 
Table 4.2. Comparison of variables at birth between cases, controls and standard 
values 
  Females Males 
  Median IQR Median IQR 
     
Standard values     
Weight 3.2 2.9-3.6 3.3 3.0-3.7 
Length  49.1 47.9-50.4 49.9 48.6-51.2 
Head circumference 33.9 33.1-34.7 34.5 33.6-35.3 
     
Cases     
Weight 3.0 2.2-3.4 3.3 2.9-3.5 
Length  50.0 44.4-50.0 49.5 47.0-52.0 
Head circumference 33.0 31.0-35.5 34.0 33.5-35.0 
     
Controls     
Weight 3.0 2.3-3.4 3.3 3.3-3.5 
Length  49.5 47.0-50.0 52.0 50.0-53.0 
Head circumference 33.2 30.0-34.5 35.0 34.0-37.0 
IQR, interquartile range.
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Table 4.3. Variables with Kendall’s W higher than 0.6 
Variabili W 
Cases   Controls   
SE SP p-value 
No Yes Unknown No Yes Unknown 
           
STEP 1           
Feeding difficulties in the newborn period  0.62 22 49 9 54 24 2 69.0 69.2 <0.0001 
Standing 0.83 12 62 6 10 68 2 83.8 12.8 0.55 
Walking 0.88 12 66 2 10 70 0 84.6 12.5 0.60 
Speech 0.69 41 38 1 43 37 0 48.1 53.8 0.82 
Self feeding 0.62 35 25 6 39 53 2 52.7 32.1 0.05 
Overall judgement of developmental delay 
(severe vs. moderate/mild/no) 
0.65 19 52 2 24 50 1 73.2 32.4 0.63 
Epilepsy 0.84 19 52 9 24 50 6 73.2 32.4 0.47 
Infantile spasms 0.61 42 16 22 48 6 26 27.6 88.9 0.03 
           
STEP 2           
Obesity 0.62 79 0 1 66 14 0 0.00 82.5 <0.0001 
Hypotonia 0.65 22 41 17 50 20 10 65.1 71.4 <0.0001 
Overall judgement of developmental delay 
(severe vs. moderate/mild/no) 
0.69 51 29 0 45 35 0 36.3 56.3 0.33 
           
Feeding difficulties in the newborn period + 
hypotonia 
0.63 39 29 12 70 9 1 36.3 87.5 <0.0001 
                      
W, Kendall’s W; SE, sensitivity; SP, specificity.
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Table 4.4. Degree of diagnostic accuracy 
 Step 1 Step 2 Step 3 
 idic(15) Diagnosis Case Control Case Control Case Control 
 N (%) N (%) N (%) N (%) N (%) N (%) 
No 21 (26.25) 46 (57.50) 20 (25.00) 44 (55.00) 26 (32.50) 46 (57.50) 
Uncertain 13 (16.25) 13 (16.25) 17 (21.25) 17 (21.25) 13 (16.25) 18 (22.50) 
Probable 37 (46.25) 18 (22.50) 38 (47.50) 16 (20.00) 31 (38.75) 14 (17.50) 
Yes 9 (11.25) 3 (3.75) 5 (6.25) 3 (3.75) 10 (12.50) 2 (2.50) 
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5. PREVALENCE, PROGNOSIS AND ANTIEPILEPTIC DRUG RETENTION OF 
EPILEPSY IN A WELL-DEFINED POPULATION OF NORTHERN ITALY 
(EPIRES STUDY) 
The next study provides added value to the knowledge of the epidemiology, prognosis and 
treatment of drug-resistant epilepsy in Italy, by investigating the long-term outcome of 
patients not responding to two or more antiepileptic drugs (Kwan et al, 2010)) and providing 
the practising physicians with instruments to test treatment efficacy in clinical practice. 
Three manuscript have been published about this topic: 
- Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, Beghi E; EPIRES Group. 
A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy 
Behav 2016;55:30-7.  
- Giussani G, Canelli V, Bianchi E, Erba G, Franchi C, Nobili A, Sander JW, Beghi E; 
EPIRES Group. Long-term prognosis of epilepsy, prognostic patterns and drug resistance: a 
population-based study. Eur J Neurol 2016;23:1218-27.  
- Giussani G, Bianchi E, Canelli V, Erba G, Franchi C, Nobili A, Sander JW, Beghi E, and 
the EPIRES Group. Antiepileptic drugs discontinuation by people with epilepsy in the 
general population. Epilepsia 2017, in press. 
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Fig.5. Map of the study area: district of Lecco, Lombardy, Northern Italy. 
 
 
Abstract 
The aims of the study were: 1. To calculate the prevalence of active epilepsy and DRE in a 
cohort of patients from a well-defined geographic area, using as reference the ILAE 
definition; 2. To calculate the proportion of incident cases developing DRE;  3. To assess 
seizure outcome (and prognostic patterns) in a community-based cohort of people with 
epilepsy; 4. To identify prognostic indicators among selected demographic and clinical 
factors; 5. To define the outcome of epilepsy and the prognostic patterns of people with DRE 
ILAE 2010 definition compared with the rest of the cohort; 6. To estimate the retention rate 
of AEDs according to the order of administration (first, second, or subsequent) in general 
and by drug; 7. To investigate the reasons for stopping AEDs with reference to the sequence 
of drug assignment; 8. To ascertain possible predictors of treatment discontinuation with 
reference to the commonest reasons for discontinuing the assigned drug. 
Giussani G. 
 
108 
 
The study population (146,506; year 2008) resided in the province of Lecco, Northern Italy. 
The medical records of 123 general practitioners were reviewed to identify patients with 
epilepsy diagnosed by a neurologist during the period 2000-2008. The point prevalence of 
active epilepsy and DRE were calculated on December 31 2008. Remission was defined as 
uninterrupted seizure freedom lasting 2 years or longer. Prognostic patterns were early 
remission, late remission, remission followed by relapse, no remission. Cumulative 
probabilities of AED withdrawal for specific reasons were estimated using cumulative 
incidence functions. The probabilities of withdrawing for terminal remission, or of achieving 
sustained remission while still on treatment, were also evaluated. Sex, age at diagnosis, 
seizure types, duration at diagnosis and syndrome were assessed with hazard ratios (HR) and 
95% confidence intervals (95% CI).  
The sample included 747 prevalent patients with epilepsy, 684 with active epilepsy, and 342 
incident cases. DRE was 15.6% (107/684) of all active epilepsies and 10.5% (36/342) of 
incident cases. Point prevalence was 0.73 per 1,000. Standardized prevalence of DRE was 
0.7 per 1,000 (Italian population) and 0.8 per 1,000 (World population).  
428 (59%) patients were seizure-free. The probability of achieving 2-year remission was 
18% at treatment start, 34% at two years, 45% at five, 52% at ten and 67% at 20 years 
(terminal remission, 60%). Epilepsy syndrome and drug resistance were the only 
independent predictors of 2- and 5-year remission. Early remission was seen in 101 people 
(19%), late remission in 175 (33%), remission followed by relapse in 85 (16%), and no 
remission in 166 (32%). Treatment response was the only variable associated with differing 
prognostic patterns.  
In this sample, the three commonest drugs were valproate, carbamazepine and phenobarbital. 
Reasons for AED withdrawal were, in decreasing order, terminal remission, ineffectiveness 
and adverse events. The probability of withdrawing the first AED for terminal remission was 
1.0% at one year and increased to 20.0% at twenty years. Corresponding rates for 
Giussani G. 
 
109 
 
ineffectiveness were 2.9% and 12.6%; and for adverse events 0.5% and 3.3 %. Reasons for 
withdrawal varied with age, sex, disease characteristics, and drugs. 
These data indicate that 1/6 patients with active epilepsy in the general population has DRE 
and 1/10 patients with newly diagnosed epilepsy will develop DRE within nine years from 
the diagnosis. Furthermore, the long-term prognosis of epilepsy is favourable in most cases. 
Early seizure remission is not invariably followed by terminal remission and seizure 
outcome varies according to specific patterns. Prolonged seizure remission and prognostic 
patterns can be predicted by broad syndromic categories and by the failure of two 
antiepileptic drugs. The initial AED given was retained in the majority of cases. Terminal 
remission, lack of efficacy and adverse effects were, in decreasing order, the commonest 
reasons for AED discontinuation. Withdrawal could be predicted by age at diagnosis, sex 
and clinical characteristics and varied among drugs. 
 
5.1 Introduction 
5.1.2 Drug-resistant epilepsy 
As decribed above, DRE has been variously defined in published reports but in 2010. The 
ILAE issued a new definition of DRE (Kwan et al, 2010) and no studies have as yet been 
done to assess the frequency of DRE in well-defined populations conforming to this 
definition. 
5.1.3 Prognosis of epilepsy 
Epilepsy has a high potential for seizure remission. Studies in well-defined populations with 
newly diagnosed epilepsy have consistently shown a 1-year remission in up to 95% of people 
(Annegers et al, 1979;  Sillanpää and Schmidt, 2006; Berg et al, 2015; Lindstene et al, 2001; 
Camfield et al, 2010; Camfield et al, 2013; Nicoletti et al, 2009; Wakamoto et al, 2000) and 
up to 71% are in remission at last observation with or without drugs (Annegers et al, 1979;  
Sillanpää and Schmidt, 2006; Berg et al, 2015; Wakamoto et al, 2000; Goodridge and 
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Shorvon, 1983; Geerts et al, 2010). A few studies have investigated the timing and outcome 
of prolonged periods of seizure freedom (the so called prognostic patterns) (Sillanpää and 
Schmidt, 2006; Berg et al, 2015; Goodridge and Shorvon, 1983; Geerts et al, 2010; Shorvon 
and Sander, 1986; Neligan et al, 2011; Brodie et al, 2012). These studies show that early 
remission predicts favourable long-term outcomes. Some who fail to achieve early remission 
can, however, still enter remission during the course of the condition; some who experience 
early remission may relapse and eventually fail to achieve further remission while others 
may again become seizure-free. Factors including the presence of a neurological disability 
(Berg et al, 2015; Wakamoto et al, 2000; Cockerell et al, 1997), aetiology (Annegers et al, 
1979;  Sillanpää and Schmidt, 2006; Nicoletti et al, 2009; Geerts et al, 2010), seizure type 
(Annegers et al, 1979; Nicoletti, et al, 2009), high seizure frequency before treatment 
(Wakamoto et al, 2000) and during the first months after treatment start (Geerts et al, 2010; 
MacDonald et al 2000), age at diagnosis (Annegers et al, 1979), disease duration 
(MacDonald et al, 2000), number of antiepileptic drugs (AEDs) used (Wakamoto et al 2000), 
and selected epilepsy syndromes (Sillanpää and Schmidt, 2006; Wakamoto et al 2000) are 
positive or negative predictors of remission. Age per se does not influence the prognosis of 
the disease, but epilepsy syndromes thought to have differing prognostic significance vary 
between children and adults (Berg et al, 2010). 
This complex picture is the background against which the recent definition of DRE (Kwan 
et al, 2010) must be assessed.  
5.1.4 Retention of AEDs 
The response to AEDs is an important indicator of the prognosis of epilepsy. AEDs are 
generally efficacious in controlling seizures. In clinical practice, seizure freedom is seen in 
about 50% of people with previously untreated epilepsy (Annegers et al, 1979; Sillanpää and 
Schmidt, 2006; Kwan and Brodie, 2001). In people who do not respond to the first AED, the 
use of a second drug leads to complete seizure control in a lower proportion of cases and 
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there is a further decrease with each subsequent treatment change (Brodie et al, 2012; Berg 
et al, 2009; Berg et al 2006; Schiller et al, 2009). If the first drug fails, however, seizure-free 
rates vary across studies and, although DRE has been defined as the failure of two 
appropriate AEDs (Kwan et al, 2010), there are reports of people achieving seizure freedom 
even after having failed several AEDs (Berg et al, 2009; Luciano and Shorvon, 2007; 
Callaghan et al, 2007; Neligan et al, 2012). While withdrawal of ineffective drugs, when 
given as first or subsequent treatments, is usually clearly documented, the information 
becomes fragmentary regarding the reasons for discontinuation. Additionally, with some 
exceptions (Lhatoo et al, 2001; Wang et al, 2006; Huang et al, 2014), AED retention has not 
been assessed in a population-based sample. Lastly, there are no data on the history of AED 
treatment in samples of children and adults with epilepsy from the same population and 
followed for a prolonged period of time. 
 
5.2 Aims of the study 
1. To calculate the prevalence of active epilepsy and DRE in a population sample from a 
well-defined geographic area, using as reference the ILAE definition;  
2. To calculate the proportion of incident cases developing DRE;  
3. To assess seizure outcome (and prognostic patterns) in a community-based cohort of 
people with epilepsy;  
4. To identify prognostic indicators among selected demographic and clinical factors;  
5. To define the outcome of epilepsy and the prognostic patterns of people with DRE ILAE 
2010 definition compared with the rest of the cohort;  
6. To estimate the retention rate of AEDs according to the order of administration (first, 
second, or subsequent) in general and by drug;  
7. To investigate the reasons for stopping AEDs with reference to the sequence of drug 
assignment;  
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8. To ascertain possible predictors of treatment discontinuation with reference to the 
commonest reasons for discontinuing the assigned drug. 
 
5.3 Methods 
The study was a retrospective, cross-sectional, non-interventional investigation extending 
over a nine-year period (January 1, 2000 – December 31, 2008). Patients with epilepsy 
residing in the province of Lecco were the study population. The local population is almost 
entirely of Caucasian origin (96%) and is fairly stable, with a migration rate of 3.3% for the 
year 2008 (emigration 1.2%; immigration 2.1%) according to the Italian Statistics Institute 
(ISTAT: http://demo.istat.it). 
5.3.1 Health care provision in the study area 
In Italy, primary care is administered free of charge by general practitioners (GPs) to all 
residents. Each GP follows up to 1,500 individuals. Essential medical information on each 
person is collected by the GP in electronic records that are made available to the new GP in 
the infrequent case that an individual with an established chronic condition joins his/her 
practice. Further details on the medical history (including treatments) are collected in 
electronic or paper records. Children and adolescents (ie, persons aged less than 18 years) 
and adults are assigned to two distinct GP categories having different education and 
background, according to the patient’s needs. Except for age, the populations assigned to 
each GP are comparable in their demographic and socio-economic characteristics. As for 
other chronic diseases, epilepsy is entitled to receive free of charge all medical consultations, 
diagnostic aids and treatments for the detection and management of the disease. The 
exemption certificate is always released by a neurologist who has examined the patient, and 
confirmed the diagnosis. Through the exemption certificate the GP can have access to the 
diagnosis and all related diagnostic tests. 
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5.3.2. Sources of case ascertainment 
A total of 263 GPs were active in the area during the study period. All were contacted and 
123 of them (47%) volunteered to participate in the study. The GPs were requested to 
identify the medical records of all patients with seizures followed in their practice. These 
patients could be traced through diagnostic codes, EEG records, antiepileptic drug 
prescriptions, and disease-specific exemption codes. In addition, to ensure an accurate data 
collection, all GPs received a de-identified list of patients under their care with presumed 
diagnosis of epilepsy based on information contained in the database of the claims of health 
care services for the province of Lecco. This list was generated applying a validated 
algorithm including requests of EEGs and the prescriptions of drugs (Giussani et al, 2014; 
Franchi et al, 2013). All medical records of patients with epilepsy available in the GPs’ office 
were reviewed by two trained junior investigators who interacted with the GP to confirm the 
diagnosis and exclude individuals not fulfilling the study’s inclusion criteria. They also 
reviewed the records of patients assigned to the GPs but currently followed in other in- and 
out-patients facilities of the province (hospitals, nursing homes, ambulatory clinics).  
When necessary, the same investigators called the neurologists (including those outside the 
study area) following the enlisted patients, to confirm the diagnosis or to complete the data 
needed to identify epilepsy syndrome and drug response.  
5.3.3. Inclusion criteria and study definitions 
Included were children, adolescents and adults fulfilling the diagnosis of epilepsy (ie. two 
or more unprovoked seizures 24+ hours apart), followed by the participating GPs, and 
residing in the area for at least one year during the study period. Excluded were patients with 
acute symptomatic seizures, neonatal seizures, single unprovoked seizures, and paroxysmal 
events other than epilepsy. In all cases, the diagnosis had been established through 
neurological consultation on the basis of clinical assessment prior the study, interictal EEG 
findings and, in some cases, brain neuroimaging (CT, MRI). 
Giussani G. 
 
114 
 
In keeping with the ILAE guidelines for epidemiologic studies in epilepsy (Commission, 
1993), active epilepsy was defined as either being currently under treatment and/or having 
had at least one seizure in the previous five years. DRE was defined as the failure of adequate 
trials of two tolerated and appropriately chosen and used antiepileptic drugs (AED), as 
monotherapy or in combination, to achieve sustained seizure freedom (Kwan et al, 2010). In 
conformity with this definition, patients with DRE were identified as those in whom at least 
two AEDs had been discontinued for lack of efficacy or those in whom a third AED, either 
in combination or in substitution of the previous treatment, was prescribed. Adequacy of 
treatment was verified by two of us by reviewing all data available for each patient (see 
below). Drug plasma levels were not used to verify the appropriateness of treatment 
schedules.  
Seizures and epilepsy syndromes were classified using the contemporaneous ILAE 
recommendations (Commission, 1981; Commission, 1989).  The new classification of the 
epilepsies (Scheffer et al, 2017), not available during the study period, was not applied. As 
detailed information was not available in all cases, seizures and syndromes were classified 
using broad categories. Seizures were classified as focal, generalized or unclassifiable. 
Syndromes were classified as partial (idiopathic, symptomatic or cryptogenic), generalized 
(idiopathic, symptomatic/cryptogenic), undetermined and special. 
 
5.3.4. Data collection 
For each eligible case, the information was collected retrospectively until December 31, 
2008, out-migration or death, whichever came first. The following data were collected 
anonymously: 1. Main demographics; 2. Seizure type(s), disease duration (from the first 
seizure to the diagnosis), epilepsy syndrome, duration of follow-up (from diagnosis); 3. 
Number and type of drugs including drug starting date, daily doses and changes, and timing 
of administration, withdrawal date or last follow-up date, whichever came earlier (see the 
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Appendix). The reasons for discontinuation of each drug were also collected; these included 
lack of efficacy, adverse events and poor tolerability, seizure freedom, or other (pregnancy, 
death, etc.). In rare instances, where the medical records were not sufficiently detailed on 
the duration of treatments, the history of treatments and health care utilization was collected 
from the administrative records that include details on when each drug was started and 
discontinued. Using these sources, all putative epilepsy cases were traced, relevant data on 
epilepsy were collected, and patients with active epilepsy and DRE were identified.  
Seizure outcome and prognostic patterns were classified according to pre-selected 
definitions. Remission was a period of uninterrupted seizure freedom lasting 2 years or 
longer at any time after diagnosis. We investigated 2-year and 5-year remission periods. 
Sustained remission was defined as seizure remission for at least 2 years at any time after 
diagnosis and continuing until last follow-up. Terminal remission was defined as seizure 
remission for at least 2 years at last follow-up with or without previous seizure relapses. 
Prognostic patterns were defined as: 1. Early remission: 2-year seizure freedom starting 
within two years from treatment start which is sustained; 2. Late remission: 2-year remission 
starting more than two years after treatment start which is sustained; 3. Remission followed 
by relapse: early or late remission followed by relapse with/without terminal remission; 4. 
No remission: never entering 2-year remission during the entire follow-up. 
5.3.5. Statistical analysis 
Statistical analyses were performed using SAS (version 9.2; SAS Institute, Inc, Cary, NC, 
USA).  
The prevalence of active epilepsy was calculated on December 31 2008. The population at 
risk was calculated as the total number of patients assigned to the participating GPs at the 
prevalence date. Incident epilepsy cases, a subset of the prevalent cases, were identified as 
those who received the diagnosis during the period 2000-2008.  
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Prevalence of DRE was calculated on December 31 2008 in the population at risk. Incident 
DRE cases were calculated as a subset of incident epilepsy cases. We also stratified point 
prevalence of epilepsy and DRE by age and sex. Ninety-five percent binomial confidence 
intervals (95% CIs) were calculated for prevalence. Prevalence was then standardized by the 
direct method to the Italian population, 2001 census (ISTAT http://demo.istat.it) and to the 
World population, mid-year 2000 (http://www.census.gov/cgi-bin/broker).    
All descriptive statistics were reported as count and percentage. The variables analyzed were 
age, sex, type of seizures, epilepsy syndromes, disease duration, and duration of follow-up. 
Drug-resistant and non-drug-resistant patients were compared in both the prevalent and 
incident population and the differences were tested using the chi-square test. To identify 
predictors of drug resistance, multivariable logistic regression models were used, with DRE 
as dependent variable and age, sex, disease duration, duration of follow-up and epilepsy 
syndrome as covariates. The overall significance of the model and the goodness-of-fit were 
verified respectively with the Wald statistics and the Hosmer-Lemeshow test. The results are 
reported as odds ratios (ORs) with 95% CIs. The cumulative risk to become drug resistant 
in the incident population was estimated with the Kaplan Meier survival curves, first in the 
whole sample then separately by age classes, sex and epileptic syndrome. Survival curves 
were compared using the log-rank test and Sidak’s adjusted pairwise comparisons. The 
association between each variable and DRE was also tested with univariate and multivariate 
Cox’s proportional hazards function models. Proportionality assumption was verified 
including in the model time dependent covariates for each predictor. Results were reported 
as hazard ratios (HRs) and adjusted hazard ratios (adjHRs), with 95% CIs. The significance 
level was set at 0.05. As only few patients reported missing data, they were excluded from 
the analysis. Descriptive statistics for prognostic patterns are presented as frequencies, 
medians (with range), means (with standard deviations) or proportions, as appropriate. The 
cumulative time-dependent probability to achieve 2-year and 5-year remission, and to 
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achieve 2-year and 5-year terminal remission, was calculated in patients followed for at least 
two and five years respectively, using Kaplan-Meier curves comparing sex, age group at 
diagnosis, the main syndromic categories and those with or without DRE, using the log-rank 
test. Independent predictors of 2-year and 5-year remission (ever and terminal) were 
identified using the Cox multivariable proportional hazards function. Prognostic patterns 
were assessed in individuals with at least five years of follow-up, comparing all demographic 
and clinical variables with the Chi square test (or the Fisher exact test where required), 
followed by post-hoc step-down Šidák adjusted contrasts, comparing each category versus 
all other categories grouped together, within each prognostic pattern. Multivariable 
multinomial logistic regression models were used to correlate prognostic patterns with age, 
sex, disease duration, epilepsy syndrome, and number of AEDs. Statistical significance was 
set at the 5% level (p<0.05).  
Descriptive statistics for AEDs withdrawal are presented as counts and percentages. 
Administration frequencies and cause-specific withdrawal frequencies were calculated for 
each active principle and by prescription order. AEDs were also grouped in two different 
classes: old and newer (marketed before and after 1990). Old drugs included barbexaclone 
(BSC), carbamazepine (CBZ), clobazam (CLB), clonazepam (CNP), ethosuximide (ESM), 
phenobarbital (PB), phenytoin (PHT), primidone (PRM), valproate (VPA), valpromide 
(VPM); newer drugs included gabapentin (GBP), levetiracetam (LEV), lamotrigine (LTG), 
oxcarbazepine (OXC), pregabalin (PGB), tiagabine (TGB), topiramate (TPM), vigabatrin 
(VGB), zonisamide (ZNS). 
To account for competing risks, cumulative probabilities of AED withdrawal from specific 
causes over twenty years from treatment start were estimated using cumulative incidence 
functions. The cumulative probability of cause-specific AED withdrawal was calculated for 
the first, second, and third AED, for the most common AEDs (i.e. used by more than 100 
people), and for new and old AEDs separately. Differences in the cumulative incidence 
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functions between new and old AEDs were assessed using Gray’s test (Gray, 1988). For the 
first AED, the cumulative probability of withdrawing for terminal remission (ie, seizure 
freedom for at least two years at last follow-up) while still on treatment, was also evaluated. 
The association between drug discontinuation and sex, age at diagnosis (<15, 15-64, 65+ 
years), seizure types (focal, generalized, unclassifiable), duration from first seizure to 
diagnosis, and epilepsy syndrome (idiopathic, cryptogenic/symptomatic, 
special/undetermined) was assessed using univariable Cox proportional hazards models. 
Models for the most commonly used AEDs were adjusted for the number of previous drugs 
taken. Results were presented as Hazard Ratios (HR) with 95% Confidence Intervals 
(95%CI). Missing data were handled using the listwise deletion method. 
5.3.6 Ethics and confidentiality 
The study was approved by the Ethics Committee of the Provincial Hospital of Lecco 
(Register number: 2011-003428-11). Local Health Service authorization was obtained to 
collect anonymous data from the GPs. Where GPs needed to collect additional information 
from individuals, informed consent was obtained. All the data were managed according to 
the current Italian privacy rules. 
 
5.4 Results 
5.4.1 Prevalence of active epilepsy and DRE 
The 123 participating GPs represented a population of 146,506 for the year 2008. Except for 
a slight predominance of children and a slight under-representation of elderly individuals, 
this population was fairly comparable to the entire population of the province of Lecco, as 
shown in Supplementary Table 5.1. 
A total of 1,021 patients’ charts were screened in the GPs’ archives including thirty-four 
cases previously assigned to the GPs but living in nursing homes. After excluding other 
diagnoses, coding errors and duplicate records, a total of 747 patients (381 males) with 
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epilepsy and 684 patients with active epilepsy were identified (Figure 5.1). These patients 
have been followed for a total of 11,045.5 person-years (median, 9.5; interquartile range, 
4.5-22.5).  
The prevalence of active epilepsy (as of December 31 2008) was 4.67 per 1,000 (Table 5.1). 
The disease was slightly more prevalent in males and peaked in people aged 75 years or 
older.  
Standardized prevalence of epilepsy was 4.8 per 1,000 (Italian population) and 4.5 per 1,000 
(World population).  
On December 31 2008, patients with prevalent DRE were 15.6% (n=107) of the entire 
population with active epilepsy (n=684), which translate into a prevalence of 0.73 per 1,000. 
DRE was more prevalent in women than in men at all ages except in the >75 years group 
where it was more prevalent in men (Table 5.2). 
In the incident epilepsy population (n= 342) patients developing DRE during the period 
2000-2008 were 10.5% (n=36).  
Table 5.3 illustrates the main demographic and clinical characteristics of patients with DRE, 
as compared to non-drug-resistant patients. In the prevalent population, significant 
differences were found for sex, age and epilepsy syndrome: DREs was more prevalent in 
women than in men, in younger individuals and in patients with generalized 
cryptogenic/symptomatic or undetermined epilepsies (see also Supplemetary Table 5.2). In 
the incident population, significant differences between drug-resistant and non-drug-
resistant patients were found only for age and epilepsy syndrome. These differences were 
confirmed by multivariable regression models, which also showed an increasing prevalence 
of DRE with increasing duration of follow-up (Table 5.4). 
The cumulative risk to become drug-resistant among incident cases during the period 2000-
2008 was 3.7% at 1 year from diagnosis, 6.5% at 3 years from the diagnosis, and 12.3% at 
5 years from diagnosis (Figure 5.2). The mean estimated time to develop drug-resistance 
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was 5.6 years from diagnosis. A significant difference in the cumulative risk to develop drug-
resistance was found for age and epilepsy syndrome, but not for sex (Figure 5.3, 5.4 and 
5.5). Specifically, the cumulative risk to become drug-resistant was highest among patients 
less than 15 years old: 11.4% at 1 year, 17.8% at 3 years and 29.1% at 5 years from diagnosis 
(Figure 5.4). In this age group the mean estimated time to develop drug-resistance from 
diagnosis was 3.8 years.  
Irrespective of age, the risk was highest in patients with generalized 
cryptogenic/symptomatic epilepsies (Figure 5.5): 15.6% at 1 year, 23.5% at 3 years, and 
39.1% at 5 years from diagnosis. In this syndromic category the mean estimated time to 
develop drug resistance from diagnosis was 3.3 years.  
Younger age and having a generalized symptomatic/cryptogenic or undetermined epilepsy 
showed a significant association with drug resistance, also after adjusting for sex. Compared 
to the oldest age class, the adjHR for patients <15 years was 13.80 (95%CI 1.76,108.22). 
Compared to partial idiopathic epilepsies, the adjHR for generalized 
symptomatic/cryptogenic epilepsies was 8.46 (95%CI 1.08,66.55) and for undetermined 
epilepsies was 16.13 (95%CI 1.58,164.89). 
5.4.2 Long-term prognosis and prognostic patterns  
To calculate prognostic patterns, the considered study population included 405 prevalent 
cases (on January 1 2000) and 342 incident cases (newly diagnoses between January 1 2000 
and December 31 2008). The two samples differed according to age and sex and in the 
proportion of drug resistant individuals, but not with reference to the main syndromic 
categories (Supplementary Table 5.3). However, when children (patients less than 18 years) 
and adults (patients 18 years or older) were compared, the two samples differed in a number 
of variables, except for disease duration (Supplementary Table 5.4).  
Six hundred and fifty-seven individuals (88.0%) were followed for at least two years, 540 
(72.3%) for at least five years, 365 (49%) for at least 10 years, and 207 (27.7%) for at least 
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20 years from diagnosis. Details are presented in Table 5.5. In 42.7% of cases epilepsy 
diagnosis was at less than 15 years old. Partial seizures were the predominant type (61.6%). 
Partial symptomatic epilepsies were the commonest syndromic category (35.5%), followed 
by partial cryptogenic epilepsies (22.4%) and idiopathic generalized epilepsies (20.6%).  
As of December 31st 2008, 428 people (57%) had been seizure-free for at least 2 years, 110 
of them off-treatment. Thirty-one people had died at last follow-up. The cumulative time-
dependent probability of starting 2-year remission was 18% at treatment start, 33.5% at two 
years, 44.7% at five years, 52.4% at ten years, and 67.2% at 20 years (Fig. 5.6.1A). The 
probability of having started 2-year sustained remission at 20 years was 59.7% (Fig. 5.6.1B). 
The probability of starting 5-year remission was 14.5% at treatment start and 21.5% at two 
years, 29.8% at five years, 34.7% at ten years and 50.2% at 20 years (Fig. 5.6.1C). The 
corresponding probability of 5-year sustained remission at 20 years was 42.6% (Fig. 5.6.1D). 
Men had a higher probability than women of starting 2-year remission and 2-year sustained 
remission (Tables 5.6A and 5.6B). Apart from individuals a75+ years at diagnosis, the 
probability of starting a 2-year remission and 2-year sustained remission increased with the 
age at diagnosis (Tables 5.6A and 5.6B). People with partial idiopathic epilepsy had the best 
prognostic outlook, followed by those with idiopathic generalized epilepsies and partial 
cryptogenic epilepsies (Table 5.6A and 5.6B). Compared to people starting a 2-year 
remission after treatment with one or two AEDs, those with DRE had a significantly lower 
chance of entering a 2-year remission and to be in remission at last follow-up (Table 5.6A 
and 5.6B). The differences were similar for the probability of attaining 5-year remission and 
sustained remission (see Tables 5.6C and 5.6D). Only epilepsy syndrome and drug resistance 
were confirmed as independent predictors of 2-year and 5-year remission (ever and 
sustained) (Table 5.7).  
Syndromes and drug-resistance (ILAE definition) were significantly different between those 
in 2-year and 5-year terminal remission and those not. Partial and generalized idiopathic and 
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partial cryptogenic epilepsy was more prevalent in the remission group, while generalized 
symptomatic/cryptogenic epilepsy was more prevalent in those not in remission at last 
follow-up than in other groups. Sex and age at diagnosis were unremarkable (data not 
shown).  
Thirteen individuals followed for at least five years had incomplete data and were excluded 
from the prognostic patterns assessment. The 527 remaining had: 1. Early remission: 101 
(19%); 2. Late remission: 175 (33%); 3. Remission followed by relapse: 85 (16%); 4. No 
remission: 166 (31%). Table 5.8 shows the prognostic patterns according to clinical and 
demographic factors. Only epilepsy syndrome, number of drugs used and response to AEDs 
significantly determined long-term prognostic patterns. Late remission was more prevalent 
in generalized idiopathic, partial cryptogenic and idiopathic epilepsy than in other 
syndromes while in generalized symptomatic/cryptogenic epilepsy or partial symptomatic 
epilepsy no remission was the predominant pattern. 36.5% of people with generalized 
symptomatic/cryptogenic epilepsies attained early or late remission. Post-hoc comparisons 
revealed that partial idiopathic epilepsy was highly represented in late remission (52%, 
p=0.0466) and underrepresented in the group never entering remission (10.5%, p=0.0267), 
while generalized symptomatic/cryptogenic and partial symptomatic epilepsies were 
strongly represented in the remission never group (48.1%, p=0.0379 and 38.5%, p=0.0229, 
respectively). 
Almost one fifth (17%) of people taking one AED never attained remission. The percentage 
increased to 34% in those receiving two different drugs and to 62% in those receiving to 
three or more drugs. The post-hoc comparisons confirmed that patients taking one AED were 
rare in early and late remission (29.7%, p<0.0001 and 40.2%, p=0.0009, respectively) and 
less present in the group never entering remission (17.1%, p<0.0001), while patients taking 
three or more AEDs were rare in early and late remission (1.9%, p<0.0001 and 17.0%, 
p=0.0004, respectively) and most represented in the group never entering remission (62.2%, 
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p<0.0001). 69.6% of people who failed two or more drugs never entered remission while 
18% experienced remission followed by relapse and 11.4% had late remission. In the logistic 
regression models, the response to treatment was the only variable associated with differing 
prognostic patterns. In people with drug-resistant epilepsy, the odds ratio (OR) of having 
early remission was 0.03 (95% CI 0.01 to 0.25). The corresponding OR for late remission 
was 0.11 (95% CI 0.05 to 0.25) and for remission followed by relapse was 0.39 (95% CI 
0.19 to 0.82) (p<0.0001).  
5.4.3 AEDs withdrawal 
The study sample consist of 747 people with epilepsy aged 11 months through 94 years and 
followed for a total of 11,045.5 person-years (mean 14.8 years; interquartile range 4.5-22.5). 
Clinical characteristics are provided in Table 5.5; 731 people (98%) were treated with at 
least one AED. 
The use of each compound as first, second, third, or fourth to ninth AED is shown in Table 
5.9. The three AEDs most commonly used as first drug were valproate, carbamazepine and 
phenobarbital and the same drugs were also the commonest second option. The third option 
included, in decreasing order, carbamazepine, levetiracetam and topiramate.  
The commonest reasons for drug withdrawal were, in decreasing order, terminal remission, 
ineffectiveness and adverse events. Table 5.10 shows the reasons for withdrawal with 
reference to the sequence of drug assignment. For the first AED, the main reasons for 
withdrawal were terminal remission followed by ineffectiveness; for the second AED the 
main reasons were ineffectiveness followed by terminal remission; for the third and the 
fourth AED the main reason was ineffectiveness, followed by adverse events. Withdrawal 
for ineffectiveness increased from the first to the seventh drug, while withdrawal for terminal 
remission decreased progressively after the first drug. Adverse events showed a moderate 
increase from the first to the last assigned drugs. 
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Reasons for drug withdrawal for each AED are provided in Table 5.11. The percentages of 
withdrawal of carbamazepine, phenobarbital and valproate due to ineffectiveness were in 
general lower than the percentages reported for other AEDs.  
5.4.3.1. Cumulative probabilities and predictors of withdrawal of the first, second and 
third AED 
1. First AED.  
The cumulative probability of withdrawal of the first AED for ineffectiveness increases from 
2.9% at one year to 12.6% at twenty years (Supplementary Table 5.5). The only predictor 
was age at diagnosis: compared to those aged less than 15 years, those in the 15-64 year 
group were less likely to withdraw due to ineffectiveness (HR 0.46, 95% CI 0.28-0.75), 
while those in the oldest group showed no significant differences (HR 1.26, 95% CI 0.61-
2.59). The cumulative probability of withdrawing the first AED for terminal remission 
increased from 1.0% at one year to 20.0% at twenty years. The variables associated with 
first AED withdrawal due to seizure freedom were age at diagnosis, sex and epilepsy 
syndrome. Compared to those aged less than 15 years, those in the 15-64 year group were 
less likely to withdraw the drug (HR 0.58, 95% CI 0.40-0.86) while those in the oldest group 
had a similar HR although this was not statistically significant. Females had a lower 
probability than males of withdrawing the drug (HR 0.56, 95% CI 0.39-0.82). Those with 
cryptogenic/symptomatic epilepsies (HR 0.43, 95% CI 0.29-0.63) had a lower probability of 
withdrawing the drug than those with idiopathic epilepsies. The cumulative probability of 
withdrawing the first drug for adverse events was 0.5% at one year and increased to 3.3% at 
twenty years. The probability of withdrawing the first drug for other reasons was 0.2% at 
one year and 6.6% at twenty years. Predictors for adverse events and other reasons were not 
assessed, due to the small numbers. No significant differences were observed between old 
and new AEDs given as first treatment (Supplementary Table 5.6). Four hundred and sixty 
people never withdrew the first antiepileptic treatment and 224 of them (50.9%) started a 
Giussani G. 
 
125 
 
period of remission lasting until the end of follow-up. The cumulative probability of either 
withdrawing the first AED for seizure freedom or of achieving sustained remission while 
still on treatment was 23.1% at one year and increased to 48.0% at twenty years. 
2. Second AED. The cumulative probability of withdrawing the second drug at twenty years 
for ineffectiveness was 15.8%, for adverse events 4.3%, for terminal remission 13.3%, and 
for other reasons 7.7% (Supplementary Table 5.5). The only variable associated with 
discontinuation of the second AED for ineffectiveness was seizure type: compared to partial 
seizures, generalized seizures were more likely to lead to drug withdrawal (HR 2.05, 95% 
CI 1.10-3.83). Due to the small number of events, predictors for other reasons for the 
withdrawal of the second AED were not evaluated. No significant differences were found 
between old and new AEDs (Supplementary Table 5.6). 
3. Third AED. The cumulative probability of withdrawing the third AED at twenty years for 
ineffectiveness was 39.3%, for adverse events 8.0%, for seizure freedom 4.3%, and for other 
reasons 5.0% (Supplementary Table 5.5). Due to the small numbers, predictors for the third 
AED withdrawal were not assessed. The comparison between old and new AEDs showed 
no significant differences (Supplementary Table 5.6). 
5.4.3.2. Cumulative probabilities and predictors of withdrawal of the most commonly 
used AEDs 
At 20 years, the cumulative time-dependent probability of withdrawal of carbamazepine for 
ineffectiveness was 10.8%. The corresponding values were 13.5% for phenobarbital and 
12.3% for valproate (Figure 5.7A). The 20-year probability of withdrawal for terminal 
remission was 12.9% for carbamazepine, 14.8% for phenobarbital and 27.4% for valproate 
(Figure 5.7B).  
Predictors of withdrawal due to ineffectiveness were seizure type for carbamazepine and age 
for phenobarbital. No predictors were found for valproate. Generalized seizures were more 
likely than partial seizures to lead to withdrawal of carbamazepine for ineffectiveness (HR 
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3.07, 95% CI 1.35-6.98). Individuals in the 15-64 years group had a lower probability of 
withdrawing phenobarbital due to ineffectiveness than the youngest age group (HR 0.24, 
95% CI 0.11-0.54), while those in the oldest group had a similar HR although this was not 
statistically significant.  
Variables associated with drug withdrawal due to seizure freedom were sex for 
carbamazepine and age, sex and syndrome for valproate. No predictors were found for 
phenobarbital. Females had a lower probability of withdrawing carbamazepine for seizure 
freedom than males (HR 0.47, 95% CI 0.22-0.99). Compared to people in the <15 year 
group, those aged 15-64 years were less likely to withdraw valproate due to ineffectiveness 
(HR 0.30, 95%CI 0.13- 0.70), while those in the oldest group had a similar HR although this 
was not statistically significant; females had a lower probability of withdrawing the drug 
than males (HR 0.52, 95% CI 0.30-0.91); compared with idiopathic epilepsies, those with 
cryptogenic/symptomatic epilepsies were less likely to have drug withdrawal (HR 0.35, 95% 
CI 0.19-0.65). 
Due to the small number of events, cumulative probabilities and predictors of 
carbamazepine, valproate and phenobarbital withdrawal for adverse events and other reasons 
were not assessed. 
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5.4.4 Tables and Figures  
Table 5.1. Prevalence (Pr) of active epilepsy as of December 31 2008 
 Prevalence 
Population N N prevalent cases Pr*1,000 95%CI 
     
M 71,541 341 4.77 4.26 , 5.27 
W 74,965 343 4.58 4.09 , 5.06 
Total 146,506 684 4.67 4.32 , 5.02 
       
M       
<15y 15,700 51 3.25 2.36 , 4.14 
15-34y 15,361 82 5.34 4.19 , 6.49 
35-54y 21,380 104 4.86 3.93 , 5.80 
55-74y 14,920 74 4.96 3.83 , 6.09 
75+y 4,180 30 7.18 4.62 , 9.74 
       
W       
<15y 15,152 49 3.23 2.33 , 4.14 
15-34y 15,214 80 5.26 4.11 , 6.41 
35-54y 20,960 103 4.91 3.97 , 5.86 
55-74y 15,868 74 4.66 3.60 , 5.72 
75+y 7,771 37 4.76 3.23 , 6.29 
       
Total       
<15y 30,852 100 3.24 2.61 , 3.88 
15-34y 30,575 162 5.30 4.48 , 6.11 
35-54y 42,340 207 4.89 4.22 , 5.55 
55-74y 30,788 148 4.81 4.03 , 5.58 
75+y 11,951 67 5.61 4.27 , 6.94 
Legend: 95%CI = 95% Confidence Interval; M = Men; W = Women; y = Years. 
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Table 5.2. Prevalence (Pr) of drug resistant epilepsy in the year 2008  
 Prevalence 
Population N N prevalent cases Pr*1,000 95%CI 
       
M 71,541 39 0.55 0.37 , 0.72 
W 74,965 68 0.91 0.69 , 1.12 
Total 146,506 107 0.73 0.59 , 0.87 
       
M       
<15y 15,700 10 0.64 0.24 , 1.03 
15-34y 15,361 7 0.46 0.12 , 0.79 
35-54y 21,380 14 0.65 0.31 , 1.00 
55-74y 14,920 6 0.40 0.08 , 0.72 
75+y 4,180 2 0.48 0.00 , 1.14 
       
W       
<15y 1,5152 14 0.92 0.44 , 1.41 
15-34y 15,214 16 1.05 0.54 , 1.57 
35-54y 20,960 23 1.10 0.65 , 1.55 
55-74y 15,868 15 0.95 0.47 , 1.42 
75+y 7,771 0 0.00 0.00 , 0.00 
       
Total       
<15y 30,852 24 0.78 0.47 , 1.09 
15-34y 30,575 23 0.75 0.44 , 1.06 
35-54y 42,340 37 0.87 0.59 , 1.16 
55-74y 30,788 21 0.68 0.39 , 0.97 
75+y 11,951 2 0.17 0.00 , 0.40 
Legend:95%CI = 95% Confidence Interval; W = Women; M = Men; y = Years. 
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Table 5.3. Demographic and clinical characteristics of non drug-resistant and drug resistant epilepsy in the prevalent and incident population 
(n=684). 
  Prevalent population  Incident population 
Variable Category Total Non-drug-resistant Drug-resistant  Total Non-drug-resistant Drug-resistant 
    N N % N %  N N % N % 
             
Gender W 343 275 80.2 68* 19.8  154 135 87.7 19 12.3 
 M 341 302 88.6 39 11.4  188 171 91.0 17 9.0 
             
Seizures Focal 432 365 84.5 67 15.5  218 198 90.8 20 9.2 
 Generalized 227 193 85.0 34 15.0  105 92 87.6 13 12.4 
 Unclassifiable 25 19 76.0 6 24.0  19 16 84.2 3 15.8 
             
Syndrome PI 44 43 97.7 1** 2.3  23 22 95.7 1
# 4.3 
 PS 253 209 82.6 44 17.4  133 120 90.2 13 9.8 
 PC 157 134 85.4 23 14.6  78 72 92.3 6 7.7 
 GI 129 117 90.7 12 9.3  59 56 94.9 3 5.1 
 GC/GS 71 51 71.8 20 28.2  33 23 69.7 10 30.3 
 
Undetermined 24 19 79.2 5 20.8 
 
12 
9 75.0 3 25.0 
 Special 6 4 66.7 2 33.3  4 4 100.0 0 0.0 
 
 
      
 
     
Age§ <15y 100 76 76.0 24*** 24.0  120 97 80.8 23
## 19.2 
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 15-34y 162 139 85.8 23 14.2  70 69 98.6 1 1.4 
 35-54y 207 170 82.1 37 17.9  62 55 88.7 7 11.3 
 55-74y 148 127 85.8 21 14.2  69 65 94.2 4 5.8 
 75+y 67 65 97.0 2 3.0  21 20 95.2 1 4.8 
             
Disease duration <1year 609 512 84.1 97 15.9  302 267 88.4 35 11.6 
at the time of 
diagnosis 
≥1year 72 62 86.1 10 13.9  39 38 97.4 1 2.6 
 Missing data 3 3 100.0 0 0.0  1 1 100.0 0 0.0 
             
Legend: W = women; M = Men; PI = Partial Idiopathic; PS = Partial Symptomatic; PC = Partial Cryptogenic; GI = Generalized Idiopathic; GC/GS = 
Generalized Cryptogenic/Generalized Symptomatic; y = Years. 
*P=0.0025 **P=0.0019; ***P=0.0054 (compared to non drug-resistant epilepsy) 
#P=0.0024; ##P=0.00012 (compared to non drug-resistant epilepsy) 
§In the incident population, age was calculated at diagnosis. 
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Table 5.4. Factors associated with drug-resistant epilepsy in multivariable logistic regression models. 
 
  Prevalent population  Incident population 
Variable Category OR 95% CI P-value  OR 95% CI P-value 
Gender    0.0030    0.3995 
 W  2.0 1.3 - 3.2   1.4 0.6 - 3.0  
 M (ref.) 1.0    1.0   
Syndrome    0.0032    0.0280 
 PI (ref.) 1.0    1.0   
 PS 20.6 2.7 - 157.3   6.5 0.7 - 56.4  
 PC 16.2 2.1 - 126.8   5.3 0.6 - 50.5  
 GI 7.0 0.9 - 56.3   1.7 0.2 - 18.0  
 GC/GS 21.6 2.7 - 170.9   14.4 1.6 - 128.4  
 Spec. 50.9 3.5 - 734.3   - -  
 Undet. 25.0 2.6 - 240.0   20.7 1.6 - 269.4  
Age*    <0.0001    0.0039 
 <15y  25.2 5.2 - 122.3   7.9 0.9 - 67.6  
 15-34y 8.3 1.8 - 38.4   0.4 0.02 - 7.0  
 35-54y 6.4 1.4 - 28.6   2.9 0.3 - 26.0  
 55-74y 5.1 1.1 - 23.5   1.5 0.5 - 15.0  
 75+y (ref.) 1.0    1.0   
Disease duration         
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at the time of 
diagnosis    0.4030 
 
  0.1160 
 <1 year (ref.) 1.0    1.0   
 >=1 year 0.7 0.3 - 1.5   0.2 0.02 - 1.1  
Duration of 
follow-up 1 year increase 1.05 1.02 - 1.06 <0.0001 
 
0.9  0.8-1.1 0.3247 
 
Legend: 95%CI = 95% Confidence Interval; W = Women; M = Men; y = Years; OR = odds ratio; PI = Partial Idiopathic; PS = Partial Symptomatic; PC 
= Partial Cryptogenic; GI = Generalized Idiopathic; GC/GS = Generalized Cryptogenic/Generalized Symptomatic. *In the incident population, age was 
calculated at diagnosis. 
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Figure 5.1. Study flow-chart 
 
Legend: GPs= General practitioners; PWE = Patients with epilepsy; PNES =Psychogenic 
non-epileptic seizures; AED = Antiepileptic drugs. 
*AED prophylaxis in cerebrovascular accidents (49), in brain tumors (31) and in traumatic 
brain injury (21). 
**Other conditions: Psychiatric diseases (50), Migraine/ neuropatic pain (17), 
Parkinson/dementia (7), Peripheral neuropathies (5), Neonatal hypoxia (4), Hydrocephalus 
(2), Restless leg syndrome (1), Behçet syndrome (1), Lupus erythematosus (1), Dizziness 
(1). 
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Figure 5.2. Cumulative time-dependent probability of drug resistance in incident 
patients with epilepsy in the overall sample 
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Figure 5.3. Cumulative time-dependent probability of drug resistance in incident 
patients with epilepsy by sex 
Legend: F= female; M = male. The shadows represent the 95% confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
Giussani G. 
 
136 
 
Figure 5.4. Cumulative time-dependent probability of drug resistance in incident 
patients with epilepsy by age 
Legend: The shadows represent the 95% confidence interval. 
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Figure 5.5. Cumulative time-dependent probability of drug resistance in incident 
patients with epilepsy by syndrome 
 
Legend: The shadows represent the 95% confidence interval. 
 
 
Legend: PI = Partial Idiopathic; PS = Partial Symptomatic; PC = Partial Cryptogenic; GI = 
Generalized Idiopathic; GC/GS = Generalized Cryptogenic/Generalized Symptomatic. 
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Figure 5.6. Cumulative time-dependent probability of attaining 2-year remission (A), 
2-year sustained remission (B), 5-year remission (C), and 5-year sustained remission 
(D) in the study cohort 
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Table 5.5. General characteristics of the sample (n=747) 
Variable Category N % 
 
Gender F 366 49.0 
 M 381 51.0 
    
Family history of Yes 111 14.9 
seizures No 584 78.2 
 Unknown 52 6.9 
 
Seizures Partial 460 61.6 
 Generalized 260 34.8 
 Unclassifiable 27 3.6 
    
Syndrome GC/GS 74 9.9 
 GI 154 20.6 
 PC 167 22.4 
 PI 54 7.2 
 PS 265 35.5 
 Undetermined 26 0.9 
 Special 7 3.5 
 
Age at diagnosis <15y 318 42.7 
 15-34y 183 24.6 
 35-54y 120 16.1 
 55-74y 100 13.4 
 75+y 24 3.2 
 Missing 2  
    
Disease duration  <1y 666 89.5 
at diagnosis ≥1 y 78 10.5 
 Missing 3  
    
Drug resistant No 640 85.7 
  Yes 107 14.3 
 
Age at diagnosis for broad categories <15y 318 42.7 
 15-64y         353        47.4 
 65+y 74 9.9 
 Missing 2  
    
    
Number of AEDs 0        16          2.1 
 1        393         52.6 
 2        199         26.6 
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 3 74 9.9 
 4+ 65  8.7 
Legend:   W women; M Men; GC/GS Generalized Cryptogenic/Generalized Symptomatic; 
GI Generalized Idiopathic; PC Partial Cryptogenic; PI Partial Idiopathic; PS Partial 
Symptomatic;  
y Years; AED Antiepileptic drug. 
*Any type of seizures in all known relatives. 
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Table 5.6. Cumulative time dependent probability of attaining 2-year remission, 2-year sustained remission, 5-year remission, 5-year sustained 
remission by selected demographic and clinical variables. Univariate analysis 
 A. Cumulative probability of starting a 
2-year remission 
 
B. Cumulative 
probability of 
starting a 2-year 
sustained 
remission 
 
C. Cumulative 
probability of 
starting a 5-year 
remission 
 
D. Cumulative 
probability of 
starting a 5-year 
sustained 
remission  
Years of 
follow-up 
0 2 5 10 20 
p-
valu
e 
0 2 5 10 20 
p-
valu
e 
0 2 5 10 20 
p-
valu
e 
0 2 5 10 20 
p-
valu
e 
Sex      
0.003
5 
     
0.020
2 
     
0.002
0 
     
0.015
0 
M 21.5 37.6 49.9 56.7 72.4  
14
.6 
28
.9 
41
.3 
49
.2 
65
.6 
 
14
.4 
26
.1 
35
.8 
39
.1 
57
.4 
 
9.
8 
19
.4 
28
.0 
31
.7 
49
.5  
W 14.0 28.9 39.0 47.7 62.0  
10
.9 
23
.1 
32
.6 
40
.5 
54
.1 
 
9.
5 
16
.9 
23
.7 
30
.1 
43
.6 
 
7.
5 
14
.0 
20
.1 
25
.0 
36
.8  
Age at 
diagnosis 
     
<0.0
001 
     
<0.0
001 
     
0.000
1 
     
<0.0
001 
<15y 13.3 27.3 36.1 43.3 57.1  
9.
6 
20
.4 
28
.4 
35
.5 
48
.0 
 
8.
0 
15
.5 
22
.1 
27
.1 
41
.4 
 
5.
3 
11
.3 
17
.0 
21
.1 
33
.4  
15-34y 20.8 35.2 47.5 54.0 70.8  
13
.9 
25
.8 
37
.8 
44
.8 
62
.3 
 
15
.0 
22
.9 
32
.9 
36
.9 
55
.4 
 
10
.0 
16
.9 
24
.7 
28
.4 
46
.0  
35-54y 22.2 36.4 48.2 56.3 79.1  
17
.2 
31
.2 
43
.0 
50
.5 
76
.3 
 
15
.2 
26
.6 
32
.9 
40
.9 
57
.6 
 
12
.7 
23
.1 
29
.8 
36
.5 
54
.4  
55-74y 20.8 45.5 60.6 78.6 91.5  
16
.9 
39
.2 
55
.0 
75
.6 
90
.2 
 
14
.8 
35
.2 
46
.5 
49
.2 
77
.8 
 
13
.0 
28
.7 
41
.2 
44
.1 
75
.5  
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75+y 27.8 44.4 62.5 62.5  -  
11
.8 
32
.1 
54
.2 
54
.2 
 -  
16
.7 
25
.0 
41
.7 
41
.7 
 -  
8.
3 
17
.5 
35
.8 
35
.8 
 - 
 
Syndrome      
<0.0
001 
     
0.000
1 
     
0.000
1 
     
0.000
1 
GC/GS 6.5 17.7 17.7 32.9 40.9  
4.
8 
11
.6 
11
.6 
27
.9 
33
.7 
 
7.
7 
11
.5 
11
.5 
20
.3 
26
.2 
 
5.
8 
5.
8 
5.
8 
15
.1 
18
.2  
GI 21.1 35.3 52.3 59.8 73.9  
14
.3 
24
.5 
41
.3 
48
.5 
65
.5 
 
14
.2 
23
.0 
37
.2 
42
.5 
59
.1 
 
9.
7 
18
.2 
30
.7 
34
.3 
52
.1  
PC 19.9 36.9 52.2 60.8 72.8  
13
.6 
29
.2 
45
.5 
54
.4 
65
.6 
 
14
.2 
23
.3 
31
.7 
35
.8 
47
.3 
 
10
.0 
18
.0 
26
.1 
29
.3 
37
.7  
PI 23.9 45.7 54.4 66.2 86.4  
19
.6 
39
.1 
48
.8 
62
.1 
83
.1 
 
13
.9 
25
.0 
41
.7 
51
.2 
80
.4 
 
11
.2 
22
.7 
34
.6 
45
.4 
75
.6  
PS 15.2 30.9 40.3 44.4 61.6  
12
.0 
26
.2 
34
.7 
38
.5 
55
.3 
 
8.
3 
20
.1 
25
.4 
28
.2 
44
.2 
 
7.
1 
16
.3 
21
.9 
24
.0 
38
.9  
Special 40.0 60.0 60.0 60.0 60.0  
20
.0 
46
.7 
46
.7 
46
.7 
46
.7 
 
40
.0 
60
.0 
60
.0 
60
.0 
60
.0 
 
20
.0 
46
.7 
46
.7 
46
.7 
46
.7  
Undetermine
d 
30.0 40.0 45.0 50.5 62.9  
15
.0 
27
.1 
27
.1 
34
.4 
42
.6 
 
18
.8 
25
.0 
31
.3 
37
.5 
52
.4 
 
6.
3 
13
.5 
13
.5 
21
.3 
30
.1  
Drug 
resistant 
     
<0.0
001 
     
<0.0
001 
     
<0.0
001 
     
<0.0
001 
No 20.6 37.6 50.1 58.5 74.9  
15
.2 
30
.3 
42
.7 
51
.6 
68
.6 
 
13
.7 
24
.5 
34
.1 
39
.8 
58
.4 
 
10
.2 
19
.7 
28
.2 
33
.5 
51
.6  
Yes 3.2 10.6 14.0 17.9 24.9  
0.
0 
3.
4 
5.
7 
8.
5 
12
.6 
 
2.
5 
5.
1 
6.
3 
7.
7 
11
.5 
 
0.
0 
0.
0 
1.
3 
1.
3 
1.
3  
 
Legend:   W = women; M = Men;   GC/GS = Generalized Cryptogenic/Generalized Symptomatic;  PC = Partial Cryptogenic;   PI = Partial Idiopathic;    
PS = Partial Symptomatic; y = Years. 
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Table 5.7. Selected demographic and clinical predictors of 2-year and 5-year remission. Multivariate analysis 
    2-year remission   5-year remission 
  All  Sustained  All  Sustained 
Variable Category HR 95% CI p-value   HR 95% CI p-value   HR 95% CI p-value   HR 95% CI p-value 
 
Gender    0.3160    0.7963    0.1041    0.3859 
 F ref.    ref.    ref.    ref.   
 M 1.11 0.91 - 1.36   1.03 0.82 - 1.29   1.25 0.96 - 1.63   1.14 0.85 - 1.54  
Age at diagnosis    0.6724    0.7587    0.2096    0.3169 
 <15y ref.    ref.    ref.    ref.   
 15-34y 1.20 0.93 - 1.54   1.16 0.87 - 1.55   1.39 0.99 - 1.93   1.32 0.91 - 1.93  
 35-54y 1.04 0.76 - 1.42   1.08 0.77 - 1.53   1.38 0.90 - 2.09   1.48 0.93 - 2.34  
 55-74y 1.18 0.84 - 1.65   1.22 0.85 - 1.75   1.65 1.03 - 2.64   1.64 0.98 - 2.74  
 75+y 1.08 0.57 - 2.05   0.92 0.44 - 1.92   1.35 0.53 - 3.45   1.17 0.41 - 3.35  
Syndrome    <0.0001    <0.0001    0.0002    0.0002 
 GC/GS 0.33 0.20 - 0.54   0.27 0.16 - 0.47   0.27 0.14 - 0.51   0.20 0.09 - 0.43  
 GI 0.63 0.44 - 0.92   0.51 0.34  - 0.77   0.58 0.37 - 0.92   0.51 0.31 - 0.84  
 PC 0.58 0.39 - 0.85   0.50 0.33 - 0.76   0.42 0.25 - 0.69   0.35 0.20 - 0.61  
 PI ref.    ref.    ref.    ref.   
 PS 0.45 0.31 - 0.65   0.38 0.26 - 0.58   0.38 0.24 - 0.60   0.36 0.21 - 0.59  
 Special 0.67 0.21 - 2.21   0.51 0.12 - 2.15   1.10 0.33 - 3.72   0.89 0.20 - 3.87  
 Undetermined 0.68 0.37 - 1.25   0.54 0.26 - 1.09   0.55 0.26 - 1.14   0.39 0.16 - 0.97  
                 
Drug resistant    <0.0001    <0.0001    <0.0001    0.0002 
 No ref.    ref.    ref.    ref.   
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  Yes 0.28 0.19 - 0.43     0.16 0.09 - 0.28     0.18 0.09 - 0.35     0.02 0.01 - 0.98   
                 
 
Legend:   HR = Hazard Ratio; 95%CI = 95% Confidence Interval; F = female;   M = Male;   GC/GS = Generalized Cryptogenic/Generalized Symptomatic;  
   PC = Partial Cryptogenic; PI = Partial Idiopathic; PS = Partial Symptomatic;   y = Years 
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Table 5.8. Prognostic patterns by selected demographic and clinical variables 
    Early remission Late remission 
Remission-
relapse Remission never   
Variable Category N % N % N % N % p-value* 
           
Gender F 43 16.6 89 34.4 39 15.0 88 34.0 0.3469 
 M 58 21.6 86 32.1 46 17.2 78 29.1  
           
Seizures Partial 61 19.2 103 32.4 48 15.1 106 33.3 0.5234 
 Generalized 38 19.5 68 34.9 32 16.4 57 29.2  
 Unclassifiable 2 14.3 4 28.6 5 35.7 3 21.4  
           
Syndrome GC/GS 4 7.7 15 28.8 8 15.4 25 48.1 0.0046 
 GI 25 21.0 45 37.8 22 18.5 27 22.7  
 PC 27 22.1 38 31.2 20 16.4 37 30.3  
 PI 9 23.7 20 52.6 5 13.2 4 10.5  
 PS 32 18.4 52 29.9 23 13.2 67 38.5  
 Special 2 40.0 0 0.0 1 20.0 2 40.0  
 Undetermined 2 11.8 5 29.4 6 35.3 4 23.5  
           
Age at diagnosis <15y 35 14.9 75 31.9 41 17.5 84 35.7 0.3039 
 15-34y 26 18.4 50 35.5 26 18.4 39 27.7  
 35-54y 21 25.9 27 33.3 8 9.9 25 30.9  
 55-74y 16 28.1 20 35.1 7 12.3 14 24.5  
 75+y 3 23.1 3 23.1 3 23.1 4 30.7  
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 Missing          
           
Disease duration  <1y 88 18.6 161 34.0 73 15.4 152 32.1 0.2914 
at diagnosis ≥1 y 13 24.5 14 26.4 12 22.6 14 26.4  
           
Number of AED 0 0 0.0 0 0.0 1§ 20.0 4^ 80.0 <0.0001 
 1 80 29.7 108 40.2 35 13.0 46 17.1  
 2 19 12.9 49 33.3 29 19.7 50 34.0  
 3+ 2 1.9 18 17.0 20 18.9 66 62.2  
           
Drug resistant No 100 22.3 166 37.0 71 15.9 111 24.8 <0.0001 
  Yes 1 1.3 9 11.4 14 17.7 55 69.6   
           
 
Legend:   W = women; M = Men; GC/GS = Generalized Cryptogenic/Generalized Symptomatic; GI = Generalized Idiopathic; PC = Partial Cryptogenic;  
PI = Partial Idiopathic; PS = Partial Symptomatic;  y = Years; AED = antiepileptic drugs. 
* Univariable chi-square; ^ 1 patient, age 15, with GI epilepsy; 2 patients, age 88 and 74, taking only diazepam at the time of the seizures; 1 patient, age 
83, with brain tumor; § 1 patient, age 31, with GI epilepsy. 
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Table 5.9. Administration frequency of first, second and third drug by active 
principle 
  First drug Second drug Third drug 
Fourth to ninth 
drug 
  N % N % N % N 
BSC 18 2.5 7 2.1 1 0.7 1 
CBZ 203 27.8 60 17.8 18 12.9 4 
CLB 2 0.3 22 6.5 12 8.6 7 
CNP 2 0.3 31 9.2 8 5.8 16 
ESM 9 1.2 4 1.2 4 2.9 2 
GBP 2 0.3 6 1.8 4 2.9 6 
LEV 13 1.8 32 9.5 18 12.9 29 
LTG 4 0.5 32 9.5 13 9.4 15 
OXC 31 4.2 16 4.7 5 3.6 10 
PB 197 26.9 39 11.5 9 6.5 3 
PHT 27 3.7 20 5.9 1 0.7 1 
PGB 1 0.1 3 0.9 6 4.3 4 
PRM 0 0.0 3 0.9 8 5.8 3 
TGB 1 0.1 0 0.0 0 0.0 2 
TPM 4 0.5 13 3.8 14 10.1 10 
VGB 3 0.4 4 1.2 5 3.6 2 
VPA 211 28.9 44 13.0 12 8.6 7 
VPM 3 0.4 2 0.6 1 0.7 1 
ZNS 0 0.0 0 0.0 0 0.0 3 
        
Total N 
patients* 
731  338  139  65 
        
Old AEDs 672 91.9 232 68.6 74 53.2 45 
New 
AEDs 
59 8.1 106 31.4 65 46.8 81 
 
AED Antiepileptic drugs, BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam,  
CNP Clonazepam, ESM Ethosuximide, GBP Gabapentin, LEV Levetiracetam, LTG 
Lamotrigine, OXC Oxcarbazepine, PB Phenobarbital, PHT Phenytoin, PGB Pregabalin, 
PRM Primidone,  
TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate, VPM Valpromide,  
ZNS Zonisamide. 
*16 did not start drugs. 
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Table 5.10. Reasons of drug withdrawal by order 
Ranking 
Patients 
treated 
Ineffectivenes
s 
Adverse 
events 
Terminal 
remission 
Other* 
Never 
withdrawn 
 N N % N % N % N % N % 
First 731** 83 11.3 20 2.7 117 16.0 45 6.2 460 62.9 
Second 338** 45 13.3 11 3.2 24 7.1 20 5.9 232 68.6 
Third  139 33 23.7 6 4.3 4 2.9 6 4.3 90 64.7 
Fourth 65 22 33.8 3 4.6 0 0.0 2 3.1 38 58.5 
Fifth 31 11 35.5 2 6.5 2 6.5 0 0.0 16 51.6 
Sixth 18 6 33.3 0 0.0 1 5.6 0 0.0 11 61.1 
Seventh  7 3 42.9 0 0.0 0 0.0 0 0.0 4 57.1 
Eighth 3 0 0.0 2 66.7 0 0.0 0 0.0 1 33.3 
Ninth 2 0 0.0 1 50.0 0 0.0 0 0.0 1 50.0 
 
*Death, drug out of production, pregnancy, own volition. 
** Missing information about AED withdrawal in six. 
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Table 5.11. Frequency of reasons of drug withdrawal by active principle 
  
Patients 
treated 
Ineffectiveness Adverse events 
Terminal 
remission 
Other* 
Never 
withdrawn 
  N N % N % N % N % N % 
BSC 27 6 22.2 1 3.7 4 14.8 9 33.3 7 25.9 
CBZ 285 31 10.9 16 5.6 29 10.2 15 5.3 194 68.1 
CLB 43 12 27.9 0 0.0 2 4.7 2 4.7 27 62.8 
CNP 57 6 10.5 1 1.8 1 1.8 2 3.5 47 82.5 
ESM 19 4 21.1 0 0.0 6 31.6 0 0.0 9 47.4 
GBP 18 12 66.7 0 0.0 0 0.0 0 0.0 6 33.3 
LEV 92 12 13.0 5 5.4 3 3.3 0 0.0 72 78.3 
LTG 64 15 23.4 1 1.6 2 3.1 4 6.3 42 65.6 
OXC 62 10 16.1 3 4.8 5 8.1 3 4.8 41 66.1 
PB 248 34 13.7 7 2.8 34 13.7 23 9.3 150 60.5 
PHT 49 16 32.7 3 6.1 2 4.1 4 8.2 24 49.0 
PGB 14 1 7.1 0 0.0 0 0.0 2 14.3 11 78.6 
PRM 14 2 14.3 0 0.0 1 7.1 1 7.1 10 71.4 
TGB 3 2 66.7 1 33.3 0 0.0 0 0.0 0 0.0 
TPM 41 11 26.8 4 9.8 4 9.8 1 2.4 21 51.2 
VGB 14 7 50.0 0 0.0 2 14.3 0 0.0 5 35.7 
VPA 274 27 9.9 3 1.1 55 20.1 8 2.9 181 66.1 
VPM 7 0 0.0 0 0.0 1 14.3 1 14.3 5 71.4 
ZNS 3 0 0.0 0 0.0 0 0.0 0 0.0 3 100.0 
            
Old AEDs 1023 138 13.5 31 3.0 135 13.2 66 6.5 654 63.9 
New AEDs 311 70 22.2 14 4.5 16 5.1 10 3.2 201 64.6 
AED Antiepileptic drug, BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam, CNP Clonazepam, ESM Ethosuximide,  
GBP Gabapentin, LEV Levetiracetam, LTG Lamotrigine, OXC Oxcarbazepine, PB Phenobarbital, PHT Phenytoine, PRG Pregabalin, PRM 
Primidone, TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate, VPM Valpromide, ZNS Zonisamide. 
* Death, drug out of production, pregnancy, own volition withdrawal. 
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Figure 1. Cumulative incidence functions for withdrawal of carbamazepine, 
phenobarbital and valproate, for ineffectiveness (A) and terminal remission (B). 
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6. DISCUSSION 
Epilepsy is a chronic neurological disorder with heterogeneous phenotype. The 
heterogeneity of the disease has several diagnostic and therapeutic implications. A relevant 
diagnostic implication is represented by the common misdiagnosis of PNES as epilepsy with 
consequent negative reflections for the response to the available antiepileptic drugs. The 
frequency of DRE is perhaps inflated by a number of patients who have PNES without 
genuine epileptic seizures. The exclusion of these patients may not only lead to a more 
correct management of the disease but it also helps defining the true burden of DRE. 
Unfortunately, in the absence of VEM, the differential diagnosis can only rest on the 
contribution of history, clinical signs and, if available, video recording of the seizure(s). 
Based on our findings, videos themselves help making a correct diagnosis of PNES 
characterized by motor signs. In about one third of cases a confident diagnosis of PNES/ES 
can be established by trained epileptologists on clinical ground based on video data alone 
and our results benefit all affected patients, particularly those with no access to VEM units.  
In all the patients with PNES, we found a number of variables to differentiate PNES from 
ES. Investigating the patients themselves and their witnesses using ad-hoc structured 
questionnaires, some variables have been identified with high SE and SP, some of them also 
reaching statistically significance. These instruments may be useful clinical tools applicable 
in settings not offering the facilities for a correct diagnosis and in cases where the gold 
standard has failed. 
When psychiatrists have been included in the study, they demonstrated to be less accurate 
than neurologists in diagnosing PNES but were more attuned to capture the subtleties of 
human behaviour, or subjective experiences as the effects of hidden internal conflicts, and 
they contributed a new lexicon in defining PNES. The different elements valued by 
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neurologists and psychiatrists imply the need to have joint consultations to refine the 
diagnosis. 
 
In the study on the characterization of idic(15) syndrome, epilepsy was used as disease tracer. 
It was found to be one of the few symptoms on which satisfactory agreement was found. 
regarding its presence or absence. Unfortunately, epilepsy was present in similar proportions 
in the idic(15) and in the syndromes characterized by intellectual disability and abnormal 
behaviour. Epilepsy is thus a reliable diagnosis but is not a marker of this genetic syndrome. 
Other focused studies are needed to further investigate this issue. 
To verify if the epilepsy phenotype is static or dynamic and can be affected by the response 
to the available drugs, a population based-study in a well-defined area of Italy was 
performed. Our data indicate that 1/6 patients with active epilepsy in the general population 
has DRE and 1/10 patients with newly diagnosed epilepsy will develop DRE within nine 
years from the diagnosis.  
Furthermore, the long-term prognosis of epilepsy is favorable in most cases. However, early 
seizure remission is not invariably followed by terminal remission and seizure outcome 
varies according to well-defined patterns. Also drug-resistant patients can reach terminal 
remission. This is a demonstration of the dynamic phenotype of epilepsy and, most 
importantly, DRE. 
Prolonged seizure remission and prognostic patterns can be predicted by broad syndromic 
categories and the failure of two antiepileptic drugs. We also observed that the AED given 
at diagnosis is retained in the majority of cases. Seizure freedom, lack of efficacy and adverse 
effects were, in decreasing order, the commonest reasons for AED discontinuation. 
Withdrawal can be predicted by age at diagnosis, sex, disease characteristics and varies 
among drugs. 
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In the following subsections I report an extended and focused discussion for each research 
project. 
 
6.1 MI-RO PNES Study 
6.1.1 Discussion about the prediction of the diagnosis of PNES versus ES 
This study offered an opportunity to define how experts in the field of epilepsy utilize visual 
clues to establish the diagnosis of epilepsy versus non-epilepsy. Raters’ attention was 
focused on the presence of elementary signs typically associated with ES or PNES, and at 
the same time on how these signs are linked and develop, either in a progressive evolution 
that follows the CNS organization or in a disorganized manner, incongrous with neurological 
pathophysiology. This conforms to the pre-learned model of ES and PNES that includes a 
number of positive signs associated with, or exclusive of, the diagnosis of either diagnosis. 
It also explains why in the raters’ comments the term “semiology” was the most frequently 
mentioned as key to the diagnosis. This approach was most likely successful in cases with 
ES or PNES but almost always failed when the diagnosis was Other NES. There are two 
possible explanations for this observation: 1) motor manifestations, that we found directly 
correlated with the ability to match the GS diagnosis, are more likely to be represented in 
ES and PNES than in Other NES; 2) for the diagnosis of Other NES, additional information 
about the prodromal symptoms and the results of monitoring other physiological parameters 
(EKG telemetry, blood pressure, etc.) is necessary. Raters were quite aware of these 
limitations and chose in many such cases to withhold a diagnosis (Cannot Say) stating: 
“diagnosis impossible” or “cannot be reached with confidence based on video alone”.  
An important factor affecting raters’ accuracy was the number of diagnostic clues detected. 
The presence of multiple signs and objective symptoms increased accuracy because 
objective signs are more reliable than subjective reports and the joint occurrence of various 
signs increases specificity, as reported by others (Sayed et al, 2011).      
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Our study, investigating the reliability of video data alone, duplicates the results of a 
previous study (Benbadis et al, 2009). Interrater variability in interpreting videotaped events 
was present in about equal measure, whether the EEG was included or excluded. Kappa 
values in the two studies for the overall group and for each diagnostic category were very 
close. Interrater agreement in predicting the GS diagnosis was comparable. This finding was 
corroborated by the additional observation that in our study, among the three “best” raters, 
the two (R-1 and R-4), both blind to the patients’ history and EEG findings, performed just 
as well as R-5 who was not blind.  This suggests that, in some cases, the video provides key 
information so typical that knowledge of the simultaneous EEG has little impact on 
diagnostic accuracy.  
Our findings underscore the position of the ILAE Task Force (LaFrance et al, 2013) that in 
the majority of cases a correct diagnosis is based on the convergence of (1) history, (2) 
witnessed semiology, (3) monitoring of multiple physiological functions (EEG, EKG, other 
autonomic). At the same time, our data indicate that not in all cases the three elements are 
essential to reach the diagnosis, confirming the observation that not infrequently 
epileptologists are quick in differentiating ES from PNES on video before viewing the EEG.  
Since it is proven that the ability to discriminate one type of seizure from another is a learned 
skill and requires neurological training (Ristić et al, 2015; Seneviratne et al 2014; 
MacDonalds et al, 2012) one note of caution is that reviewers must be properly trained and 
experienced. One major cause of concern is the variable degree of competence among 
reviewers and how it affects inter-rater agreement.  
Our 5 raters, interpreting video data alone, were not exempt from such liability. Two raters 
performed consistently at a lower level of accuracy compared to the other three. That may 
be explained, at least for one who was a child neurologist, by lower exposure during clinical 
practice to the adult population that was the focus of this investigation. However the 
diagnosis based on video alone showed concordance among all five raters and was correct 
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in almost one third of the videos reviewed. In this study motor seizure semiology diagnoses 
fared better than non-motor seizures, confirming the results of a previous study (King et al, 
1982). As reported by others (Seneviratne et al, 2012), some seizure types were easier than 
others to diagnose based on videos. In our sample these seizures were represented by focal 
seizures with secondary generalization and complex and rhythmic motor PNES. The reasons 
for that are in the raters comments, indicating that video alone was not useful, was inadequate 
and at times misleading in the case of non-motor, sensory and dyscognitive seizures. 
 A correct prediction of the putative diagnosis also depends on video quality. Videos 
recorded in hospital rooms during VEM, are not constantly supervised and capture 
spontaneous events that often go unnoticed or are only partially witnessed by staff. Indeed, 
missing relevant features such as the proper display of the subject and subject’s behaviour, 
a dysfunctional audio or lack of intervention by bystanders, were the most common reasons 
for the video rated below the minimum desirable standard. However, after removing poor 
quality videos from analysis, interrater agreement improved only slightly. This can be 
explained by the differing reasons given by the raters to qualify a video as inadequate, some 
of which unlikely to affect the diagnosis, and by the non-unanimous quality assessment 
among raters. Nonetheless, efforts to improve video quality would be valuable. For example, 
the use of a video made through a mobile device can have a higher quality and the caregiver 
could be trained to frame the face or body movements and to record the audio. The problem 
could be the missing of the seizure start, but not in the case in which prodromal symptoms 
are present, because a family member could be alerted and start to record the video. It is a 
problem for an epileptic seizure (focal or generalized). 
The main strenghts of this investigation are the prospective approach, the inclusion of all 
eligible candidates consecutively admitted for monitoring, and a collection of data prior to 
the diagnosis. This provided a cohort of patients with mixed seizure disorders reflecting the 
current referral pattern to epilepsy monitoring units and allowed to investigate these subjects 
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without bias, contrary to many previous PNES studies based on retrospective data. Our main 
contribution is a closer insight on how epileptologists utilize the information, displayed on 
video of events recorded during hospital monitoring. Such approach has however inhertent 
constraints. For instance, while some events such as rhythmic motor PNES are possible to 
diagnose on video alone, others such as sensory, non-motor or autonomic events, are not.  
This study presents some limitations. First, the number of cases investigated in this 
feasibility study is small. Second, our restricted cohort did not include “hypermotor 
PNES”, a rather uncommon type that is notoriously difficult to differentiate from 
hypermotor frontal lobe seizures. Third, patients with other NES diagnosis were only four 
and no patients with a double diagnosis of ES + PNES were enrolled. Fourth, patients were 
enrolled only in a single epilepsy unit. Patients seen in other tertiary referral centers/ 
epilepsy units’ may be different. In addition, we cannot exclude that subjects with other-
socio-cultural background present with different phenotype. In order to solve this 
questions, we need a large prospective international comparing different populations. Fifth, 
the number and background of our raters is fairly small and selected, which may have 
affected the results.  
On the other hand, our results were worthwhile for a number of reasons. First, they provide 
useful information for the power analysis of larger studies. Second, they generate new 
hypotheses and stimulate new research. Third, our experience proves that international 
collaboration is possible in compliance with privacy regulations, and exchange of personal 
information such as video images through the Internet is acceptable. This is an opportunity 
for exploring patient populations where manifestations and frequency of PNES may vary in 
relation to cultural differences (Asadi-Pooya and Sperling, 2015). Most importantly, it may 
spur new interest in the video format, once defined as “the closest proxy to witnessed events” 
(MacDonald et al, 2012). A greater use of this modality may be particularly beneficial when 
VEM is not available. This is relevant not only for future research but also for clinical 
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purposes. The utilization of homemade videos as a method of screening patients before 
admission to a full monitoring unit and its diagnostic value could be further explored. 
Finally, because clinical assessment based on video alone can easely lead to misdiagnosis, 
further investigations are needed to identify clinical parameters necessary to corroborate a 
video diagnosis in settings where full VEM investigation is not accessible. 
 
6.1.2 Discussion about the prediction of the diagnosis of PNES versus ES engaging 
psychiatrists. 
By most statistical measures, experienced epileptologists were more skilful than a group of 
practicing psychiatrists in blindly predicting the GS diagnosis, based exclusively on the 
physical semiology of a “seizure”. This result was expected considering that, contrary to 
epileptologists, psychiatrists seldom have the opportunity to directly scrutinize events on 
video. However, whereas degree of interrater agreement within groups was quite different, 
success rate in the two groups was almost comparable when the opinions of individual raters 
examining each single video were compared. The comments presented to justify the 
diagnosis of choice may explain this apparent contradiction. They indicate that psychiatrists, 
encouraged by training, during the unfolding of an event, detect subtle psycho-dynamic 
indicators that can be utilized as diagnostic tools in addition to pure semiology. Such signs 
or manifestations are implicitly part of the currently accepted definition of PNES but can be 
easily ignored by professionals with less psychodynamic experience.   
According to the ILAE recommendations (LaFrance et al, 2013), the diagnosis of PNES is 
essentially based on the following criteria: inconsistent semiology with clinical 
manifestations that do not conform to a coherent neurological scheme as ES do; lack of the 
required neuro-physiological substrate (ictal EEG discharges); evidence of risk factors that 
may lead to the “episodic impairment of self-control” as defined by Reuber (Reuber, 2008). 
The ILAE definition, like the DSM III definition, fails to unravel the underlying mechanisms 
Giussani G. 
 
158 
 
of PNES also described as “experiential or behavioural responses to emotional or social 
distress” (LaFrance et al, 2013). The experiment reported here was an attempt to determine 
how different and complementary would be the observations of fully boarded psychiatrists 
compared to those of experienced epileptologists. The results have been somewhat 
perplexing but encouraging. Despite limited training and unfamiliarity with the type of video 
material submitted, the individual psychiatrists in our panel, blind to patient’s history and 
EEG findings, were very close to experienced epileptologists in predicting the GS diagnosis. 
However, they were clearly inferior and in greater disagreement with each other when 
challenged as a group. It is possible that such discrepancy in interrater agreement as a group 
and as individual pairs (high for epileptologists, low for psychiatrists) reflects the different 
approach in the interpretation of the video material adopted by the two groups. 
Epileptologists, by training, tend to strictly adhere to pre-set criteria based on semiological 
features validated in published material. Such disciplined approach confers considerable 
uniformity to the raters as individuals and as a groups. Conversely, psychiatrists, though 
paying due attention to the same indicators, are not exclusively bound to evidence-based 
criteria, displaying greater sensitivity to nuances and to the significance of subtle behavioural 
features. Table 6 shows examples of how psychiatrists read into body language and interpret 
subtle behavioural manifestations or subjective experiences as the effects of hidden internal 
conflicts. This willingness to explore beyond the mere facts and to capture cryptic signals 
otherwise ignored in a more orthodox approach, probably explains the success of the 
psychiatric raters in predicting the correct diagnosis when considering a single case.  
There are no data in the literature that prove the validity and reliability of this approach. Our 
preliminary data indicate that out of 14 videos where at least one of the raters included 
psychodynamic observations in his comments to justify the diagnostic choice, the diagnosis 
was correct in 9 (7 PNES; 2 ES) and incorrect in the remaining 5 videos (4 ES and 1 NDP). 
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This suggests that psychiatrists are more successful in diagnosing PNES than other types of 
seizures.  
Though the sample was small, it clearly indicates that the psychodynamic interpretation of 
certain behavioural signs can be helpful in diagnosing PNES but can also be misleading, 
especially in differentiating non-motor PNES from complex focal seizures. Other 
explanations can be given to interpret the different findings when comparing the diagnostic 
attitudes of psychiatrists and neurologists. Psychiatrists lost the habit of diagnosing PNES, 
as patients with this clinical condition directly go to the neurologist, who makes the first 
differential diagnosis. On the other hand, the neurologist deals with the "physical" body, that 
corresponds to the “homunculus” (sensory and / or motor) in the CNS, while the psychiatrists 
deal with the symbolic body (Focault, 2006), that corresponds to the representative language 
of an original trauma and whose semiology does not correspond to any “homunculus” of the 
CNS. The expertise that the psychiatrist put in the field, in addition to the epileptologist, 
consists in reading the symbolic body language, as previously observed in the "indifference", 
in the "partially in touch with the context / hesitating as if wanting to gain time”, or in 
"putting herself at the center of attention".  
Indeed, psychiatrists seem to have poor skills in non-PNES and non-ES attacks, where 
symbolic body language is virtually absent, while they add elements to the diagnosis of 
PNES, where the symbolic body language is present (Cornaggia et al, 2017, submitted). 
Conversely, epileptologists seem to have good skills in motor ES, where topodiagnosis 
appears more straightforward and simple, while they appear to have less skill in seizures 
where the relationship between seizure semiology and “homunculus” is less obvious. For 
this kind of seizures, a simple video documentation seems unsatisfactory, whether made by 
the epileptologist or by the psychiatrist, because of the intricate overlap between the somatic 
and the symbolic body. In these instances, VEM or linguistic analysis assume an essential 
role. 
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It is well known from the epilepsy literature that, so far, no single indicator has proved 
pathognomonic for the diagnosis of either ES or PNES. Rather, a constellation of signs or 
symptoms may be more indicative (Sayed et al, 2011). It appears that assessing the 
diagnostic weight of any single feature mentioned by the psychiatrists may be equally 
problematic. Our results indicate that certain observations can be misleading even for 
experienced psychiatrists. Signs must be interpreted carefully, in context, and gain 
significance if supported by additional evidence. In this respect, the convergence of 
multidisciplinary observations made by epileptologists in collaboration with psychiatrists 
should be ideal.  
In recent years, psychiatrists have been deterred from directly participating in the diagnostic 
process of identifying PNES by several factors. First, the replacement in the DSM III of the 
term “hysteria” with a phenomenological classification of symptoms and manifestations 
devoid from etiological content. That, in itself, has curbed their interest in the condition. 
Second, the realization that diagnosing PNES has become, by default, a responsibility of the 
epileptologists who, by necessity, work with physical evidence and physiological 
parameters. Third, there is a widespread trend in medicine of relying primarily on evidence-
based data and downplaying the importance of intuitive contributions. As a result, we have 
been paying great attention to external manifestation and less to what the patient has to 
express or communicate subliminally. A first sign of renewed interest in the hidden signals 
contained in patients’ behaviour has been a series of publications on the differences in 
linguistic expression between subjects with ES compared to PNES (Cornaggia et al, 2012; 
Reuber et al, 2009; Schwabe et al, 2007).  
This experiment was undertaken to explore the observations psychiatrists had to offer. We 
decided to challenge them with material ostensibly more suitable for epileptologists for the 
sake of comparing the two groups. More trials will be necessary using more appropriate 
material such as recorded patient’s interviews, rather than, or in addition to, the events 
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recorded on video. Though only tentative, some of the observations reported here should 
make us reflect on the opportunities we are missing. Psychiatrists, by training, are more 
attuned to capture the subtleties of human behaviour than neurologists and can contribute a 
new lexicon in defining PNES. Thus, they can play an important complementary role not 
only in establishing the diagnosis but also, by offering a glimpse onto the possible 
pathophysiological mechanisms of this disorder, paving the way to effective treatment. Thus, 
the issue is with pursuing further by continuing the dialogue and fostering more active 
collaboration between epileptologists and psychiatrists in the management of patients with 
PNES.  
This study has limitations. First, the number of raters who took part in the study is fairly 
small. This, in itself, can affect the results. Second, we tried to involve individuals with 
varying degree of seniority and diverse knowledge and experience about seizure disorders, 
who were representative of practicing psychiatrists. Nonetheless, the participating 
psychiatrists may not reflect the background and experience of all psychiatrists in clinical 
practice in Italy and, perhaps even more important, in other countries. Most importantly, 
our finding that individual psychiatrists may be as accurate as individual epileptologists 
even without specific training must be interpreted with caution, keeping in mind that the 
level of expertise of the single participating raters is crutial. Clearly, the addition of one 
poor rater, or of one excellent rater, to either side could substantially change the accuracy 
ratio between the two groups. However, our results, though far from definite, provide 
insight in a fairly unexplored field and can be used as the background to stimulate new 
research. 
6.1.3 Discussion about the use of a new questionnaire for differentiating PNES from 
ES. 
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The use of questionnaires to discern PNES from ES is not new. Devices used so far have 
varied greatly in format and size, depending on the intended purpose and targeted population. 
In general, their content has focused on the somatic manifestations of the events, (Rugg-
Gunnet al., 2001; Rosemergy et al., 2013; Sen et al., 2007), or on specific features (eyes 
forcefully closed / changes in amplitude and rhythm of body movements) (Sadan et al., 
2016). Other characteristics like history of chronic fatigue and fibromyalgia (Benbadis 2005) 
and the frequency of panic symtpoms in patients with PNES and epilepsy (Hendrickson et 
al, 2014) and also in other non epileptic events (syncope) (Rawlings et al, 2017) should be 
considered in future instruments to distinguish PNES from other diagnosis. An abbreviated 
version of review of systems questionnaires has recently proved useful in differentiating 
PNES from ES (Asadi-Pooya AA et al., 2016), including only ten questions about ten 
different systems and asking for presence/absence of abnormalities. Relatively little 
attention has been given to the personality characteristics and emotional dysregulation that 
constitute an important component in the pathogenesis of PNES (Reuber M et al., 2004). 
Only more recently, and in a few, isolated instances, investigators have inquired about 
emotional states and subjective experiences such as anxiety and depersonalization, asking 
patients and witnesses to fill ad-hoc questionnaires, the Paroxysmal Event Profile (PEP) for 
patients and the Paroxysmal Event Observer (PEO) for witnesses. (Reuber M et al., 2011). 
The PEP questionnaire was also used in a more recent study to explore the diagnostic 
potential of this instrument in patients with PNES and transient loss of consciousness 
(TLOC) (Reuber et al, 2016). In another study, patients were asked to describe their 
symptoms freely and through structured interviews (revised version of the Psychosensory-
Psychomotor Phenomena Interview) (Sharrack S and Garlovsky J, 2015). Other 
investigators have tailored instruments for specific purposes such as a rapid screening of 
patients presenting with seizures in the Emergency Department (DePaola et al., 2016) or 
extensive questionnaires for self-reporting. However, the methodology of this last study 
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(Syed et al., 2009) was quite selective, excluding eyewitness and “sensitive” questions (i.e. 
history of abuse) because responses could be unreliable. Moreover, it did not include in the 
analysis the large contingent of PNES characterized by pure subjective or minimal 
manifestations because, in the absence of EEG abnormalities, they were undistinguishable 
from simple focal seizures. Thus, the study missed potential sources of valuable information.  
Different results are reported about the engagement of witnesses. In some prospective 
studies, they were not able to indentify clinical sign useful to epileptologists after in-person 
or telephone interview (Syed et al, 2008, Syed et al 2011). But in another retrospective study 
that involves seizure witnesses using a 34-item questionnaire, they turned out to be more 
aware of seizure triggers and a relationship between PNES and emotional stress than patients 
(Reuber et al, 2011). Clinicians have totake note of the different sources of information 
during the diagnostic process (Reuber et al, 2011).  
Overall, lack of standardization, differences in methodology and the perception that results 
are often conflicting, have generated among professional uneasiness and skepticism about 
the use of questionnaires as clinical tools. Such attitude is justified by the belief that a face-
to-face interview, especially if combined with VEM, is the best approach. Since this remains 
the undisputed gold standard, so far screening questionnaires have been recommended 
primarily as a way to accelerate, rather than reduce, referrals to epilepsy centers. For this 
reason, we devised an eclectic, easy to manage instrument that could be incorporated in the 
assessment of patients presenting with seizures, as review of system questionnaires have 
become routine part of medical consultations. Our questionnaires were empirically based on 
a mix of data reported in the literature as diagnostic predictors and anecdotal clinical 
observations that, in our judgment, could help differentiating PNES from ES. We included 
all types of seizures without exception but asked each subject to specify which types, if they 
had more than one. We asked all questions deemed pertinent, including those that could 
cause embarrassment and retained two separate questionnaires because in clinical practice, 
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especially in the absence of VEM, clinicians must rely on both patients’ and eyewitnesses 
reports. Finally, since the aim of our study was to identify a tool helpful in the differential 
diagnosis, we chose as best predictors the SE and SP of each variable against the final 
diagnosis.  
Our results, in accordance with previous reports, indicate that structured questionnaires can 
help differentiating PNES from ES though the number of diagnostic predictors is limited. 
Quantitatively, this study identified only 7 variables above the pre-set discriminating 
threshold for Questionnaire A and 2 for Questionnaire B.  
Qualitatively, some of the predictive variables emerged from Questionnaire A (direct 
patient’s response) distinctly call attention to the state of anxiety and emotional turmoil 
fostering the events. They consist of prominent subjective manifestations of anxiety 
(headache, heart racing, tingling and numbness) that probably correspond to the changes in 
cardiac system activity preceding and following PNES recently described (Reinsberger et 
al., 2012).  Contrary to the systematic search for the aura when suspecting ES, this is an area 
that is scarcely investigated when suspecting PNES. Likewise, the other predictive variables 
highlight the recurring themes of hypersensitivity to pain (pre-ictal headache / post-ictal 
pain) and tendency toward somatization (history of chronic fatigue), all common in patients 
with PNES. Surprisingly, among the history of abuse, only physical abuse, frequent in PNES 
and rare in ES, reached the discriminating threshold (SE =58.8/ SP 81.8). By resetting the 
discriminatory threshold to a lower value of SE and SP, we identified additional variables 
retaining some degree of diagnostic value (Table 3.3.2). They include; two triggering factors: 
sensitivity to lights and feeling overwhelmed, probably reflecting vulnerability to suggestion 
and weak coping ability; one post-ictal manifestation: trouble speaking (SE 64.71 / SP 
63.64); history of emotional abuse (SE 52.94 / SP 63.64), frequently reported in both 
syndromes and only slightly more common in PNES. History of self-inflicted injury (“hurt 
yourself”) were predominantly present in PNES and absent in ES. Surprisingly, sexual abuse 
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(SE 29.41 / SP 81.82), seldom reported and, when present, reported about equally in either 
syndrome, was relegated among the non-discriminatory variables (see Table e-1). 
Conversely, the contribution of Questionnaire B (report by witnesses) was restricted to two 
discriminating variables. They both highlight the critical role of ictal eye closure and side-
to-side head movements in differentiating ES from PNES. In our sample, the presence of 
these easily recognizable features was highly indicative of PNES and virtually excluded the 
diagnosis of ES (SE 66.7/ SP100). The differential diagnosis with hypermotor seizures of 
frontal lobe epilepsy, presenting similar semiology, is relatively simple because, by rule, 
they occur primarily during sleep. Reversibly, the absence of these key features was 
consistent with ES though did not exclude PNES. Of note, both variables were present in the 
majority of patients with PNES and absent in all subjects with ES who responded to these 
questions, suggesting that the presence of these signs is not compatible with, and thus may 
exclude, the diagnosis of epilepsy. 
One of the 4 variables below threshold emerged from Questionnaire B (Table 4) (ictal 
movements “on/off”) is also distinctive for being predominantly absent in ES. (SE 50.00 / 
SP 90). This suggests that while eyewitnesses may find difficult to identify such feature 
when it occurs during PNES, they may find it easier to say when it does not occur. Overall, 
it appears that sub threshold variables have a complementary role and, therefore, should not 
be automatically excluded. Furthermore, such observations imply that not only the presence 
of a sign may be suggestive of a diagnosis but also its absence can be relevant.       
Among the advantages of questionnaires are the low cost, the easy administration, the wide 
spectrum of issues that can be systematically explored and the completeness of the feedback, 
always with a clear indication of whether a sign is present or absent. The original 
contributions of our study include first, the confirmation that both patients and eyewitnesses 
can provide unique and different information and, therefore, are best approached with two 
separate instruments. Second, the concept that questionnaires focused primarily on typical 
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signs of the event’s semiology may be helpful to specialized professionals but have little 
impact on patients who, as a rule, are unaware during the events. Likewise, questionnaires 
are bound to be rather unproductive when addressing eyewitnesses, notoriously unfit to 
appreciate many of the classic “trade mark” signs identified by epileptologists (Azar et al., 
2010; Syed et al., 2011; Rugg-Gunn et al., 2001; Heo et al., 2008).  Nonetheless, while 
eyewitness contributions are limited to the few, concrete observations made during events 
seen in the past and depend on later recall, patients can provide a wealth of details about 
their subjective experiences and symptoms before and after the events. This part of seizure 
semiology may go unnoticed to the eye of a reviewer during VEM but can be easily identified 
by directly asking the patient through the questionnaire.  
There are several limitations to be considered in our study. The small number of eligible 
patients could have affected the SE and SP of single variables. The analysis of questionnaire 
B was based on a dataset of only 16 cases (6 PNES, 10 ES), and undermine the validity of 
any conclusion drawn. Furthermore, the results reflect the comparison between only PNES 
and ES diagnosis, the only two groups numerically adequate for analysis. Patients with dual 
diagnosis of PNES + ES (1 case) and patients with other diagnoses unrelated to epilepsy or 
PNES (for example syncope) (4 cases) had to be excluded. Though the content of our 
questionnaires seemed broad and comprehensive for screening purposes, the selection of 
items to be investigated was empirical and based on the clinical judgment of the authors. 
Thus, we suspect it was neither exhaustive nor complete. We found particularly difficult 
documenting history of somatization and midway we felt compelled to revise questionnaire 
A and remove from this domain a few questions deemed inadequate. Despite the high 
number of missing data, a positive history of chronic fatigue turned out to be among the 
discriminatory signs for PNES. This indicates that somatization is an important component 
of this disorder and should be explored systematically, perhaps with the aid of review of 
system questionnaires. Another source of perplexity is the reliability of self-reported 
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information. We presume responders are unbiased and trustworthy, even when confronted 
with sensitive issues in their personal history. However, other investigators have felt 
differently and for good reasons (Syed et al., 2009).  
In conclusion, a larger sample will be needed to confirm the predictors emerged from this 
study and to determine whether more borderline variables reach the significance threshold. 
It is foreseeable that a standardized questionnaire for universal use will be trimmed down to 
the essential information lay people, patients and eyewitnesses, can provide easily rather 
than being geared to the criteria utilized by professionals. 
Self-reporting questionnaires, though will never reach the degree of certainty provided by 
VEM, may offer a probability score, based on the presence or absence of relevant variables 
and their SE/SP values, that may lead to a tentative diagnosis with measurable degree of 
reliability.  
 
6.2 Discussion about the characterization study of the diagnosis of idic(15) syndrome 
The primary objective of the study was the identification of symptoms, signs and 
instrumental findings, singly or in various combinations comparing patients with idic(15) 
syndrome to patients with other neurodevelopmental disorders considered in the differential 
diagnosis. The research question to be addressed was that idic(15) syndrome differs from 
other neurodevelopmental disorders in a number of symptoms and/or signs whose 
combination defines a peculiar clinical phenotype. Another important aim was to verify the 
detection of specific symptoms (including seizures and epilepsy) by different experts in a 
homogeneous and objective way. 
Clinical charts with history of the disease, videos of neurological examinations and 
instrumental examination of 32 patients were examined by 5 independent raters in order to 
find a cluster of signs and symptoms able to discriminate the idicdisease from other diseases 
having similar characteristics. 
Giussani G. 
 
168 
 
Cases and controls were enrolled by child neurologist in two participating centers and 
matched for age and sex. The two groups were no different with reference to standard values 
of WHO (who.int/childgrowth/en) for gestational age, birth weight, length at birth, head 
circumference and Apgar score. 
Battaglia (Battaglia, 2008) reported that the main clinical characteristics of idic(15) 
syndrome in more than 75% of cases are: hypotonia, developemental delay/intellectual 
disability, autistic behaviour, epilepsy, minor dysmorphic features mainly involving face. In 
25%-50% of patients brain abnormalities, genitourinary tract defects and growth retardation 
are expected. In less than 25% of patients congenital heart diseases and microcephaly could 
be find. 
The results obtained in this study indicate that variables easily recognized in patients by 
raters with a good agreement (>0.6 calculated with Kendall’s coefficient W) where almost 
the same of those described by Battaglia (2008), but high scores of SE and SP were found 
only for hypotonia and feeding difficulties in the newborn period. When considering this 
two variables as present in the same patients, SP increased and SE decreased. These results 
may have a significant value for physicians when assessing a new patient in their clinical 
practice. These two variables, when combined, help to discriminate idic(15) syndrome from 
other neurodevelopemental disorders.. A number of cases presenting hypotonia and feeding 
difficulties in the newborn period could be identified with high accuracy in a population with 
disability. In particular, 76% of patients with these signs have the disease and 64% of patients 
without this signs cannot be diagnosed with idic(15) syndrome. 
Another problem is that some signs/symptoms could be predictive of the diagnosis but are 
not uniformly recognized by physicians and for this reason may not lead to the proper 
diagnosis if the patient is examined by different investigators. 
Analysing the results reported in the three steps by the raters, step 1 and 2 made a greater 
contribution to the correct diagnosis than step 3 (instrumental tests examination). EEG, MRI 
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and CT-Scan deviated raters from a correct differential diagnosis. Probably because the 
characteristics of idic(15) syndrome are less diagnostic and recognizable through 
instrumental examinations but more identifiable investigating the history and performing  
general and neurological examinations.  
The limitation of this study was the limited sample size. The proportion of cases/controls in 
this sample is rather artifactual but it reflects a setting in which the caring physician is 
knowledgeable of idic(15) syndrome as a possible diagnosis. The raters were selected among 
specialists with expertise in the field of rare diseases associated with intellectual disability 
and epilepsy. The external validity of our results is thus limited.  
Future aim is to empower the sample in order to have a larger and more heterogeneous 
population and to verify if some signs/symptoms could be more predictive of the diagnosis.  
The study design used here could serve as a model for the clinical assessment of rare 
neurodevelopmental disorders in the field of disability, in clinical practice and in the research 
setting. 
 
6.3 The EPIRES Study 
6.3.1 Discussion about the results of prevalence of active epilepsy and DRE in a well 
defined population of Norther Italy 
The prevalence of active epilepsy and DRE (conforming to the ILAE definition) (Kwan et 
al, 2010) in the district of Lecco, a well-defined area of Northern Italy, was determined. The 
proportion of patients with DRE among incident cases was also calculated. 
The prevalence of active epilepsy in the local population was 4.67 per 1,000, which falls 
within the range of rates (2.3-15.9 per 1,000) previously found in high-income countries 
(Bell et al, 2014).  The rates were fairly similar in men and women until age 54 years, while 
beyond that age the disease peaked in older men, in keeping with other reports (Olafsson 
and Hauser, 1999; Rocca et al, 2001). Our data on the prevalence of epilepsy in the older age 
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classes are comparable with previous reports (Olafsson and Hauser, 1999; Wiebe et al, 1999; 
Luengo et al, 2001; Oun et al, 2003; Al Rajeh et al, 2001).  
According to our data the prevalence of DRE at the end of the study period was 0.73 per 
1,000 of the local population. Patients with DRE were 15.6% of the population with active 
epilepsy. The percentage of DRE found by Sillanpää & Schmidt (Sillanpää & Schmidt, 
2006), and by Berg et al. (Berg et al, 2012) (both in a pediatric population), as well as by 
Picot et al. (Picot et al, 2008) (in a population over 15 years of age) ranged from 15.6 to 
22.5%, overlapping our results. By contrast, cohort studies conducted in referral centers 
(Kong et al, 2014; Brodie et al, 2012; Schiller, 2009) reported higher percentage of DRE 
(21.5-25.3%), possibly because patients with mild varieties of the disease were not seen in 
those centers. 
In the age group <15 years, we found that the percentage of DRE was 20%, which is in 
accordance with other community-based studies in pediatric populations (Sillanpää & 
Schmidt, 2006; Berg et al, 2012). Mohanraj and Brodie (Mohanraje and Brodie, 2006) also 
found uncontrolled epilepsy less common in the elderly compared to adolescents and adults. 
These authors also stated that old patients are more likely to have a more favorable outcome 
than the remaining epilepsy population. Our data seem to be in support of that assumption. 
Comparing patients with DRE to those with drug-responsive epilepsy, significant 
differences were found for sex, syndrome and age in prevalent cases, but no differences 
between men and women in the incident population. The predominance of DRE in women 
with prevalent epilepsy is difficult to explain and cannot be due to treatment changes for the 
use of safer medications. Six women stopped medications for fear of teratogenicity. These 
cases were not counted as drug failures. Generalized symptomatic or cryptogenic epilepsies 
and partial symptomatic epilepsies were the commonest syndromes among DRE patients 
both in the prevalent and incident population. These results are in keeping with most 
literature reports (Kong et al, 2014; Sillanpää & Schmidt, 2006; Picot et al, 2008; Brodie et 
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al, 2012; Schiller, 2009). In our sample, patients with DRE were younger than drug-
responsive patients: the age groups most represented were <15 years and 35-54 years, 
whereas the least represented was 75+ years. Our data partly overlap those of Kong et al. 
(Kong et al, 2014) who found the highest frequency of DRE in the 40-49 year group and the 
lowest frequency in the 60-69 year group. The peak of DRE in the youngest age groups 
reflects the predominance of more severe epilepsy syndromes in younger individuals. 
Undetermined epilepsies were also at high risk for drug resistance. This is not an unexpected 
finding. In a large Italian population with refractory epilepsy, undetermined epilepsies 
accounted for 16.8% of pediatric cases (Alexandre et al, 2010). In these cases, the failure of 
two or more drugs may not be uncommon leading to diagnosis of DRE mainly because of 
inappropriate use of AEDs. 
The cumulative risk to become drug-resistant is time-dependent and varies in relation to age 
and syndromes. Our findings are in keeping with other reports using the same definition of 
DRE (Berg et al, 2006; Geerst et al, 2012). Differences are partly explained by the source 
population, the age and the duration of follow-up. However, in these studies there was an 
increasing risk of failure of two drugs with time, that finds confirmation in our study. In 
addition, their finding that the risk of DRE is highest among children with catastrophic 
epilepsies compares well with our data indicating that patients with generalized symptomatic 
or cryptogenic epilepsies are more prone to develop drug resistance. 
The main strength (and the originality) of this study is the population-base approach. 
Another strength is the fairly large sample of patients collected over a 9-year screening 
period. The first limitation is the use of a definition of DRE only partially conforming to the 
ILAE definition, that specifies that “the seizure-free period should be less than three times 
the pre-intervention inter-seizure interval or 12 months, whichever is longer” (Kwan et al, 
2010). Because the frequency of seizures before treatment was unavailable in our cases, we 
were unable to assess the duration of seizure-free periods by application of the “rule of 
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three”. Because of the retrospective nature of the study, there are several limitations: the data 
collection: in the absence of a predefined modality to collect the necessary information, the 
identification of patients with DRE has been sometimes difficult; it was not possible to 
determine with certainty whether the diagnosis of epilepsy established by the neurologist 
consulted on the case was correct; DRE might be underestimated in light of our definition 
and the limited follow-up; an underascertainment of DRE in elderly individuals cannot be 
excluded because some of them were not in the direct control of the GPs’; we have been 
unable to collect follow-up information on patients who left the province during the study 
period; the nine-year period of the study ended in 2008. However, our findings are not 
outdated because the frequency and treatment of epilepsy has been virtually unchanged in 
the last few years. Finally, the small numbers found in some age and sex categories may 
have a strong influence on the precision of our estimates. 
According to the results of this study, 1/6 patients with active epilepsy in the general 
population have DRE and about 1/10 patients with newly diagnosed epilepsy will develop 
DRE within nine years from the diagnosis. However, drug resistance is a dynamic process 
covering several years, which may present a different course in men and women, children 
and adults, and in different epileptic syndromes. In this regard, the ILAE definition has 
limitations when used for epidemiological purposes because in clinical practice the medical 
decisions (including the assessment of treatment failure) cannot be standardized. In addition, 
as drug resistance is a function of time, its frequency depends on the characteristics of the 
cohort at risk (whether incident or prevalent) and the duration of the follow-up. The 
assessment of the prevalence of DRE is meaningless unless it is calculated within a well-
defined period of time and, even in this context, it does not take into account the possibility 
of drug failures outside the study period.  
This scenario adds to the complexity of the long-term prognosis of epilepsy, a topic 
discussed in the following paragraph. 
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6.3.2. Discussion about the long-term prognosis of epilepsy, prognostic patterns and 
drug resistance in a well defined population of Northern Italy 
Using the recent ILAE definition of DRE and the same prognostic patterns we found that at 
20 years 67% of people with epilepsy had attained a 2-year remission of seizures and 50% a 
5-year remission. 60% of patients with 2-year remission and 43% of patients with 5-year 
remission had sustained remission. Seventeen percent of people with at least 2 years of 
follow-up were off treatment at last observation. This is in keeping with other reports. In a 
prospective study of 144 people with epilepsy of childhood onset in Finland (selected from 
a cohort of 245 children), followed for an average of 37 years (Sillanpää & Schmidt, 2006), 
48% of people were in 5-year terminal remission (early remission, 16%; late remission, 
32%). The UK National General Practice Study of Epilepsy included 729 people of all ages 
from 275 general practices, followed for a median of 7.1 years (Cockerell et al, 1997). 
Seventy-one percent entered 5-year remission and 54% were in terminal remission. 
Remission rates higher than ours have also been reported. In a retrospective study of people 
with newly diagnosed epilepsy in Rochester, Minnesota, and followed for at least 5 years 
(Annegers et al, 1979) 76% attained 5-year remission at 20 years and 50% were off-drugs at 
last follow-up. That was an incident cohort while ours was a prevalent cohort that, by 
definition, may have missed people with childhood-onset epilepsy who entered remission 
outside the study period. Our lower probability of 2-year and 5-year remission can be also 
explained by the shorter period of follow-up after diagnosis. In an extended follow-up of a 
retrospective cohort of people with epilepsy seen in a UK population of 6,000 from a single 
general practice (the Tonbridge study) (n=122 in 1983 and n=126 in year 1993), 74% of 
individuals achieved 4-year remission at 10 years (Cockerell et al, 1995). That study 
included individuals with at least one non-febrile convulsion and this implies the inclusion 
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of people with single unprovoked seizures, who have a lower risk of relapse (Hauser et al, 
1998; Hesdorffer et al, 2009).  
Seizure remission rates tended to increase with age at diagnosis (apart from the oldest age 
group). Other studies in childhood-onset epilepsy provided 5-year remission rates higher 
than ours (Berg et al, 2015; Wakamoto et al, 2000; Geerts et al, 2012). The role of age in 
predicting the long-term outcome of seizures is contradictory (Annegers et al, 1979; Hart et 
al, 1990) and in our study, although those with onset of seizures below age 15 years had the 
lowest chance of experiencing seizure remission, conversely to some genetic generalized 
epilepsy of infancy (Rolandic epilepsy) associated with higher rates of remission, a trend 
was not confirmed.  
People with generalized symptomatic/cryptogenic epilepsies and those with partial 
symptomatic or cryptogenic epilepsies had lower remission rates than those with other 
epilepsy syndromes, in line with expectations. Remission can also occur in these syndromic 
categories, as previously reported (Sillanpää & Schmidt, 2006; Berg et al, 2015; Geerts et 
al, 2010). These findings support the concept that the long-term prognosis of epilepsy in 
people with epileptic encephalopathies is not invariably poor in the general population. 
About one fifth of our individuals entered early remission, one third entered late remission, 
one sixth had remission followed by relapse, and one third never entered remission. These 
findings cannot be compared with other reports as the definitions of the patterns differ. In 
the Tonbridge study (Cockerell et al, 1995), 49% of people with seizures only at the early 
stage entered terminal remission (“burst” pattern, to some extent comparable with our early 
and late remission), 12% had remission periods followed by relapses (“intermittent” pattern, 
partly overlapping our remission followed by relapse pattern) and 21% had no remission 
(“continuous” pattern, not dissimilar from ours who never remitted). The differences can be 
explained by the shorter follow-up in the Tonbridge study; some people with a “burst” 
pattern might have later relapsed and enterd the “intermittent” pattern. Remission followed 
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by relapse was observed in 6% of people in the Rochester, Minnesota cohort (Annegers et 
al, 1979). A more detailed definition of prognostic patterns has been used in a study that 
followed 516 children with epilepsy for 10+ years. That study identified eight patterns 
ranging from early 1-year remission, no relapse and complete remission at last follow-up 
(33%) to never achieving 1-year remission (5%) (Berg et al, 2015). The shorter period of 
remission (1-year vs. 2-year in our study) may explain in part the higher rates of individuals 
with early remission and the lower rates of people never achieving remission.  
The classification of an individual as drug resistant according to the ILAE definition was 
compatible with a 30% chance of early or late remission after treatment failure. These 
findings are in keeping with population-based studies done in children and adults followed 
for prolonged periods of time (Neligan et al, 2011; Brodie et al, 2012; Geerts et al 2012; 
Berg et al, 2009) and confirm the concept that the failure of two AEDs is still compatible 
with subsequent prolonged seizure remission. Our findings are in line with a report on a 
cohort of adults with chronic refractory epilepsy with long-term follow-up in an epilepsy 
clinic (Neligan et al, 2012). 
The only variable predicting the prognostic pattern was the response to AEDs and, more 
specifically, drug resistance (ILAE definition). Prognostic patterns can be anticipated by the 
response to the first treatments rather than the inclusion of an individual in a broad syndromic 
category.  
Strengths and limitations of the EPIRES study have been discussed in the previous 
paragraph.  
The long-term prognosis of epilepsy in a community-based cohort is favourable in about 
one-half of cases. Seizure remission is followed by discontinuation of treatment in one sixth. 
Early seizure remission does not, however, invariably lead to terminal remission. Seizure 
outcome varies according to specific patterns and prolonged seizure remission and 
prognostic patterns can be predicted only by the response to the first two AEDs. The poor 
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response to two appropriate AEDs is, however, still compatible with the possibility of 
entering prolonged remission and even achieving terminal remission, stressing the dynamic 
nature of drug-resistance.  
 
6.3.3. Discussion about antiepileptic drugs discontinuation by people with epilepsy in a 
well defined population of Northern Italy 
People in our cohort have used a large number of AEDs over a 15-year period. However, 
during this time, the three most common drugs given at the start of treatment were valproate, 
carbamazepine and phenobarbital and only 10 percent of people started treatment with a new 
AED. Terminal remission was the commonest explanation for discontinuation of the first 
drug (20% at twenty years), followed by lack of efficacy (12.6%). Withdrawal of the first 
drug for adverse events was only 0.5% at one year and increased to 3.3% at twenty years. 
While the discontinuation of a drug for terminal remission tended to decrease with AED 
order, treatment stop for ineffectiveness and for adverse events tended to increase even 
though clear trends could not be detected because of the small samples at the highest 
rankings. The reasons for drug withdrawal varied with age, sex and disease characteristics. 
The probability of retaining the first drug in the treatment schedule and starting a period of 
remission lasting until the end of follow-up, or of stopping the first treatment for terminal 
remission, was high, 48% at 20 years. Others found that the proportion of seizure-free 
individuals on the first AED ranged from 5.4% to 62% (Kwan and Brodie, 2001; Brodie et 
al 2012; Lhatoo et al, 2001; Dluglos et al, 2001; Wirrel et al, 2001; Zhang et al, 2013); 63% 
of our patients never withdrew the first AED and 51% of them started a period of remission 
lasting until the end of follow-up. This finding supports the concept that in clinical practice 
the majority of people with epilepsy can be easily controlled with any of the available 
compounds, appropriately chosen among the available drugs for different epilepsies, even 
after long follow-up periods.  
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In our study, the cumulative probability of discontinuing the first drug at 12 months for lack 
of efficacy or adverse events was only 3.4%. Our findings are fairly similar to the results of 
a Lebanese study of people with newly diagnosed focal epilepsy, which found a 12-month 
retention rate of 93.6% (Beydoun et al, 2015). Our data only partly agree, however, with 
other long-term follow-up studies. In the UK National General Practice Study of Epilepsy 
(Lhatoo et al, 2001) the first assigned drug was discontinued for lack of efficacy in 21% of 
cases (compared to our 12.6%) but the discontinuation rate for adverse events was 11.5% 
(compared to 3.3% in our study). This difference may be explained by the use of 
carbamazepine, phenytoin, valproate or phenobarbital in 96% of the UK cases as compared 
to 87% in our cohort. The use of fairly low daily doses for some drugs in our study (see 
Supplementary Table 5.7) could be another explanation. No differences were found in 
retention rates when comparing old and new AEDs. Our findings are in keeping with a study 
in children (Bourgeois et al, 2015) but differ from a study in older adults (Arif et al, 2010) 
in which the 12-month retention rates ranged from 12.5% (oxcarbazepine) to 90% 
(valproate). In this latter study, however, the rates were calculated in people with refractory 
epilepsy.  
When comparing drugs in our study, differences in retention were seen. Discontinuation for 
lack of efficacy was most common with GABAergic drugs while discontinuation for adverse 
events was mostly seen with topiramate, phenytoin, carbamazepine and levetiracetam in 
decreasing order. These findings are not unexpected even though the rates differ from those 
of other reports (Chung et al, 2007; Peltola et al, 2009; Boostma et al, 2009; Kuba et al, 
2010; Lhatoo et al, 2000; Hufnagel et al, 2011) on account of differing prescribing patterns 
and different populations at risk. 
People in our cohort taking carbamazepine, valproate or phenobarbital discontinued the 
assigned treatment for adverse events in 5.6, 1.1 and 2.8% of cases respectively. Our rates 
are significantly lower than those reported by others (carbamazepine, valproate and 
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lamotrigine stopped in 27, 13 and 10% of cases respectively) (Kwan and Brodie, 2001). 
Possible explanations for this difference are the source population and the data acquisition, 
as our study is a retrospective population-based study and the Scottish study was not, and 
the use of different daily doses. 
Children and elderly subjects tended to stop the first drug mostly for lack of efficacy and, 
less frequently, due to terminal remission. Childhood and adolescent syndromes less 
responsive to the current treatments and the need to resort to complex therapeutic regimens 
in people with comorbidities are possible explanations.  
The lower rates of treatment withdrawal due to terminal remission in women than in men 
likely reflects the higher proportion of females in the age class <15 years (59% versus 41% 
of male children) who continued the first treatment, perhaps because of the fear of 
withdrawal in a period of hormonal and emotional changes. As expected, people with 
idiopathic epilepsies and/or generalized seizures were most likely to respond to the assigned 
treatments. 
As described in the previous sections of this project, because of the retrospective nature of 
the study, the limitations concern the data collection, in particular it was not possible to 
determine with certainty whether the diagnosis of epilepsy established by the neurologist 
consulted on the case was correct; the study period ended in 2008; small numbers of patients 
have been found in some age and sex categories and this could have influenced our results; 
data about etiology were not sufficiently detailed. 
As limitation of this study, we do not know whether a drug was discontinued after having 
been given at the highest tolerated dose. Our aim, however, was to explore treatment changes 
as performed in clinical practice, where the selected daily dose generally represents a 
compromise between seizure control, adverse events, and individual preference. Another 
limitation is the time frame during which we started the follow-up. To include people with 
newly diagnosed epilepsy in the cohort with reasonable follow-up, we started the observation 
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at a time in which mainly older AEDs were available. We are thus uncertain whether our 
findings apply to cohorts starting treatment with a new AED. In keeping with our findings, 
however, there is no evidence from more recent reports (Wilby et al, 2005; Marson et al, 
2007; Lee et al, 2014; Weijenberg et al, 2010; Tomson, 2004; Perucca, 2002; Rowan et al, 
2005; Steinhoff et al 2003) that new AEDs have advantages over older compounds. Thus, 
we do not expect significant differences in other therapeutic contexts. Furthermore, the 
cumulative time-dependent probability of withdrawal of AEDs other than carbamazepine, 
phenobarbital and valproate was not assessed because of small numbers. The limited sample 
size can also explain some non-significant correlations between demographic and clinical 
variables and drug withdrawal. Lastly, we did our best to verify whether the indication for 
each drug was appropriate. However, we cannot entirely exclude that drug failure was due 
to incorrect use of a given drug in a given individual. 
In conclusion, the majority of people with epilepsy living in a community and followed for 
a prolonged period of time remain treated with the first assigned drug. Seizure remission is 
the main reason for drug discontinuation, followed by lack of efficacy and adverse events. 
Withdrawal of the first drug for ineffectiveness and for adverse events tends to increase by 
AED order, while decreasing for terminal remission. Withdrawal of the first AED for 
ineffectiveness can be predicted by age at diagnosis while withdrawal of the second drug is 
predicted by seizure type, and reflects the predominance of more severe epilepsy syndromes 
in younger individuals. These findings can help the practicing physician to predict the 
response to the assigned treatment at diagnosis and when a treatment change is required. 
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6.4 Description of my involvement and roles in each project 
 
To explain better my personal efforts on every study presented and discussed before, I report 
here a summary table: 
Project Name MI-RO PNES Idic(15)  EPIRES 
Protocol design  X  X   
Start-up procedures X a X  X  
Study coordination X a X  X  
CRF design and production X  X  X  
Data collection X  X  X  
Data management  X X X 
Data analysis X b X b X b 
Results interpretation and discussion  X  X  X  
Papers preparation and publication X  (To be prepared) X  
a Only for the Italian group 
b With the biostatistician 
 
As here reported, my involvement was not only practical (sturt-up procedures, CRF 
production, data management, data analysis) but also more conceptual in the context of 
protocol design, interpretation and discussion of the results and paper writing. 
Within these different projects, I enriched my knowledge about epilepsy and epilepsy 
research in humans from different points of view. 
In particular, I learned about different diagnostic, prognostic and therapeutic aspects of the 
disease. Furthermore, I learned to apply different methodologies to investigate the diagnosis, 
frequency, prognosis and treatment of epilepsy in an evidence-based perspective. 
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8. Supplementary tables 
Supplemetary table 3.3.1. Patient questionnaire. PNES vs. ES: list of variables with sensitivity or specificity less than 60. 
Variable 
PNES   ES SE SP p-value 
Present Absent 
Not 
indicated 
  Present Absent 
Not 
indicated 
   
Trigger 11 3  3  6 4 1 78.6 40.0 0.3926 
     "     tired 9       8 .  6 5 . 45.4 52.9 1.0000 
     "      alcohol  4       13       .  0 11 . 23.4 100.0 0.1324 
     "      sleep deprived 9       8  .  7 4 . 36.36 52.94 0.7047 
     "      menses                                               0       17 .  3 8 . 0.00 72.73 0.0504 
     "      emotion 12       5 .  7 4 . 70.59 36.36 1.0000 
     "      pain 6       11 .  0 11 . 35.29 100.00 0.0549 
Warning 14       1 2  7 0 4 93.33 0.00 1.0000 
     "      fast deep breath  8       9 .  2 9 . 47.06 81.82 0.2264 
     "      nausea 5       12 .  1 10 . 29.41 90.91 0.3547 
     "      headache 8 9 .  2 9 . 47.06 81.82 0.2264 
     "      upset       4 13 .  1 10 . 23.53 90.91 0.6195 
     "      angry 1 16 .  1 10 . 5.88 90.91 1.0000 
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     "      irritable 5 12 .  0 11 . 29.41 100.00 0.1247 
     "      anxious 9 8 .  6 5 . 52.94 54.55 1.0000 
     "     sad 4 13 .  1 10 . 23.53 90.91 0.6195 
     "      afraid 8 9 .  2 9 . 47.06 81.82 0.2264 
     "      physical pain 5 12 .  0 11 . 29.41 100.00 0.1247 
     "      déjà vu 4 13 .  2 9 . 23.53 81.82 1.0000 
     "      bad smell 2 15 .  0 11 . 11.76 100.00 0.5053 
     "      metallic taste 4 13 .  1 10 . 23.53 90.91 0.6195 
     "      coloured spots 6 11 .  1 10 . 35.29 90.91 0.1914 
     "     visual image 1 16 .  0 11 . 5.88 100.00 1.0000 
     "      sounds 4 13 .  0 11 . 23.53 100.00 0.1324 
During seizure            
     "  "    aware able to respond 7 10 .  3 8 . 41.18 72.73 0.6888 
     "  "    aware unable to respond 7 10 .  3 8 . 41.18 72.73 0.6888 
     "  "      not aware 11 6 .  10 1 . 64.71 9.09 0.1914 
     "  "      bite side tongue  8 9 .  4 7 . 47.06 63.64 0.7047 
     "  "      bite tip tongue  2 15 .  2 9 . 11.76 81.82 1.0000 
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     "  "      wet yourself 6 11 .  2 9 . 35.29 81.82 0.4188 
     "  "      lose bowel control 1 16 .  0 11 . 5.88 100.00 1.0000 
     "  "      severe injury 4 13 .  0 11 . 23.53 100.00 0.1324 
After seizure            
     "  "      trouble remembering 14 3 .  10 1 . 82.35 9.09 1.0000 
     "  "      trouble recognising people 7 10 .  4 7 . 41.18 63.64 1.0000 
     "  "      trouble understanding 12 5 .  6 5 . 70.59 45.45 0.4443 
     "  "      headache  16 0 .  7 4 . 100.00 36.36 0.0188 
     "  "      normal 1 16 .  4 7 . 5.88 63.64 0.0618 
     "  "      exhausted 15 2 .  9 2 . 88.24 18.18 1.0000 
     "  "      confused 10 7 .  8 3 . 58.82 27.27 0.6888 
     "  "      emotional  7 10 .  5 6 . 41.18 54.55 1.0000 
Remote history           
     "  "      Febrile seizures 1 16 .  1 10 . 5.88 90.91 1.0000 
     "  "      Brain infection 1  16 .  3 8 . 5.88 72.73 0.2694 
     "  "      Stroke 2 15 .  3 8 . 11.76 72.73 0.3531 
     "  "      Other neurol. illness/injury 4 13 .  1 10 . 23.53 90.91 0.6195 
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     "  "      Death of close relative 8 9 .  4 7 . 47.06 63.64 0.7047 
     "  "      Neglect 5 12 .  3 8 . 29.41 72.73 1.0000 
     "  "      Sexual abuse 5 12 .  2 9 . 29.41 81.82 0.6683 
     "  "      Exposure to violence 9 8 .  5 6 . 52.94 54.55 1.0000 
Last 6 months history           
     "  "      Head injury  4 13 .  0 11 . 23.53 100.00 0.1324 
     "  "      Brain infection  0 17 .  0 11 . 5.88 100.00 1.0000 
     "  "      Other neurol. illness/injury  2 15 .  1 10 . 11.76 90.91 1.0000 
     "  "      New health problem  7 10 .  1 10 . 41.18 90.91 0.0987 
     "  "      Worsening health problem  6 11 .  1 10 . 35.29 90.91 0.1914 
     "  "      Surgery  5 12 .  1 10 . 29.41 90.91 0.3547 
     "  "      Increase family demands  2 15 .  1 10 . 11.76 90.91 1.0000 
     "  "      Job change  2 15 .  3 8 . 11.76 72.73 0.3531 
     "  "      Divorce/separation  2 15 .  1 10 . 11.76 90.91 1.0000 
     "  "      Loss of contact with close 
relative/friend 
3 14 .  2 9 . 17.65 81.82 1.0000 
     "  "      Neglect  1 16 .  1 10 . 5.88 90.91 1.0000 
     "  "      Physical abuse  2 15 .  1 10 . 11.76 90.91 1.0000 
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     "  "      Sexual abuse  1 16 .  0 11 . 5.88 100.00 1.0000 
     "  "      Emotional abuse  2 15 .  2 9 . 11.76 81.82 1.0000 
     "  "      Re-exposure to former abuser  3 14 .  1 10 . 17.65 90.91 1.0000 
     "  "      Exposure to violence  3 14 .  1 10 . 17.65 90.91 1.0000 
Past symptoms           
     "  "      Joint stiffness 2 4 11  1 6 4 33.33 85.71 0.5594 
     "  "      Nausea/vomiting 2 4 11  0 7 4 33.33 100.00 0.1923 
     "  "      Constipation/diarrhoea 2 4 11  0 7 4 33.33 100.00 0.1923 
     "  "      Pain with menses/sex/urination 0 6 11  0 7 4 . 100.00 ND 
Past diagnosis           
     "  "      Low blood pressure 5 12 .  0 11 . 29.41 100.00 0.1247 
     "  "      Sleep apnea 2 4 11  0 7 4 33.33 100.00 0.1923 
     "  "      Irritable bowel syndrome 2 15 .  1 10 . 11.76 90.91 1.0000 
     "  "      Crohn disease 0 6 11  0 7 4 . 100.00 ND 
     "  "      Brain tumor 1 16 .  3 8 . 5.88 72.73 0.2694 
     "  "      TBI 2 15 .  0 11 . 11.76 100.00 0.5053 
     "  "      Chronic pain syndrome 2 15 .  0 11 . 11.76 100.00 0.5053 
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     "  "      Chronic fatigue syndrome 1 16 .  0 11 . 5.88 100.00 1.0000 
     "  "      Fibromyalgia 4 13 .  0 11 . 23.53 100.00 0.1324 
     "  "      Pnes 4 13 .  0 11 . 23.53 100.00 0.1324 
Past surgeries           
     "  "      Brain surgery 2 15 .  3 8 . 11.76 72.73 0.3531 
     "  "      Neck/back surgery  2 15 .  0 11 . 11.76 100.00 0.5053 
     "  "      Cholecistectomy 6 11 .  1 10 . 35.29 90.91 0.1914 
     "  "      Exploratory laparoscopy 4 13 .  0 11 . 23.53 100.00 0.1324 
     "  "      Hysterectomy 2 15 .  1 10 . 11.76 90.91 1.0000 
     "  "      Carpal tunnel surgery 1 16 .  0 11 . 5.88 100.00 1.0000 
Education history           
     "  "      Learning disability 6 11 .  3 7 1 35.29 70.00 1.0000 
     "  "      School additional help 5 12 .  3 8 . 29.41 72.73 1.0000 
     "  "      Work 4 13 .  2 9 . 23.53 81.82 1.0000 
     "  "      Applying for disability  8 9 .  9 2 . 47.06 18.18 0.1150 
     "  "      On disability payments 6 10 1  0 11 . 37.50 100.00 0.0536 
Psychiatric history           
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     "  "      Depression 6 11 .  1 10 . 35.29 90.91 0.1914 
     "  "      Anxiety 5 12 .  1 10 . 29.41 90.91 0.3547 
     "  "      Bipolar illness 1 16 .  1 10 . 5.88 90.91 1.0000 
     "  "      Borderline personality 1 16 .  0 11 . 5.88 100.00 1.0000 
     "  "      Schizophrenia 0 17 .  0 11 . . 100.00 ND 
     "  "      Conversion disorder 0 17 .  0 11 . . 100.00 ND 
     "  "      ADHD 3 14 .  0 11 . 17.65 100.00 0.2579 
     "  "      Counseling or therapy 13 4 .  6 5 . 76.47 45.45 0.4087 
     "  "      Hospitalization for   
 emotional/behavioural 
problems 
3 14 .  1 10 . 17.65 90.91 1.0000 
     "  "      Medications for  
 emotional/behavioural 
problems 
8 9 .  1 9 1 47.06 90.00 0.0912 
           
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
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Supplementary table 3.3.2. Witness questionnaire. PNES vs. ES: list of variables with sensitivity or specificity less than 60.   
Variable PNES   ES SE SP p-value 
Present Absent Not 
indicated 
  Present Absent Not 
indicated 
   
Seizure onset            
     "  "      stopping/staring 3 3 .  8 2 . 50.00 20.00 0.2995 
     "  "      high-pitched cry 1 5 .  2 8 . 16.67 80.00 1.0000 
     "  "      humming/vocalization 1 5 .  1 9 . 16.67 90.00 1.0000 
     "  "      change feeling/sensation 2 4 .  2 8 . 33.33 80.00 0.6044 
     "  "      odd smell 0 6 .  0 10 . . 100.00 ND 
     "  "      odd taste 0 6 .  0 10 . . 100.00 ND 
     "  "      deja vu 0 6 .  1 9 . 0.00 90.00 1.0000 
     "  "      visual image 1 5 .  0 10 . 16.67 100.00 0.3750 
     "  "      tunnel vision 0 6 .  0 10 . . 100.00 ND 
     "  "      blurred vision 1 5 .  0 10 . 16.67 100.00 0.3750 
     "  "      nausea 1 5 .  1 9 . 16.67 90.00 1.0000 
     "  "      abdominal rising sensation 0 6 .  0 10 . . 100.00 ND 
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     "  "      tingling numbness 1 5 .  0 10 . 16.67 100.00 0.3570 
     "  "      pain 0 6 .  0 10 . . 100.00 ND 
     "  "      heart racing 0 6 .  1 9 . 0.00 90.00 1.0000 
     "  "      dizziness 2 4 .  0 10 . 33.33 100.00 0.1250 
     "  "      other 2 4 .  2 8 . 33.33 80.00 0.6044 
During seizure           
     "  "      shaking/stiffening 6 0 .  10 0 . 100.00 . ND 
     "  "      sudden  3 3 0  1 7 2 50.00 12.50 0.2448 
     "  "      gradual build-up  3 3 0  1 7 2 50.00 12.50 0.2448 
     "  "      one side only 1 5 0  1 8 1 16.67 88.89 1.0000 
     "  "      both sides equally 2 4 0  6 3 1 66.67 33.33 1.0000 
     "  "      alternating sides/same seizure 2 4 0  1 8 1 33.33 88.89 0.5253 
     "  "      alt. sides in different seizures 0 6 0  0 9 1 . 100.00 ND 
     "  "      sudden ending  1 4 1  2 8 . 20.00 80.00 1.0000 
     "  "      gradual ending  1 4 1  3 7 . 80.00 30.00 1.0000 
     "  "      not responsive at all  2 4 .  3 7 . 66.67 30.00 1.0000 
     "  "      looks at but not responsive 0 6 .  1 9 . 0.00 90.00 1.0000 
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     "  "      speaks nonsense 2 4 .  0 10 . 33.33 100.00 0.1250 
     "  "      speaks/follows commands 1 5 .  3 7 . 16.67 70.00 1.0000 
     "  "      head turning to one side 2 4 0  3 6 1 33.33 66.67 1.0000 
     "  "      eyes open 3 3 0  9 0 1 50.00 0.00 0.0440 
     "  "      staring 2 4 .  6 4 . 33.33 40.00 0.6084 
     "  "      wandering around 1 5 .  3 7 . 16.67 70.00 1.0000 
     "  "      picking at things 0 6 .  4 6 . 0.00 60.00 0.2335 
     "  "      one arm ben/stretched 2 4 .  3 7 . 33.33 70.00 1.0000 
     "  "      brief jerks arms legs 2 4 .  3 7 . 66.67 30.00 1.0000 
     "  "      agitated behaviour 1 5 .  1 9 . 16.67 90.00 1.0000 
     "  "      making loud noises 0 6 .  2 8 . 0.00 80.00 0.5000 
     "  "      sobbing/crying 2 4 .  0 10 . 33.33 100.00 0.1250 
     "  "      trashing/flopping 2 4 .  3 7 . 33.33 70.00 1.0000 
     "  "      out of sync limb movements 2 4 .  3 7 . 33.33 70.00 1.0000 
     "  "      back arching  1 5 .  2 8 . 16.67 80.00 1.0000 
     "  "      hip trusting 0 6 .  0 10 . 0.00 100.00 ND 
     "  "      normal breathing 2 4 .  5 5 . 33.33 50.00 0.6329 
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     "  "      fast/heavy breathing 1 5 .  3 7 . 16.67 70.00 1.0000 
     "  "      patient falling 3 2 1  6 3 1 60.00 33.33 1.0000 
     "  "      slow, gradual slumping 0 5 1  0 9 1 0.00 100.00 ND 
     "  "      sudden stiff/toppling over 1 4 1  1 8 1 20.00 88.89 1.0000 
     "  "      < 2 min. duration 3 3 .  7 3 . 50.00 30.00 0.6066 
End of seizure           
     "  "      cough 1 5 .  2 8 . 16.67 80.00 1.0000 
     "  "      wiping nose 1 5 .  1 9 . 16.67 90.00 1.0000 
     "  "      noisy/congested breathing 2 4 .  4 6 . 33.33 60.00 1.0000 
     "  "      deeply asleep 1 5 .  1 9 . 16.67 90.00 1.0000 
     "  "      awake confused/disoriented 4 2 .  8 2 . 66.67 20.00 0.6044 
     "  "      normal       2 4 .  3 7 . 33.33 70.00 1.0000 
Legend: PNES psychogenic non-epileptic seizures; ES epileptic seizures; SE sensitivity; SP specificity. 
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Supplementary Table 5.1. Age and sex distribution of the population of the study area (Lecco province) comparing participating general 
practitioners (GPs) to GPs who declined participation 
_________________________________________________________________________________________________________________________ 
Variable Total population Participating GPs’ population Declining GPs’ population 
 N % 95% CI N % 95% CI N % 95% CI 
Sex 
 M 165,.211 49.02 48.85-49.18 71,541 48.83 48.58-49.09 101,521 49.15 48.93-49.36 
 F 171,851 50.98 50.82-51.15 74,965 51.17 50.91-51.42 105,036 50.85 50.64-51.07 
 Total 337,062 100.00 100.00-100.00 146,506 100.00 100.00-100.00 206,557 100.00 100.00-100.00 
Age, years (M) 
 <15 24,455 7.26 7.17-7.34 15,700 10.72 10.56-10.87 10,073 4.88 4.78-4.97 
 15-34 38,181 11.33 11.22-11.43 15,361 10.48 10.33-10.64 24,665 11.94 11.80-12.08 
 35-54 53,190 15.78 15.66-15.90 21,380 14.59 14.41-14.77 34,297 16.60 16.44-16.76 
 55-74 37,791 11.21 11.11-11.32 14,920 10.18 10.03-10.34 24,523 11.87 11.73-12.01 
 75+ 11,594 3.44 3.38-3.50 4,180 2.85 2.77-2.94 7,963 3.86 3.77-3.94 
Age, years (F) 
 <15 23,558 6.99 6.90-7.08 15,152 10.34 10.19-10.50 9,693 4.69 4.60-4.78 
 15-34 36,544 10.84 10.74-10.95 15,214 10.38 10.23-10.54 23,065 11.17 11.03-11.30 
 35-54 50,656 15.03 14.91-15.15 20,960 14.31 14.13-14.49 32,099 15.54 15.38-15.70 
 55-74 39,967 11.86 11.75-11.97 15,868 10.83 10.67-10.99 25,889 12.53 12.39-12.68 
 75+ 21,126 6.27 6.19-6.35 7,771 5.30 5.19-5.42 14,290 6.92 6.81-7.03 
Age, years (total) 
 <15 48,013 14.24 14.13-14.36 30,852 21.06 20.85-21.27 19,766 9.57 9.44-9.70 
 15-34 74,725 22.17 22.03-22.31 30,575 20.87 20.66-21.08 47,730 23.11 22.93-23.29 
 35-54 103,846 30.81 30.65-30.97 42,340 28.90 28.67-29.13 66,396 32.14 31.94-32.35 
 55-74 77,758 23.07 22.93-23.21 30,788 21.01 20.81-21.22 50,412 24.41 24.22-24.59 
 75+ 32,720 9.71 9.61-9.81 11,951 8.16 8.02-8.30 22,253 10.77 10.64-10.91 
_______________________________________________________________________________________________________________________ 
Legend:  95% CI = 95% Confidence Interval; F = Female; M = Male. 
  
Supplementary Table 5.2. Age and sex-specific frequencies of the main syndromic categories in patients with DRE.  
Syndromes 0-14y    15-34y  35-54y  55-74y  75+y  Total  
 N  (%) N  (%) N  (%) N  (%) N  (%) N  (%) 
Women       
PI 0. (0.00) 1 (100.00) 0. (0.00) 0. (0.00) 0. (0.00) 1 (1.47) 
PS 4 (15.38) 4 (15.38) 11 (42.31) 7 (26.92) 0 (0.00) 26 (38.24) 
PC 1 (6.25) 6 (37.50) 5 (31.25) 4 (25.00) 0 (0.00) 16 (23.53) 
GI 1 (12.50) 2 (25.00) 4 (50.00) 1 (12.50) 0 (0.00) 8 (11.76) 
GC/GS 6 (50.00) 1 (8.33) 3 (25.00) 2 (16.67) 0 (0.00) 12 (17.65) 
Undetermined 2 (50.00) 1 (25.00) 0 (0.00) 1 (25.00) 0 (0.00) 4 (5.88) 
Special 0 (0.00) 1 (100.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.47) 
Total 
 
 
 
14 
(20.59) 
16 (23.53) 23 (33.82) 15 (22.06) 0 (0.00) 68 
(100.00) 
Giussani G. 
 
243 
 
Men 
PI 0. (0.00) 0. (0.00) 0. (0.00) 0. (0.00) 0. (0.00) 0. (0.00) 
PS 3 (16.67) 3 (16.67) 7 (38.89) 4 (22.22) 1 (5.56) 18 (46.15) 
PC 1 (14.29) 1 (14.29) 4 (57.14) 1 (14.29) 0. (0.00) 7 (17.95) 
GI 1 (25.00) 1 (25.00) 1 (25.00) 0. (0.00) 1 (25.00) 4 (10.26) 
GC/GS 5 (62.50) 2 (25.00) 1 (12.50) 0. (0.00) 0. (0.00) 8 (20.51) 
Undetermined 0. (0.00) 0. (0.00) 0. (0.00) 1 (100.00) 0. (0.00) 1 (2.56) 
Special 0. (0.00) 0. (0.00) 1 (100.00) 0. (0.00) 0. (0.00) 1 (2.56) 
Total 10 
(25.54) 
7 (17.95) 14 (35.90) 6 (15.38) 2 (5.13) 39 
(100.00) 
  
Legend: PI = Partial Idiopathic; PS = Partial Symptomatic; PC = Partial Cryptogenic; GI = Generalized Idiopathic; GC/GS = Generalized 
Cryptogenic/Generalized Symptomatic; y= years. 
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Supplementary Table 5.3. Age, sex, and epilepsy syndrome distribution in prevalent and incident cases 
_____________________________________________________________________________ 
Variable Prevalent cases Incident cases p value 
 N % N % 
___________________________________________________________________________________________ 
Sex 
 M 193 47.65 188 54.97 0.0463 
 F 212 52.35 154 45.03 
Age, years 
 <15 198 49.13 120 35.09 <0.0001 
 15-34 113 28.04 70 20.47 
 35-54 58 14.39 62 18.13 
 55-74 31 7.69 69 20.18 
 75+ 3 0.74 21 6.14 
Epilepsy syndrome 
 GC/GS 41 10.12 33 9.65 0.3988 
 GI 95 23.46 59 17.25 
 PC 89 21.98 78 22.81 
 PI 31 7.65 23 6.73 
 PS 132 32.59 133 38.89 
 Special 3 0.74 4 1.17 
 Undetermined 14 3.46 12 3.51 
 
Drug resistant 
 No 334 82.5 306 89.5 0.0065 
 Yes 71 17.5 36 10.5 
___________________________________________________________________________________________ 
Legend:  F = Female; M = Male; GC/GS = Generalized Cryptogenic/Generalized Symptomatic;      
PC = Partial Cryptogenic; PI = Partial Idiopathic; PS = Partial Symptomatic.   
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Supplementary Table 5.4. General characteristics of the sample by age group 
    Age <18 Age 18+   
Variable Category N % N % p-value 
       
Gender F 185 52.9 179 45.3 0.0399 
 M 165 47.1 216 54.7  
       
Family history of Yes 74 21.1 37 9.4 <0.0001 
seizures No 253 72.3 331 83.8  
 Unknown 23 6.6 27 6.8  
       
Seizures Partial 187 53.4 271 68.6 <0.0001 
 Generalized 154 44.0 106 26.8  
 Unclassifiable 9 2.6 18 4.6  
       
Syndrome GC/GS 47 13.4 27 6.8 <0.0001 
 GI 97 27.7 57 14.4  
 PC 52 14.9 113 28.6  
 PI 49 14.0 5 1.3  
 PS 90 25.7 175 44.3  
 Undetermined 10 2.9 16 4.1  
 Special 5 1.4 2 0.5  
       
Disease duration  <1y 317 90.6 349 88.6 0.3758 
at diagnosis ≥1 y 33 9.4 45 11.4  
 Missing   1   
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Number of AED 0 9 2.6 7 1.8 0.0125 
 1 171 48.9 220 55.7  
 2 88 25.1 111 28.1  
 3+ 82 23.4 57 14.4  
       
Drug resistant No 276 78.9 362 91.7 <0.0001 
  Yes 74 21.1 33 8.3   
 
Legend: F = Female; M = Male; GC/GS = Generalized Cryptogenic/Generalized Symptomatic; GI = Generalized Idiopathic; PC = Partial Cryptogenic; PI 
= Partial Idiopathic; PS = Partial Symptomatic; y = Years; AED = antiepileptic drug. 
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Supplementary Table 5.5. Cause specific cumulative probabilities of withdrawal of the first, second and third AED. 
      Ineffectiveness Adverse events Terminal remission Other 
  
Year 
Number at 
risk* 
n CIF*100 n CIF*100 n CIF*100 n CIF*100 
First AED 
1 664 21 2.9 4 0.5 7 1.0 2 0.2 
3 571 39 5.6 7 1.3 22 3.2 10 1.4 
5 459 51 7.6 13 2.0 59 9.3 17 2.6 
10 307 66 10.4 16 2.5 93 15.7 26 4.4 
20 175 75 12.6 19 3.3 109 20.0 35 6.6 
Second AED 
1 288 14 4.3 9 2.7 1 0.3 5 1.5 
3 215 28 9.0 9 2.7 5 1.7 7 2.2 
5 165 33 11.1 10 3.2 8 3.1 10 3.6 
10 92 39 14.9 10 3.2 21 10.3 12 4.6 
20 44 40 15.8 11 4.3 24 13.3 15 7.7 
Third AED 
1 115 12 8.8 3 2.2 1 0.7 2 1.5 
3 75 20 15.8 4 3.0 2 1.6 4 3.4 
5 48 22 18.6 4 3.0 3 2.6 4 3.4 
10 25 28 29.8 4 3.0 4 4.3 5 5.0 
20 11 31 39.3 6 8.0 4 4.3 5 5.0 
 
*Patients still in treatment for each specified time.  
CIF*100 Cumulative incidence function*100; AED Antiepileptic drug. 
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Supplementary Table 5.6. Cause specific cumulative probabilities of withdrawal of the first, second and third drug, by old and new AEDs. 
  
Ineffectiveness 
Adverse  
effects 
Terminal remission Other 
  
Year 
Number at 
risk* 
n CIF*100 n CIF*100 n CIF*100 n CIF*100 
First 
AED 
New AEDs 
1 48 1 1.7 0 0.0 0 0.0 0 0.0 
3 34 4 8.7 0 0.0 2 4.5 0 0.0 
5 16 6 15.6 1 2.5 5 14.0 1 3.5 
10 5 8 26.9 1 2.5 7 25.2 2 9.0 
20 5 8 26.9 1 2.5 7 25.2 2 9.0 
Old AEDs 
1 616 20 3.0 4 0.6 7 1.1 2 0.3 
3 537 35 5.4 7 1.1 20 3.2 10 1.6 
5 443 45 7.1 12 1.9 54 9.0 16 2.6 
10 302 58 9.6 15 2.5 86 15.3 24 4.2 
20 170 67 12.0 18 3.3 102 19.7 33 6.6 
  p-value 0.1058 0.9122 0.2738 0.9036 
Second 
AED 
New AEDs 
1 84 5 5.1 2 1.9 1 1.0 3 3.0 
3 45 13 15.0 2 1.9 2 2.3 3 3.0 
5 30 13 15.0 2 1.9 3 4.7 3 3.0 
10 11 16 27.5 2 1.9 5 12.3 3 3.0 
20 5 16 27.5 2 1.9 5 12.3 4 12.1 
Old AEDs 
1 204 9 4.0 7 3.1 0 0.0 2 0.9 
3 170 15 6.8 7 3.1 3 1.5 4 1.9 
5 135 20 9.4 8 3.6 5 2.6 7 1.4 
10 81 23 11.7 8 3.6 16 10.0 9 4.8 
20 39 24 12.6 9 4.9 19 13.2 11 7.1 
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  p-value 0.0765 0.4509 0.8685 0.4086 
Third 
AED 
New AEDs 
1 56 4 6.2 2 3.1 0 0.0 0 0.0 
3 35 6 10.6 3 5.1 0 0.0 1 2.3 
5 18 8 18.1 3 5.1 0 0.0 1 2.3 
10 7 12 38.2 3 5.1 1 4.7 2 5.4 
20 1 15 74.7 4 14.2 1 4.7 2 5.4 
Old AEDs 
1 59 8 11.1 1 1.4 1 1.4 2 2.8 
3 40 14 20.3 1 1.4 2 2.8 3 4.5 
5 30 14 20.3 1 1.4 3 4.7 3 4.5 
10 18 16 26.5 1 1.4 3 4.7 3 4.5 
20 11 16 26.5 2 4.9 3 4.7 3 4.5 
  p-value 0.4046 0.1829 0.4717 0.8666 
*Patients still in treatment for each specified time.  
CIF*100 Cumulative incidence function*100; AED Antiepileptic drug. 
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Supplementary Table 5.7. Drug daily doses (median and range) of first AED given to children (<15 years) (A) and adults (>15 years) (B). 
A. <15 years 
 Total Ineffectiveness Adverse events 
  Median Min Max Median Min Max Median Min Max 
BSC - - - - - - - - - 
CBZ 750 150 2400 800 340 1500 800 800 800 
CLB 10 10 10 10 10 10 - - - 
CNP - - - - - - - - - 
ESM 450 300 600 - - - - - - 
GBP 100 100 100 100 100 100 - - - 
LEV 925 750 1100 - - - - - - 
LTG - - - - - - - - - 
OXC 750 300 1500 - - - - - - 
PB 100 30 250 100 45 100 - - - 
PGB - - - - - - - - - 
PHT 300 100 400 100 100 100 - - - 
PRM - - - - - - - - - 
TGB - - - - - - - - - 
TPM 550 100 1000 - - - - - - 
VGB 1400 1250 2000 - - - - - - 
VPA 700 200 1900 650 300 1000 - - - 
VPM 250 200 300 - - - - - - 
ZNS - - - - - - - - - 
BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam, CNP Clonazepam, ESM Ethosuximide, GBP Gabapentin, LEV Levetiracetam, LTG Lamotrigine, OXC Oxcarbazepine, PB 
Phenobarbital, PHT Phenytoin, PGB Pregabalin, PRM Primidone, TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate. 
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A. >15 years 
 Total Ineffectiveness Adverse events 
  Median Min Max Median Min Max Median Min Max 
BSC 175 100 250 100 100 100    
CBZ 600 100 2400 800 400 1200 700 400 1000 
CLB - - - - - - - - - 
CNP 1 1 1 - - - - - - 
ESM - - - - - - - - - 
GBP 600 600 600 - - - - - - 
LEV 1000 500 2250 - - - - - - 
LTG 200 75 300 75 75 75 - - - 
OXC 900 100 1500 1050 600 1500 600 600 600 
PB 100 50 300 100 100 150 100 50 100 
PGB - - - - - - - - - 
PHT 275 100 400 150 100 400 250 250 250 
PRM - - - - - - - - - 
TGB - - - - - - - - - 
TPM 300 300 300 - - - - - - 
VGB - - - - - - - - - 
VPA 1000 150 2500 650 500 1000 1325 1250 1400 
VPM - - - - - - - - - 
ZNS - - - - - - - - - 
BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam, CNP Clonazepam, ESM Ethosuximide, GBP Gabapentin, LEV Levetiracetam, LTG Lamotrigine, OXC Oxcarbazepine, PB 
Phenobarbital, PHT Phenytoin, PGB Pregabalin, PRM Primidone, TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate. 
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9. Appendix 
9.1. MI-RO Patient Questionnaire 
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9.2. MI-RO Witness Questionnaire 
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9.3 IDIC-15 Study Case Report Form  
 
VALIDATION STUDY OF THE DIAGNOSIS OF IDIC(15) SYNDROME 
 
Case Report Form 
Version 2.0, 21/04/2015 
 
Rater’s initials  /__/__/     Patient’s initials
 /__/__/ 
Rater’s background: 
_____________________________________________________________________  
        
Date of birth /__/__//__/__//__/__/      Sex /M/
 /F/ 
Weight  Kg %ile 
Height  cm %ile 
CC  cm %ile 
  
Step 1. Medical records 
Past & present history 
Gestation week at delivery /__/__/    Apgar score /__/__/ 
Birth weight Kg %ile  Length at birth   cm %ile  CC 
 cm %ile 
Feeding difficulties in newborn period     /No/ /Yes/ 
Standing /No/ /Yes/  Age, months /__/__/ Age unknown /__/ 
Walking /No/ /Yes/  Age, months /__/__/  Age unknown /__/ 
Speech  /No/ /Yes/  Age, months /__/__/ Age unknown /__/  
    
Only minimal number of words  /__/ 
Self-feeding /No/ /Yes/  Age, months /__/__/  Age unknown /__/ 
Playing  /No/ /Yes/  Age, months /__/__/ Age unknown /__/ 
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Recurrent upper respiratory tract infections during infancy /No/ /Yes/ /Unknown/ 
Constipation     /No/ /Yes/ 
Hypogonadism     /No/ /Yes/ /Unknown/ 
 
Urinary tract defects    /No/ /Yes/ /Unknown/ 
Congenital heart defects   /No/ /Yes/ /Unknown/ 
Unilateral renal agenesis   /No/ /Yes/ /Unknown/ 
Umbilical hernias    /No/ /Yes/ /Unknown/ 
Inguinal hernias    /No/ /Yes/ /Unknown/ 
 
General examination 
Growth restriction    /No/ /Yes/        /Unknown/ 
Microcephaly     /No/ /Yes/        /Unknown/ 
Macrocephaly     /No/ /Yes/        /Unknown/  
Flat occiput     /No/ /Yes/        /Unknown/ 
Occipital groove    /No/ /Yes/        /Unknown/ 
High forehead     /No/ /Yes/        /Unknown/ 
Frontal bossing     /No/ /Yes/        /Unknown/ 
Epicanthal folds    /No/ /Yes/        /Unknown/ 
Deep set eyes     /No/ /Yes/        /Unknown/ 
Downslanting palpebral fissures  /No/ /Yes/        /Unknown/ 
Synophrys     /No/ /Yes/        /Unknown/ 
Low-set and posteriorly rotated ears  /No/ /Yes/        /Unknown/ 
Broad nose     /No/ /Yes/        /Unknown/ 
Short philtrum     /No/ /Yes/        /Unknown/ 
Anteverted nares    /No/ /Yes/        /Unknown/ 
Midface hypoplasia    /No/ /Yes/        /Unknown/ 
Large incisors     /No/ /Yes/        /Unknown/ 
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Cleft palate/highly arched palate  /No/ /Yes/        /Unknown/ 
Protruding tongue    /No/ /Yes/        /Unknown/ 
Drooling     /No/ /Yes/        /Unknown/ 
Prognathia     /No/ /Yes/        /Unknown/ 
Wide mouth     /No/ /Yes/        /Unknown/ 
Wide spaced teeth    /No/ /Yes/        /Unknown/ 
Hypopigmented skin (compared to family) /No/ /Yes/        /Unknown/ 
Light hair color (compared to family)  /No/ /Yes/        /Unknown/ 
Light eye color (compared to family)  /No/ /Yes/        /Unknown/ 
Hyperactive lower extremities   /No/ /Yes/        /Unknown/ 
Uplifted, flexed arms during ambulation    /No/     /Yes/        /Unknown/ Present at visit /__/ 
Joint hyperlaxity   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Clinodactyly     /No/ /Yes/        /Unknown/ 
Syndactyly     /No/ /Yes/        /Unknown/ 
Brachydactyly     /No/ /Yes/        /Unknown/ 
Scoliosis     /No/ /Yes/        /Unknown/ 
Obesity      /No/ /Yes/        /Unknown/ 
_____________________________________________________________________________
__________ 
Neurological examination 
Normal  /No/ /Yes/        /Unknown/  If no, please indicate abnormal 
findings: 
Hypotonia /No/ /Yes/        /Unknown/  Present at visit /__/ 
Wide-based gait with pronated or valgus-positioned ankles /No/ /Yes/        /Unknown/ 
Ataxia  /No/ /Yes/        /Unknown/  Present at visit /__/ 
Clumsiness /No/ /Yes/        /Unknown/  Present at visit /__/ 
Jerky motions /No/ /Yes/        /Unknown/  Present at visit /__/ 
Tremor  /No/ /Yes/        /Unknown/  Present at visit /__/ 
Swallowing disorders /No/ /Yes/        /Unknown/ Present at visit /__/ 
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Strabismus /No/ /Yes/        /Unknown/ 
Brisk deep tendon reflexes  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Increased sensitivity to heat  /No/ /Yes/        /Unknown/ 
Abnormal sleep-wake cycles  /No/ /Yes/        /Unknown/ 
 
Overall judgment of developmental delay  /No/ /Mild/ /Moderate/ /Severe/     
/Unknown/ 
Mental retardation    / No/ /Mild/ /Moderate/ /Severe/    
/Unknown/ 
 
Psychiatric examination 
Normal  /No/ /Yes/        /Unknown/  If no, please indicate abnormal 
findings: 
Laughter/smiling  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Happy demeanor  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Easily excitable   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Echolalia   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hand-flapping movements /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hypermotoric behavior  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Tantrums   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Stubbornness   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Verbal perseverance  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Skin picking   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hyperphagia   /No/ /Yes/        /Unknown/ 
Anxiety    /No/ /Yes/        /Unknown/ Present at visit /__/ 
Emotional lability  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Impulsivity   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Aggressiveness   /No/ /Yes/        /Unknown/ Present at visit /__/ 
 
Epilepsy /No/ /Yes/        /Unknown/  If yes, please complete the following: 
Giussani G. 
 
279  
Infantile spasms   /No/ /Yes/        /Unknown/ 
Generalized tonic-clonic seizures /No/ /Yes/        /Unknown/ 
Myoclonic seizures   /No/ /Yes/        /Unknown/ 
Atypical absence seizures  /No/ /Yes/        /Unknown/ 
Axial tonic seizures   /No/ /Yes/        /Unknown/ 
Focal seizures    /No/ /Yes/        /Unknown/ 
Refractory epilepsy   /No/ /Yes/        /Unknown/ 
 
Autistic behavior /No/ /Yes/        /Unknown/  If yes, please complete the 
following: 
ADOS score:__________________________________________________________________ 
 
Diagnosis 1. 
15q11-13 Duplication Syndrome /No/ /Yes/ /Probable/ /Uncertain/ 
Angelman Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
Pitt-Hopkins Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mowat-Wilson Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mucopolysaccharidosis type 3  /No/ /Yes/ /Probable/ /Uncertain/ 
FOXG1 Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
West Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
Autism spectrum disorder  /No/ /Yes/ /Probable/ /Uncertain/ 
Other neurodevelopmental disorder /No/ /Yes/ /Probable/ /Uncertain/ 
Please, specify: 
………………………………………………………………………………………………………………………………………. 
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Step 2. Video-recording 
General examination 
Growth restriction    /No/ /Yes/        /Unknown/ 
Microcephaly     /No/ /Yes/        /Unknown/ 
Macrocephaly     /No/ /Yes/        /Unknown/  
Flat occiput     /No/ /Yes/        /Unknown/ 
Occipital groove    /No/ /Yes/        /Unknown/ 
High forehead     /No/ /Yes/        /Unknown/ 
Frontal bossing     /No/ /Yes/        /Unknown/ 
Epicanthal folds    /No/ /Yes/        /Unknown/ 
Deep set eyes     /No/ /Yes/        /Unknown/ 
Downslanting palpebral fissures  /No/ /Yes/        /Unknown/ 
Synophrys     /No/ /Yes/        /Unknown/ 
Low-set and posteriorly rotated ears  /No/ /Yes/        /Unknown/ 
Broad nose     /No/ /Yes/        /Unknown/ 
Short philtrum     /No/ /Yes/        /Unknown/ 
Anteverted nares    /No/ /Yes/        /Unknown/ 
Midface hypoplasia    /No/ /Yes/        /Unknown/ 
Large incisors     /No/ /Yes/        /Unknown/ 
Cleft palate/highly arched palate  /No/ /Yes/        /Unknown/ 
Protruding tongue    /No/ /Yes/        /Unknown/ 
Drooling     /No/ /Yes/        /Unknown/ 
Prognathia     /No/ /Yes/        /Unknown/ 
Wide mouth     /No/ /Yes/        /Unknown/ 
Wide spaced teeth    /No/ /Yes/        /Unknown/ 
Hypopigmented skin (compared to family) /No/ /Yes/        /Unknown/ 
Light hair color (compared to family)  /No/ /Yes/        /Unknown/ 
Light eye color (compared to family)  /No/ /Yes/        /Unknown/ 
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Hyperactive lower extremities   /No/ /Yes/        /Unknown/ 
Uplifted, flexed arms during ambulation   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Joint hyperlaxity      /No/   /Yes/        /Unknown/ Present at visit /__/ 
Clinodactyly     /No/ /Yes/        /Unknown/ 
Syndactyly     /No/ /Yes/        /Unknown/ 
Brachydactyly     /No/ /Yes/        /Unknown/ 
Scoliosis     /No/ /Yes/        /Unknown/ 
Obesity      /No/ /Yes/        /Unknown/ 
_____________________________________________________________________________
__________ 
Neurological examination 
Normal  /No/ /Yes/        /Unknown/  If no, please indicate abnormal 
findings: 
Hypotonia /No/ /Yes/        /Unknown/  Present at visit /__/ 
Wide-based gait with pronated or valgus-positioned ankles /No/ /Yes/        /Unknown/ 
Ataxia  /No/ /Yes/        /Unknown/  Present at visit /__/ 
Clumsiness /No/ /Yes/        /Unknown/  Present at visit /__/ 
Jerky motions /No/ /Yes/        /Unknown/  Present at visit /__/ 
Tremor  /No/ /Yes/        /Unknown/  Present at visit /__/ 
Swallowing disorders /No/ /Yes/        /Unknown/ Present at visit /__/ 
Strabismus /No/ /Yes/        /Unknown/ 
Brisk deep tendon reflexes /No/ /Yes/        /Unknown/ Present at visit /__/ 
Increased sensitivity to heat  /No/ /Yes/        /Unknown/ 
Abnormal sleep-wake cycles  /No/ /Yes/        /Unknown/ 
 
Overall judgment of developmental delay  /No/ /Mild/ /Moderate/ /Severe/     
/Unknown/ 
Mental retardation    / No/ /Mild/ /Moderate/ /Severe/    
/Unknown/ 
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Psychiatric examination 
Normal  /No/ /Yes/        /Unknown/  If no, please indicate abnormal 
findings: 
Laughter/smiling  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Happy demeanor  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Easily excitable   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Echolalia   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hand-flapping movements /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hypermotoric behavior  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Tantrums   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Stubbornness   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Verbal perseverance  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Skin picking   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Hyperphagia   /No/ /Yes/        /Unknown/ 
Anxiety    /No/ /Yes/        /Unknown/ Present at visit /__/ 
Emotional lability  /No/ /Yes/        /Unknown/ Present at visit /__/ 
Impulsivity   /No/ /Yes/        /Unknown/ Present at visit /__/ 
Aggressiveness   /No/ /Yes/        /Unknown/ Present at visit /__/ 
 
Autistic behavior / No/ /Yes/ /Unknown/ If yes, please complete the following: 
 
Diagnosis 2. 
15q11-13 Duplication Syndrome /No/ /Yes/ /Probable/ /Uncertain/ 
Angelman Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
Pitt-Hopkins Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mowat-Wilson Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mucopolysaccharidosis type 3  /No/ /Yes/ /Probable/ /Uncertain/ 
FOXG1 Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
West Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
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Autism spectrum disorder  /No/ /Yes/ /Probable/ /Uncertain/ 
Other neurodevelopmental disorder /No/ /Yes/ /Probable/ /Uncertain/ 
Please, specify: 
………………………………………………………………………………………………………………………………………. 
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Step 3. Instrumental tests 
EEG                                             /Normal/   /Aspecific/  /Abnormal/   /Unknown/ 
If abnormal, please complete the following: 
Abnormal background rhythm /No/ /Yes/          /Unknown/ 
Spikes    /No/ /Yes/         /Unknown/ 
Slow waves   /No/ /Yes/        /Unknown/ 
Spike-slow waves  /No/ /Yes/        /Unknown/ 
Polyspike-slow waves  /No/ /Yes/        /Unknown/ 
Very high amplitude fast activity /No/ /Yes/        /Unknown/ 
Other epileptiform  /No/ /Yes/       /Unknown/ 
Other, specify: …………………………………………………………………………………………………… 
MRI                                                                  /Normal/ /Aspecific/ /Abnormal/   
/Unknown/ 
Please, specify: …………………………………………………………………………………………………… 
CT-Scan                                                          /Normal/ /Aspecific/ /Abnormal/   
/Unknown/ 
Please, specify: …………………………………………………………………………………………………… 
 
Diagnosis 3. 
15q11-13 Duplication Syndrome /No/ /Yes/ /Probable/ /Uncertain/ 
Angelman Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
Pitt-Hopkins Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mowat-Wilson Syndrome  /No/ /Yes/ /Probable/ /Uncertain/ 
Mucopolysaccharidosis type 3  /No/ /Yes/ /Probable/ /Uncertain/ 
FOXG1 Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
West Syndrome   /No/ /Yes/ /Probable/ /Uncertain/ 
Autism spectrum disorder  /No/ /Yes/ /Probable/ /Uncertain/ 
Other neurodevelopmental disorder /No/ /Yes/ /Probable/ /Uncertain/ 
Please, specify: 
………………………………………………………………………………………………………………………………………. 
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9.4 EPIRES Study Case Report Form 
EPIRES STUDY Case report Form 
(Version 1.0, 01/07/2011) 
 
Center code:                                                           Patient’s code: 
Sex:  M     [_]      F  [_]   
Birth date: _______________________________ 
Residency: ______________________________________________________ 
Telephone: _____________________________________________________ 
General Practitioner: ______________________________________________ 
 
Living status :  Alone                  [_]   
                           Hausemates          [_] 
                           Partner/family     [_] 
                   
Marital status:     Married         [_]                             Single           [_]                    
                                Divorced        [_]                            Widowed      [_]                    
Occupazione: 
           Employed       [_]                                             Student               [_]               Retired [_] 
                 Employment: _______________                  Unemployed         [_] 
 
The patient is currently followed by this center:        YES   [_]         NO  [_] 
Last visit date:  __/__/____ 
EEG:  ______________                      Caring neurologist:_________________________ 
If the patient is not longer followed by this center, please specify the reason:  
Deceased           [_]                       Cause of death: _______________ 
Compliance       [_] 
Unknown           [_] 
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Family history for epilepsy:                  YES     [_]                      NO    [_] 
 
EPILEPSY DIAGNOSI:                            YES    [_]                       
                                                                  NO    [_]        
                                                 (If not, please specify)     Acute symptomatic seizure     [_]     
                                                                                             Pseudo-seizures                   [_]     
                                                                            Other paroxsysmal events        [_]     
                                                                                             Other                                            [_]    
 Date of the diagnosis: __/__/____ 
 
Type of seizures 
 
 Partial           [_] 
Generalized           [_] 
Undetermined           [_] 
 
 Date of the first seizure: __/__/____ 
EPILEPTIC SYNDROME 
Partial symptomatic                 [_] 
Partial idiopathic                 [_] 
Partial cryptogenic                 [_] 
Generalized idiopathic                 [_] 
Generalizzata cryptogenic                 [_] 
Generalizzata symptomatic                 [_] 
 
Syntomatic 
 Aspecific etiology 
 Specific syndrome 
                
                [_] 
                [_] 
Undetermined syndrome 
 With partial and generaized seizures 
 without partial and generaized seizures 
                 
                 [_] 
                 [_] 
Other syndromes                   [_]  
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Is epilepsy associated with structural, metabolic or other disorders? 
 Infections                                                               [_] 
 Cerebrovascular diseases                                   [_] 
 Brain injury                                                            [_] 
 Brain tumor                                                           [_] 
 Metabolic and toxic encephalopathies            [_] 
 Degenerative brain disordes                             [_] 
 Mesial temporal sclerosis                       [_] 
 Neurocutaneous disorders                            [_] 
 Brain developement disorders                          [_] 
 Progressive myoclonic epilepsy                        [_] 
 Genetic disorders                                                 [_] 
 Other                                                                      [_] 
 
 
Had the patient period of remission?    YES     [_]          NO     [_] 
Number of periods of remission:    _________ 
                                           START DATE          END DATE               ONGOING 
First remission                                                                                         [_]          
Second remission                                                                                    [_]   
Third remission                                                                                        [_]   
Fourth remission                                                                                     [_] 
Fifth remission                                                                                         [_] 
Sixth remission                                                                                         [_] 
Seventh remission                                                                                    [_] 
Eighth remission                                                                                       [_] 
Ninth remission                                                                                        [_] 
Tenth remission                                                                                        [_] 
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ANTIEPILEPTIC DRUG THERAPY 
 
Drug 
MAXIMUM 
TOTAL DAILY 
DOSE 
 
ADMINISTRATION 
ROUTE 
 
START DATE 
 
END DATE 
 
DRUG 
WITHDRAWAL 
 
REASON FOR 
WITHDRAWAL 
1.     YES [_]   NO [_]  
2.     YES [_]   NO [_]  
3.     YES [_]   NO [_]  
4.     YES [_]   NO [_]  
5.     YES [_]   NO [_]  
6.     YES [_]   NO [_]  
7.     YES [_]   NO [_]  
8.     YES [_]   NO [_]  
9.     YES [_]   NO [_]  
10.     YES [_]   NO [_]  
11.     YES [_]   NO [_]  
12.     YES [_]   NO [_]  
13.     YES [_]   NO [_]  
14.     YES [_]   NO [_]  
15.     YES [_]   NO [_]  
  
